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Abstract 
Avermectins are macrocyclic lactones insecticides, used as antihelminthics in humans and 
animals, since they have low human toxicity. There is a clear role for the efflux transporter 
mdr1 controlling CNS exposure to avermectins in polymorphic animal models, but the role of 
MDR1 in limiting human avermectin exposure is less well defined, although no such 
knockout MDR1 polymorphisms have been identified to date. The aim of this study was to 
characterise the kinetics of avermectin interactions with efflux transporters in the human SH-
SY5Y neuroblastoma cell line, and compare them with mouse isoforms expressed in N2a 
cells to determine the relevance of mouse data to human avermectin exposure. 
Protein and mRNA expression of human MDR1, MRP and mouse mdr1a were identified in 
the cell lines, similar to the blood-brain barrier except BCRP and bcrp were absent.  Ki values 
for inhibition of MDR1 or MRP substrate efflux by avermectins did not differ significantly 
between human and mouse cells (P > 0.05); abamectin (MDR1 Ki = 0.95 ± 0.08µM; mdr1a 
Ki = 0.77 ± 0.25µM), emamectin benzoate (MDR1 Ki = 0.60 ± 0.07µM; mdr1a Ki = 0.56 ± 
0.02µM) and ivermectin (MDR1 Ki = 0.24 ± 0.08µM; mdr1a Ki = 0.18 ± 0.02µM), but 
ivermectin has the highest affinity for inhibition of MDR1- and mdr1a-substrate efflux.  
Cytotoxicity was apparent for emamectin benzoate above 6µM, which is 100-fold higher than 
peak exposure concentrations, but not for abamectin or ivermectin.  Expression levels of the 
chemokine genes SDF-2, AIMP1 and BDNF are candidates for biomarkers of avermectin 
exposure. These data show that SH-SY5Y cells are a good model in which to investigate 
avermectin exposure and to compare to mouse cells and have confirmed the involvement of 
MDR1 and MRP transporters. Avermectins are of global importance, so a greater 
understanding of mechanisms of human exposure is pertinent.   
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1.1. The importance of avermectin insecticides and therapeutics 
The avermectins are macrocyclic lactone compounds related to avermectin b1 
(abamectin), which was isolated from the soil microorganism Streptomyces 
avermitilis. Molecular structures are given in Figure 1. Ivermectin is the semi-
synthetic dihydro-derivative of avermectin b1, used as an anti-parasitic in humans and 
animals, where abamectin is the most abundant natural product (B1a isoform). Its 
semi-synthetic relatives, including emamectin benzoate, are used as agricultural 
insecticides. Avermectins act by binding to invertebrate neuronal GABA receptors 
and GABA-gated ion channels, causing net chloride influx leading to paralysis and 
death (Macdonald & Gledhill, 2007). They are efficiently eliminated from the CNS of 
mammals, and degrade rapidly in light and moisture, so they do not persist in the 
environment and are relatively non-toxic, with the exceptions of the mdr1- deficient 
animal models discussed below (Campbell, 1989). Figure 1.1 displays the structures 
of the avermectins used in the current study. 
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Ivermectin 
Ivermectin was first identified in 1981 as 22, 23-dihydroavermectin B1, the most 
active derivative form of a natural compound produced by the soil-dwelling organism 
Streptomyces avermitilis, found to be active against a large number of gastrointestinal 
and endo-parasites in horses, dogs, cattle and sheep including Strongylus vulgaris, 
hookworm, Haemonchus species including Haemonchus contortus, and Toxocara 
canis with usual doses of 0.2-0.3mg/kg bodyweight depending upon the species, and 
maximal doses being 1-2mg/kg (Barragry, 1987) . Due to the presence of active efflux 
pumps and the tight junction structure of the blood-brain barrier, detailed below, 
avermectins are restricted from entry into the mammalian CNS, so symptoms of 
neurotoxicity did not ensue in laboratory studies of toxicity until doses 10-fold higher 
than therapeutic concentrations were administered, that is 20-30mg/kg bodyweight 
(Barragry, 1987).  
 
In humans, ivermectin is widely used to treat parasitic infections endemic in Africa, 
namely lymphatic filariasis, at a dose of 100–200 μg/kg for reduction of micro 
filaraemia, and onchocerciasis (African River Blindness) at doses from 150 μg/kg en 
masse once a year and to sufferers, including children who weigh 15 kg or more, 
every 3-6 months (Taylor et al., 2010).        
 
Emamectin benzoate  
Emamectin benzoate is an important treatment for sea-lice infestations in farmed 
salmon, administered orally at 50µg/kg bodyweight daily for 7 days (Armstrong et al., 
2000; Lees et al., 2008). It is also used at low concentrations (6g per acre) on 
vegetable crops for the control of Lepidoptera species (Wise et al., 1997; Liguori et 
al., 2010). 
  
Abamectin  
Abamectin is the major (B1) component of the natural fermentation of Streptomyces 
avermitilis. It was active against arthropods in preliminary studies and is used against 
phytophagous mites and insect pests on ornamental plants, citrus, cotton, pears and 
vegetable crops as a spray in the range of 5 to 27 grams abamectin per hectare  
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(Lasota & Dybas, 1990). It undergoes rapid photodegradation, with a half-life of 4-6 
hours in the presence of light (Campbell, 1989), and thus does not accumulate in the 
environment. Kokoz et al. (1999) investigated the toxic effects of the natural 
aversectin C complex from Streptomyces avermitilis, which is a mixture of 8 
constituent avermectins A1a, A1b, A2a, A2b, B1a, B1b, B2a and B2b, on 
neuroblastoma B103 cells from rat brain. They found that aversectin C was selectively 
toxic to proliferating cells above density 40x10
3 
cells/cm
2
 but not to non-proliferating 
cells at 20x10
3 
cells/cm
2
, and that from the aversectin C complex, components B1 
abamectin and its dihydro-derivative ivermectin were not cytotoxic, but rather the A1 
constituents were responsible. The effect of the constituents of aversectin C on firing 
frequency of neurones from rat brain frontal cortex was examined. Aversectin C and 
the GABAα receptor activator nembutal both suppressed neuronal firing frequency, 
and this effect GABA-dependent of aversectin C was narrowed down to abamectin B1 
and B2. 
 
Other avermectins and the milbemycins 
Selamectin, doramectin and the structurally related milbemycins, lacking a sugar 
substitution on Carbon-13, are chemically modified forms of the naturally-occurring 
avermectins that have been reported to have higher potency for some applications, e.g. 
moxidectin has been proposed as an alternative to ivermectin for the treatment of 
lymphatic filariasis (Taylor et al., 2010) . Lower affinity of moxidectin for MDR1 
than either selamectin or ivermectin has been observed, and selamectin was reported 
to accumulate at lower levels in the brains of mdr1- deficient mice and to be 
equipotent with ivermectin in the inhibition of mdr1 efflux (Griffin et al., 2005). 
Selamectin also had a wider safety margin in ivermectin sensitive collies; dogs 
sensitive to 200 µg/kg ivermectin could be safely dosed with a single topical 40mg/kg 
selamectin. The normal recommended dose range for selamectin is a single dose of 6-
12mg/kg per month (Novotny et al., 2000).      
Doramectin and the structurally-related milbemycin nemadectin both inhibited 
MDR1-mediated efflux of rhodamine-123 in the adriamycin- resistant MCF-7/adr 
human breast carcinoma cell line and showed low cytoxicity similar to abamectin, 
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emamectin benzoate and ivermectin, with 8µM doramectin having no effect on cell 
survival as measured in the MTT after 48hr exposure (Gao et al., 2010). 
1.2. ABC Transporters in the Blood-Brain Barrier and CNS 
Exposure to agricultural insecticides including the avermectins has been associated 
with toxicity to the Central Nervous System (CNS). CNS exposure to these agents is 
limited by the activity of efflux transporters expressed at the blood brain barrier 
(BBB), in mammals and in insects that develop resistance to the pesticides. Important 
transporters at the BBB include the multidrug resistance transporter (MDR1), the 
multidrug resistance proteins (MRP 1, 2, 4-6), and breast cancer resistance protein 
(BCRP). These are all members of the ATP-Binding Cassette (ABC) superfamily of 
transporters, that actively transport substrates across biological membranes by binding 
and hydrolysing ATP in conserved intracellular nucleotide binding domains (NBDs) 
(Leslie et al., 2005).  
The low CNS toxicity of the avermectin insecticides in mammals is due to efficient 
elimination from the CNS by MDR1 (Schinkel et al., 1995; Pouliot et al., 1997). 
When MDR1 is absent, as in mutant strains of the mouse (Schinkel et al., 1995; 
Lankas et al., 1997) and collie dog (Mealey et al., 2001), CNS penetration of 
ivermectin increases, leading to symptoms of neurological toxicity including tremors, 
ataxia and coma. A number of polymorphisms of the MDR1 gene, ABCB1, have been 
identified in humans, although there are none so far identified that result in the 
ablation of mdr1 function present in the mouse and collie dog models described 
above. There is conflicting evidence as to whether these mutations affect MDR1 
activity or substrate specificity, however. It is possible that mutations which 
compromise MDR1 function and the interaction of substrates that compete for 
MDR1-transport may increase intracellular concentrations of substrate insecticides, 
leading to increased toxicity in animals and man. Figure 1.2 depicts important 
transporters expressed in the BBB. 
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MDR1 Efflux Transporter  
MDR1 is a well-characterised member of the ABC-transporter superfamily, first 
identified by Juliano and Ling in 1976 as a 170 kDa surface glycoprotein selectively 
expressed on the surface of colchicine-resistant Chinese hamster ovary cells, where 
higher levels of MDR1 expression were associated with increased drug resistance. In 
addition to its overexpression in drug-resistant tumour cells (Korystov et al., 2004), 
MDR1 is constitutively expressed on the apical surface of cells in the lung, liver, 
kidney (Leslie et al., 2005), jejunum, colon, pancreatic ductules, diffusely throughout 
the adrenal gland (Thiebaut et al., 1987), and on the apical surface of capillary 
endothelial cells at the blood-brain and blood-testes barriers (Cordon-Cardo et al., 
1989). Both Thiebaut and co-workers (1987) and Cordon-Cardo et al (1989) proposed 
that the localisation of MDR1 to apical surfaces of excretory compartments and 
barrier sites indicate that it has an important role in removing toxins from these 
tissues, by excreting toxins into the lower gut in bile and by limiting the entry of 
drugs and toxins into sensitive organs such as the brain. MDR1 is a 12-
transmembrane transporter analogous in structure to bacterial multidrug resistance 
transporters with two binding sites with affinity for either Hoechst 33342 or 
rhodamine 123 (Loo & Clarke, 2005; Müller et al., 2007).  
 
MDR1 substrates 
Substrates of MDR1 are structurally diverse hydrophobic molecules of molecular 
weight >300kDa (Leslie et al., 2005), Review; Table 1). Ivermectin was confirmed as 
an mdr1 substrate by Schinkel et al. in 1995.  Pouliot and co-workers showed that the 
steady-state accumulation of [
3
H]-ivermectin was lower in drug-resistant cells than 
drug-sensitive human lymphoma  cells in a similar manner to the known MDR1 
substrate [
3
H]-vinblastine, that the efflux of both drugs was energy-dependent, and 
that this efflux can be inhibited by the presence of cyclosporin A or unlabelled 
ivermectin in molar excess. Schinkel et al., (1995) provided evidence of MDR1-
mediated transport of ivermectin, cyclosporin A and digoxin, in a basal to apical 
direction in bidirectional transfer experiments in porcine kidney epithelial cells 
transfected with human MDR1 or mouse mdr1a. Radiolabelled digoxin and 
cyclosporin A accumulated at significantly higher levels (35-fold and 17-fold, 
respectively) in brains of mdr1a (-/-) null mice than mdr1a (+/+) mice 4 hours after 
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injection. Both drugs were eliminated more slowly from plasma in the mdr1a null 
mice (Schinkel et al., 1995).  Table 1.1 lists selected substrates of MDR1 or mdr1a. 
 
Table 1.1: Selected substrates of human MDR1 and mouse mdr1a. Fluorescent 
substrates are in italics; ‘potent’ = good substrate, ‘medium’ or ‘weak’ as described 
by the research groups. N.B. Cell lines and experimental methods differ between 
research groups. 
 
Compound Reference MDR1 
substrate? 
mdr1a 
substrate? 
Ivermectin Schinkel et al., (1995); Pouliot 
et al., (1997) 
potent potent 
Selamectin Griffin et al., (2005); Geyer et 
al., (2009) 
potent potent 
Abamectin Lankas et al., (1997); Brayden 
& Griffin, (2008) 
potent potent  
cyclosporin a Schinkel et al., 1995  potent potent 
digoxin potent potent 
dexamethasone medium medium 
morphine weak weak 
domperidone medium potent 
phenytoin weak weak 
budipine Uhr et al., (2005) unknown medium 
odansetron Schinkel et al., (1996) medium potent 
loperamide medium potent 
amitryptiline Laika et al., (2006); Uhr et al., 
(2007) 
medium medium 
doxorubicin Bain & LeBlanc, (1996) potent potent 
vinblastine Taub et al., (2005); Jutabha et 
al., (2010) 
potent potent 
vincristine Schaefer et al., (2006); 
Balayssac et al., (2005) 
potent potent 
verapamil Takano et al., (2006); Kodaira 
et al., (2010) 
potent potent 
cypermethrin Sreeramulu et al., 2007 In MDR1 from drug-resistant 
CHO cells endosulfan 
fenvalerate 
methyl parathion 
rhodamine123 Lespine et al., 2007) potent 
Hoechst 33342 Müller et al., (2007); Matsson 
et al., (2009) 
potent 
bodipy-fl-
paclitaxel 
Kimchi-Sarfaty et al., (2007) potent 
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Besides MDR1, other ABC-transporters expressed on the blood-brain barrier are the 
multidrug-resistance proteins (MRPs) 1, 2, 4, and 5, breast cancer resistance-
associated protein (BCRP). These transporters have both distinct and overlapping 
functions and substrates elsewhere in the body, and their co-expression with MDR1 is 
an important consideration when evaluating the transport kinetics of MDR1 substrates 
at the BBB (Leslie et al., 2005; Lespine et al., 2006). Their role in the transport of 
avermectins has not yet been established, although Lespine and co-workers showed 
that ivermectin binds to MRPs 1 and 2.  
MRP Efflux Transporters 
Multidrug resistance related proteins, or MRP transporters, are members of the 
subdivision of the superfamily of ABC-transporters that includes Cystic Fibrosis 
Transmembrane Conductance Regulator (CFTR). MRP1 was first identified in 1992, 
imparting a drug resistant phenotype to a human lung cancer cell line, H69AR, which 
did not overexpress MDR1 (Cole, 1992). MRP transporters 1-9 have distinct but 
heterogeneous distribution, and several isoforms have been found to contribute to 
drug resistance in cells, similarly to MDR1 and BCRP. Mutations in MRP proteins 
can cause disease such as Cystic Fibrosis, anaemia and retinal degeneration (Dallas et 
al. 2006, Review). MRP1, 2, 4 and 5 have been identified in the BBB of human and 
mouse (Leslie et al., 2005; Löscher & Potschka, 2005; Dallas et al., 2006; Miller, 
2010).  Mrp1 is the most highly expressed multidrug resistance protein transporter in 
mouse brain, whereas MRP5 is one of the most highly expressed mRNAs in human 
brain (Klaassen & Aleksunes, 2010 Review). MRP5 transports both endogenous 
substrates such as cAMP and cGMP and folate (McAleer et al., 1999), as well as the 
anti-cancer drug methotrexate (Wijnholds et al., 2000).  Reports have identified 
protein expression of MRP4 and MRP5 on the luminal side of the Blood-Brain 
Barrier endothelium in humans (Bronger et al. 2005) and polarised expression of 
mrp4 on the basolateral membrane of mouse choroid plexus and the apical membrane 
of endothelial cells of the mouse blood-brain barrier which mediated resistance to 
topotecan (Leggas et al. 2004). In addition human MRP4 and MRP5 are expressed in 
subcortical astrocytes and MRP5 in pyramidal neurons (Nies et al. 2004). The mouse 
choroid plexus epithelium expresses mrp1, mrp2 and mrp3 proteins, whereas mouse 
blood-brain barrier expresses mdr1a, mrp1, mrp2 and mrp5 (Soontornmalai et al. 
2006).  
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 A recent report found MRP1 expressed in the choroid plexus epithelium of human 
foetuses from early gestation (22-26 weeks) and in large pyramidal cells of the 
cerebellum in newborns, but, conversely, not in endothelial cells of the blood-brain 
barrier at any age up to adulthood, in contrast to MDR1 and BCRP (Daood et al. 
2008). Mice deficient in mrp1-/-, mdr1a-/- and mrd1b-/- (triple knockout) showed a 
tenfold greater accumulation of etoposide in CSF compared to mdr1a-/-mdr1b-/- 
double knockout (Wijnholds et al. 2000) indicating  that mrp1 has a role in drug 
efflux from CSF in the mouse, albeit with overlapping substrates.  A naturally 
occurring mrp2 deficient rat model, TR
-
, accumulated higher phenytoin 
concentrations in brain tissue than mrp2-expressing rats, suggesting that mrp2 helps 
regulate the entry of phenytoin into the brain (Potschka et al. 2003).  There are 
currently conflicting reports as to the role of MRP/mrp transporters in ivermectin 
efflux (Brayden & Griffin, 2008; Lespine et al. 2007). 
     
 BCRP Efflux Transporters 
BCRP and bcrp mRNA expression has been confirmed in brain microvessel 
endothelial cells forming the luminal surface of the blood-brain barrier in human, rat, 
mouse, pig and cow (Cisternino et al., 2004; Yousif et al., 2007; Warren et al., 2009) 
and protein function; it has been implicated in the efflux transport of mitoxantrone 
and prazosin at the mouse bbb (Kodaira et al., 2010). Bcrp and mdr1a appear to have 
overlapping substrates, since bcrp mRNA expression is up-regulated 3-fold in the 
brain of mdr1a-/- mice (Cisternino et al. 2004). Human BCRP transports H33342 if 
present (Matsson et al., 2009) and has been show to interact with cyclosporin A 
(Gupta et al., 2006) as well as showing the potential to be up-regulated when MDR1 
function is compromised, under conditions of stress e.g. epilepsy, and Alzheimer’s 
Disease (Miller, 2010). Potential roles of BCRP in avermectin handling are dealt with 
further in Chapter 4 discussion.  
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1.3.  Animal sensitivity to avermectins 
Exceptions  to the low toxicity of avermectins in animal models are the mdr1a-/- 
mouse (Schinkel et al., 1994), a subpopulation of CF-1 mice (Lankas et al., 1997) and 
of the Collie dog (Mealey et al., 2001), all of which exhibit symptoms of 
neurotoxicity including tremors, ataxia, coma and death at doses far below those 
considered safe in other animals, and  all lack a functional MDR1/mdr1 efflux 
transporter. A selection of pesticides with different structures have been shown to 
interact with human MDR1 (Bain & LeBlanc, 1996; Sreeramulu et al., 2007), 
including the avermectin insecticides, which are macrocyclic lactones (Lespine et al., 
2007). Bain and LeBlanc (1996) demonstrated that pesticides from different chemical 
classes, differing significantly in structure, can bind to MDR1 and inhibit its efflux 
transport of doxorubicin in B16/F10 mouse melanoma cells transfected with human 
MDR1 (B16/hMDR1).  
In 1994, Schinkel and co-workers provided strong evidence that mdr1a protects the 
brain from exposure to ivermectin and the anti-cancer agent and mdr1 substrate 
vinblastine when they generated homozygous mdr1a (-/-) mice that were viable and 
phenotypically normal except for extreme sensitivity to ivermectin administered 
topically to treat a mite infestation. Mice of both mdr1a (+/+) and (-/-) genotypes 
ingested the ivermectin during grooming. Subsequently only the mdr1a (-/-) mice 
exhibited symptoms of intoxication including immobilisation, recumbency, tremors 
and coma/death, whereas the homozygous mdr1a (+/+) or heterozygous mice were 
not affected (Schinkel et al., 1994). The single gene for MDR1 (ABCB1) in humans 
has two corresponding homologues in mice, mdr1a and mdr1b, which have different 
tissue distributions but together perform all the functions undertaken by MDR1 in 
humans. Mouse mdr1a is predominantly expressed in the blood-brain-barrier, 
intestine, placenta, liver and kidney, whereas mdr1b is distributed in the adrenal 
gland, endometrium, ovary, placenta, liver and kidney (Schinkel et al., 1994, 1995, 
1996; Leslie et al., 2005).  
 
Mice with the genotype mdr1a (-/-) were consistently 50-100-fold more sensitive to 
oral ivermectin than were mdr1a (+/+) mice. Mdr1 was present on the endothelium of 
brain capillaries of mdr1a (+/+) mice and was absent in those of mdr1a (-/-) mice. 
Chapter 1: Introduction  
 
13 
 
Accordingly, accumulation of [
3
H]-ivermectin was 90-fold greater in brain of mdr1a 
(-/-) mice than in that of mdr1a (+/+) mice after 24 hours, and was 8-10-fold raised in 
other tissues including gall bladder and testis. Mice homozygous for the mdr1a null 
mutation were 3-4 fold more sensitive to vinblastine toxicity than mdr1a (+/+) mice 
(Schinkel et al., 1994). These results suggested that mouse brain was protected from 
exposure to ivermectin and vinblastine if mdr1a was present, but did not provide 
direct evidence that it transported these compounds. 
 
Lankas et al. studied CF-1 mice in 1997, of which a subpopulation (c. 25%) were 
approximately 80 -100-fold more sensitive to single oral doses of both abamectin and 
ivermectin than resistant CD-1 mice. Insensitive CF-1 mice could tolerate a single 
dose of 2.5mg/kg abamectin without symptoms, whereas 0.2mg/kg intoxicated 
sensitive CF-1 mice. In 16/17 sensitive mice, no mdr1 was detected in brain by the 
monoclonal antibody C219. The remaining sensitive mouse expressed very low mdr1 
levels in brain but not jejunum. In contrast, a random sample of 17 CF-1 insensitive 
mice all expressed levels of mdr1 in cerebellum and cerebrum comparable to CD-1 
mice, none of which exhibited a toxic response to abamectin or ivermectin. 
Intoxicated CF-1 mice exhibited similar symptoms to mdr1a(-/-) mice (Schinkel et al., 
1994). These results provided further evidence that the activity of mdr1 in vivo in the 
brain protected it from exposure to the avermectins (Lankas et al., 1997). 
  
Based on previous studies noting that ivermectin-sensitive collies accumulate much 
higher levels of ivermectin in brain tissue than -insensitive collies or beagle dogs 
(Daurio et al., 1987), Mealey et al. predicted in 2001 that ivermectin sensitive collies 
might express polymorphic mdr1 at the blood-brain barrier which is altered in either 
its expression level or activity. Sequencing of the mdr1 gene revealed a homozygous 
4 base-pair deletion mutation present in 7/7 ivermectin-sensitive collies but 
heterozygous in 6/6 –insensitive animals. Stop codons were generated early on in the 
mutant sequence, which generated a severely truncated, non-functional mdr1 
transporter. 
These results together strongly suggest that the expression and function of mdr1 at the 
blood-brain barrier is essential to protect mammals from CNS exposure to the 
pesticides ivermectin and abamectin. Wise et al., (1997) found that emamectin 
benzoate causes developmental neurotoxicity in Sprague-Dawley rat pups at high 
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doses of 2.5mg/kg/day administered to the dam from gestational day 6 to lactational 
day 20, with a No Observable Adverse Effect Level (NOAEL) of 0.6mg/kg/day.  
Administration of 3.5/2.5mg/kg/day to mothers from gestational day 6 to lactational 
day 20 was associated with significantly decreased body weight gain in pups 
compared to untreated controls. Hindlimb splay and whole-body tremors were also 
exhibited by this treatment group, whereas placebo-treated controls were unaffected. 
Emamectin benzoate is not used in mammals as much as farmed salmon, with 
administered doses of 50µg/kg per day. However, its interactions in mammalian CNS 
need to be investigated, as new uses for the compound become apparent.   
 
 
1.4. Transport data for avermectins 
 
Lespine et al. (2007) tested the avermectin insecticides ivermectin, abamectin, 
doramectin, eprinomectin, selamectin and the structurally related milbemycin 
moxidectin as putative inhibitors of rhodamine123 dye efflux from porcine kidney 
epithelial cells transfected with either murine mdr1a or human MDR1. The 
cyclosporin A analogue valspodar was used as a positive control and inhibited 
rhodamine123 efflux in mdr1a-transfected but not untransfected cells, IC50 
0.11+0.03µM. All the avermectins inhibited transport of rhodamine 123 in mdr1a-
transfected cells. Abamectin inhibited transport by 83+2%, and ivermectin by 86+2% 
of the effect of valspodar; the compounds returned IC50’s of 0.11+0.01 µM and 
0.44+0.07µM, respectively, proving them relatively potent inhibitors of  the efflux 
transport of rhodamine123. 
 
 The other avermectins had similar effects, but the milbemycin moxidectin was a 
significantly weaker inhibitor with an IC50 of 4.4+0.6µM (Lespine et al., 2007). 
Similar trends were observed in the inhibition of the ATPase activity of MDR1, with 
IC50 values for abamectin and ivermectin at 0.2 and 2.0µM for basal-, and 0.02 and 
0.05µM for verapamil-stimulated ATPase activity, respectively. Abamectin and 
ivermectin were thus shown to be potent modulators of mdr1 activity in vitro in 
LLCK-PK1 mdr1a-transfected cells.  In LLCK-PK1 cells transfected with human 
MDR1, ivermectin inhibited rhodamine123 efflux with an IC50 of 1.0+0.2µM. 
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Griffin et al. (2005) investigated transepithelial transport of ivermectin, selamectin 
and moxidectin across human intestinal epithelial Caco-2 cells. All three were 
transported preferentially in a basolateral to apical direction, although the milbemycin 
moxidectin was a weaker MDR1 substrate than the avermectins, since the secretory 
flux of both ivermectin and selamectin, but not moxidectin, was decreased in the 
presence of the MDR1 inhibitor verapamil (20µM). Ivermectin and selamectin were 
potent inhibitors of rhodamine-123 secretion, with IC50’s  of 0.1µM, whereas the IC50 
for moxidectin of 10.0µM indicates much weaker inhibitory activity (Griffin et al., 
2005).  
As well as being a substrate for MDR1, Lespine et al., (2006), showed that ivermectin 
can inhibit the ATPase activity of MRPs 1, 2 and 3, and is transported by MRP1. 
They suggested that the MRP transporters may influence ivermectin transport as well 
as MDR1. Brayden and Griffin (2008) transfected MDCK canine kidney epithelial 
cell lines with either MDR1, MRP-1 or MRP-2. They found significant basal to apical 
transport of ivermectin and selamectin, similar in all four cell lines including control. 
They detected canine mdr1 expression in all four lines and concluded that this was 
responsible for the transport, which was indeed inhibited by the other MDR1/mdr1 
substrate verapamil, but not by MRP inhibitors. They therefore claimed that MRP 
transporters have negligible influence if MDR1 is expressed. An awareness of the 
influence of transporters other than MDR1 is essential though; SH-SY5Y human 
neuroblastoma cells used in our study are morphologically different from kidney.   
   
1.5. Effects of MDR1 polymorphisms on avermectin exposure in humans and 
cell line studies 
      
MDR1 polymorphisms in humans 
 
A number of single nucleotide polymorphisms (SNPs) of MDR1 have been identified 
in humans by haplotype analysis. Some are synonymous, in which a nucleotide base 
change does not result in an amino acid change, due to the degeneracy of triplet 
codons. Others result in amino acid changes. The severity of the effect of the amino 
acid change on function will be influenced by both the type of substitution and the 
position of the substitution along the sequence; amino acid changes in transmembrane 
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or nucleotide binding domains of MDR1 may have a more drastic effect on function 
than substitutions elsewhere in the sequence (Shilling et al., 2006). 
 
Association studies 
 
In view of the demonstrated importance of MDR1 in protecting the CNS from 
exposure to pesticides and associations of exposure to pesticides other than 
avermectins with adverse health effects, a number of association studies have been 
conducted to investigate whether there is a correlation between polymorphic forms of 
MDR1 and increased risk from pesticide exposure. Risks of significant exposure to 
pesticides are recognised as living in a rural area, drinking drill-well water or being 
occupationally exposed (Droździk et al., 2003). Table 2 lists MDR1 polymorphisms 
genotyped in humans. Lee et al., (2004) examined seven SNPs found by genotyping 
206 Chinese patients with Parkinson’s Disease (PD) and 224 matched normal 
controls. They found that 1236T, 2677T and 3435T were significantly over-
represented in the control group compared to the PD patients. Tan et al., (2005) also 
studied the MDR1 polymorphisms 2677 and 3435 by multiplex sequencing in a case 
control study with 185 PD patients and 206 controls. They found that a haplotype 
containing both  SNPs 2677T and 3435T occurred at significantly lower frequency in 
PD patients than in matched controls (P<0.001), and thus inferred that the 
polymorphisms 2677T with 3435T protect against PD in ethnic Chinese.  
     
Droździk et al., (2003) genotyped Polish patients with PD who had either been 
significantly exposed to pesticides for longer than 10-15 years or not exposed, 
compared to healthy controls. They found a significantly higher incidence of the 
heterozygous 3435T allele in PD patients exposed to pesticides (72.9% of 59 patients) 
than in non-exposed PD sufferers (47.9% of 48 patients), P<0.01. Drodzik and 
colleagues concluded that the risk of developing PD is approx. 5-fold higher in 
carriers of the 3435T allele (heterozygotes and homozygotes) exposed to pesticides 
than in carriers who are not exposed, however, these association studies do not 
specify to which pesticides the individuals have been exposed. The avermectin 
pesticides have not been linked to the development of neurological disorders in this 
way.  
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The data of Drodzik et al. (2003) are in agreement with the observations of  Furuno et 
al., (2002), who performed a case-control association study on 95 Parkinson’s Disease 
(25 early onset, age ≤45 years) patients and 106 controls to assess whether there is a 
link between ‘common’ MDR1 polymorphisms and Parkinson’s Disease (PD). The 
chosen polymorphisms were 3435C>T, 2677G>T/A and -129T>C. Frequency of the 
3535T/T genotype was highest in the early-onset PD group (36.0%), 22.9% in the late 
onset PD group and 18.9% in the control group, but this trend was not statistically 
significant (P=0.08) The frequency of the 3435C/C genotype was conversely highest 
in controls (26.4%) and lowest in early onset PD patients (20.0%), again without 
statistical significance. Together these data suggest that the functional effect of the 
3435T/T MDR1 genotype needs investigating further. Table 1.2 shows selected 
polymorphisms of MDR1 identified by genotyping. 
 
Table 1.2:  Polymorphisms of MDR1 investigated in vivo 
 
SNP/ Haplotype Location Study 
size 
control 
/PD 
Association 
with PD 
Reference 
1236C>T Exon12 224/206 C = PD risk Lee et al., 
2004 2677G/T/A Exon21 G= PD risk 
3435T/C Exon26  C= PD risk 
2677T_3435T e21-e26 206/185 TT= lower 
risk 
Tan et al., 
(2005) 
1236TT_2677TT_3435TT 
vs. CC_CC_CC 
e12_e21_e26 33 healthy 
males 
No effect Takano et 
al., (2006) 
3435T/C Exon26 103/107 T = PD risk Droździk et 
al., (2003) 
3435T/C Exon26 106/95 No significant 
association 
Furuno et 
al., (2002) 2677G>T/A Exon 21  
-129T>C Exon 1b 
3435C>T Exon 26 115/200 
epilepsy 
CC = drug 
resistance 
Siddiqui et 
al., (2003) 
Chapter 1: Introduction  
 
18 
 
The statistical power of all these association studies is limited by their small sample 
size and by the difficulty of examining individual SNPs separately (Macdonald & 
Gledhill, 2007). The polymorphisms need to be examined by functional studies both 
in vivo and in vitro.  
 
 
Functional studies in vivo 
 
To date, the only identified polymorphisms that result in non-functional human 
MDR1 similar to that found in collies is T3587G which causes amino acid 1196 to 
change from isoleucine (non-polar) to serine (polar) and C3583T which results in 
substitution of tyrosine for histidine at amino acid 1195. These substitution mutations 
are located in the Walker B domain of the second ATP binding region of MDR1, and 
I1196S MDR1 was found to be deficient in ATP-binding ability (Mutoh et al., 2006). 
Of 605 Japanese cancer patients analysed, 2 were heterozygous for one or both 
mutations, giving a sample frequency of 0.3% for both polymorphisms. Murine 
fibroblast NIH3T3 cells were stably transfected with T3587G MDR1 that 
corresponded to I1196S substitution, or wild type MDR1, since they express low 
levels of endogenous murine mdr1. Unlike wild type, I1196S-MDR1 was not 
expressed at the cell surface, and was also expressed at a much lower level within the 
cell. NIH3T3 cells transfected with wild type MDR1 were more resistant to 
vincristine by 22-fold and doxorubicin by 7-fold than untransfected control NIH3T3 
cells, whereas I1196S-Pgp transfectants were no more resistant than control. 
Together, these results indicate loss of functional activity in the I1196S mutant, which 
is found at very low frequency (≥0.3% of 605 patients) and only so far in 
heterozygotes (Mutoh et al., 2006). 
 
There is evidence both in support of and contradicting the idea that other identified 
MDR1 polymorphisms have effects on functionality or expression levels. An example 
is the synonymous C3435T polymorphism. When homozygous, C3435T has been 
found to be associated with 2-fold lower MDR1 gene expression and 65-fold lower 
protein expression and to result in higher plasma levels of digoxin, reflecting reduced 
activity of MDR1 in the duodenum (Hoffmeyer et al., 2000). Conversely, Brunner et 
al., (2005) compared ten MDR1 homozygotes for the haplotype (3435T, 1236T and 
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2677T) to ten controls (3435C, 2677G and 1236C) using [
11
C]-verapamil (a known 
MDR1 substrate (Hendrikse et al., 1999)). 
 
Takano et al., (2006) investigated the uptake clearance of [
11
C]-verapamil over time 
by PET in individuals homozygous for haplotypes 1236TT/2677TT/3535TT (20 
volunteers) vs. 1236CC/2677GG/3435CC (13 volunteers, mean age in both groups 23 
years). They injected all subjects with an IV bolus of [
11
C]-verapamil and measured 
radioactivity in brain and plasma for 16 minutes after the injection. They found no 
significant difference in brain/plasma concentrations between the two groups. 
Likewise, uptake clearance from brain was not significantly different at 0.053+0.011 
mL/g/min for the TTT haplotype and 0.051+0.011mL/g/min for the CCC haplotype. 
These results suggest that there is no difference in MDR1 function at the BBB 
between the two haplotypes (Takano et al., 2006). Table 1.3 lists selected in vivo 
studies on functional polymorphisms.  
Chapter 1: Introduction  
 
20 
 
Table 1.3: MDR1 polymorphisms studied in vivo  
 
SNP/Haplotype Location AA Effect Function Reference 
3587T>G Walker B of 
2
nd
 NBD 
1196 
isoleucine 
to serine 
Loss of 
surface 
expression 
Mutoh et al., 
2006 
3435C>T Exon 26 No change Lower 
expression 
in 
duodenum 
Hoffmeyer et 
al., (2000) 
1236TT_2677TT_3435TT 
vs. CC_GG_CC 
e12_e21_e26 A893T/S No effect Brunner et 
al., (2005); 
Takano et 
al., (2006) 
 
Functional studies in vitro  
 
A number of studies have been conducted in epithelial cell lines that express 
endogenous MDR1 at a low level and are then transfected with wild type or 
polymorphic MDR1, which is over-expressed. These studies have been useful for 
assessing functional activity of MDR1 within cells and revealing its interactions with 
individual substrates (Bain & LeBlanc, 1996; Morita et al., 2003; Taub et al., 2005; 
Kimchi-Sarfaty et al., 2007; Gow et al., 2008).  
 
Gow et al., (2008) transiently transfected HEK293T cells with non-synonymous SNP 
variants, reference MDR1 and a nucleotide binding domain (NBD) mutant, and 
measured intracellular accumulation of the established MDR1 substrates BODIPY-
FL-paclitaxel and calcein-AM in the presence or absence of 10µM cyclosporin A. 
Using flow cytometry, they found that intracellular calcein levels were similar to wild 
type for all variants, indicating similar transport activity, except for the NBD mutant, 
which accumulated a 20-fold higher intracellular calcein concentration than reference, 
suggesting compromised activity. The variants N21D, R669C and A893S had slightly 
increased sensitivity to inhibition of calcein transport by cyclosporin A compared to 
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reference at 100% (136+28, 139+43 and 130+22%, respectively). Intracellular 
BODIPY-FL-paclitaxel levels were increased in the A893S and V1251I mutants and 
the (N21D/1236C>T/A893S/3435C>T) haplotype compared to reference at 114+13%, 
118+12% and 124+13% respectively, indicating slightly reduced efflux transport of 
this substrate.  
 
The V1251I mutant and the haplotype N21D/1236C/A893S/3435C>T were 65 +26% 
and 53+8% less sensitive to inhibition of BODIPY-FL-paclitaxel transport, 
respectively, than the wild-type MDR1. Together, these results demonstrate 
alterations in MDR1-mediated transport in cells by the different variants that are 
substrate-specific, assuming, as noted by Gow et al. (2008), that cellular uptake of 
substrate is constant, and that differences in substrate accumulation reflect differences 
in efflux among MDR1 variants.  
 
The idea that the effects of polymorphisms on MDR1 transport are substrate-specific 
suggests that tests with a single substrate, such as 
11
C-verapamil, or calcein-AM, 
would not necessarily highlight defects in structure or function that are relevant to the 
transport of individual substrate pesticides or therapeutic agents. It follows that tests 
for the individual substrates and modulators are required for each MDR1 variant 
(Gow et al., 2008). Of relevance to this concept, a molar excess of verapamil inhibited 
energy-dependent efflux of [
3
H]-ivermectin in vinblastine-resistant human lymphoma 
cells, restoring intracellular ivermectin levels to that of drug-sensitive cells, but did 
not have the same effect on intracellular [
3
H]-verapamil (Pouliot et al., 1997). 
 
 Further support for substrate-dependent effects of polymorphisms came from  
Shilling et al. in 2006, who performed site-directed mutagenesis on amino acids in 
different regions of MDR1, and were able to demonstrate ‘hotspots’ in which 
mutations had a greater effect on transport activity, and that some mutations altered 
the affinity for one substrate but not another. Kimchi-Sarfaty et al., (2007) explored 
effects of the C3435T polymorphism in 2007 and found that, when included in 
haplotypes, it altered MDR1 affinity for verapamil, but not rapamycin. Schaefer et al., 
(2006) assessed MDR1-mediated vincristine transport in High Five insect cells 
transfected with polymorphic variants 893Ala, 893Ser or 893Thr. They found that 
vincristine accumulation was lowest for 893Ala (wild-type) and increased up to 3-fold 
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for the mutants. 893Ser was also less sensitive to inhibition of vincristine transport by 
digoxin than 893Ala or Thr. It is clear from these studies that MDR1 substrates and 
modulators interact in distinct ways, so it is necessary to take into account the effect 
of other therapeutic agents to which the CNS is exposed simultaneously with 
pesticides. Table 1.4 summarises in vitro studies on SNPs in MDR1. 
 
Table 1.4 Selected MDR1 polymorphisms studied in vitro 
 
SNP Location AA 
Effect  
Cell line Transport effect Reference 
61 Exon 2 N21D HeLa None Kimchi-
Sarfaty et 
al., (2007) 
307 Exon 5 F103L 
1107 Exon 10 G369P 
1199 Exon 11 S400N 
2677 Exon 21 A893T/S 
2995 Exon 24 A998T 
61A>G Exon 2 N21D HEK293T Increased 
sensitivity to CSA 
Gow et al., 
(2008)  
1199 Exon 11 S400N No effect 
2005C>T ? R669C 
2677G>T/A  Exon 21 A893S/T S =increased CSA 
sensitivity, T= 
increase in calcein 
transport 
3421T>A ?  S1141T No effect 
3751G>A ? V1251I Increase in calcein 
transport 
2677G/A/T Exon 21  LLC-PK1 No effect Morita et al., 
(2003) 
3435C/T Exon 26 none 
2677G>T/A Exon 21 A893S/T HighFive 
insect cells 
S/T may 
compromise 
vincristine 
clearance 
Schaefer et 
al., (2006) 
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Of further relevance to the substrate specificity of MDR1 transport function proposed 
by Gow et al. (2008), Taub et al. (2005) examined bidirectional transport of the 
MDR1 substrates tritiated paclitaxel, -vinblastine and –digoxin in MDCK cells 
transfected with MDR1, MDCK-wild type and Caco-2 cells. They found that the 
ratios of verapamil-sensitive, MDR1-mediated, basal-apical/apical-basal transport 
ratios were approx 4-fold greater ([
3
H]-paclitaxel), 5-fold greater ([
3
H]-vinblastine) 
and 7-fold greater ([
3
H]-digoxin) in MDCK-MDR1 cells than in MDCK wild type 
controls. Cyclosporin A at 3µM reduced basal-apical apparent permeability (Papp) to 
between 5 and 25% of control for [
3
H]-paclitaxel, [
3
H]-vinblastine and [
3
H]-digoxin, 
in both MDCK-MDR1 and MDCK wild-type cells, in agreement with its 
classification as a potent inhibitor of MDR1.  
 
Notably, ketoconazole and loperamide were both significant activators of transport in 
MDCK-MDR1 cells at 3µM for tritiated vinblastine (164.3+17.2% of control, 
P<0.01) and –digoxin, (124.2+4.1% of control, P<0.05) but not significantly for [
3
H]-
paclitaxel. Both agents conversely inhibited efflux transport at the 10-fold higher 
concentration of 30µM (Taub et al., 2005). Caco-2 cells were also used as a model of 
human intestinal epithelial MDR1-expressing cells, and transport of the tritiated 
substrates was not activated in this cell line by 3µM ketoconazole or loperamide. 
MDCK-MDR1, MDCK wild type and Caco-2 cells demonstrated different 
sensitivities to inhibition of MDR1 transport by quinidine. For example, 10µM 
quinidine inhibited transport of tritiated vinblastine, paclitaxel and digoxin to 25-50% 
of control (P < 0.01) in MDCK wild type cells, but had no significant effect in 
MDCK-MDR1 cells. In Caco-2 cells, 10µM quinidine inhibited tritiated-paclitaxel 
and –digoxin transport to 25-50% of control (P < 0.01), but, conversely, had no effect 
on –vinblastine transport (Taub et al., 2005). These studies suggest that modulator 
concentration- and cell line differences can have effects on MDR1 transport function, 
which highlights the pressing need for functional studies in a cell line representative 
of the human CNS, such as SH-SY5Y (Biedler et al., 1973). 
 
1.6. SH-SY5Y human cells as a model for evaluating neurotoxicity 
 
SH-SY5Y cells are a neuroblastic subclone derived from SK-N-SH cells by Biedler 
and co-workers in 1973.  Parent SK-N-SH cells were isolated from a bone marrow 
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aspiration taken in 1971 from a 4 year-old female neuroblastoma patient (Biedler et 
al., 1973). Differentiated SH-SY5Y cells were resistant to infection by the HIV type-1 
virus (Vesanen et al., 1994). SH-SY5Y cells were successfully differentiated, stained 
and visualised by Price et al., (2006). After retinoic acid-induced differentiation the 
cells produced highly branched neurites. Subsequently dibutyryl cAMP was found to 
induce morphological differentiation in a similar manner to retinoic acid (Kume et al., 
2008). Pioglitazone was used to stimulate the PPARᵞ receptor in SH-SY5Y cells, and 
thereby PPARᵞ activation was implicated in promoting neurite outgrowth (Miglio et 
al., 2009a)  since nanomolar concentrations of the PPARᵞ agonists rosiglitazone and 
pioglitazone prevented neuronal cell death induced by glucose deprivation and 
increased dendrite density in differentiated SH-SY5Y cells (Miglio et al., 2009b). 
 
Differentiation of SH-SY5Y cells with RA resulted in resistance to oxidative stress 
and a decrease in activity of the apoptotic marker caspase-3 compared to 
undifferentiated control cells after exposure to the neurotoxin 6-Hydroxydopamine (6-
OHDA) (Cheung et al., 2009). The environmental pollutant 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCCD) was investigated for its ability to induce a 
neurotoxic response in differentiated SH-SY5Y cells by Jung et al., (2009); these 
researchers found that 5nM TCCD treatment up to 6 hours after retinoic acid 
induction was sufficient to significantly decrease the percentage of “neurite-bearing 
cells” but this effect was no longer significant after 12 or 24 hours.  
 
 As a model cell line to investigate neurotoxicity in their undifferentiated state, SH-
SY5Y cells were subjected to hypoxia and subsequent reoxygenation, after which 
MTT cell proliferation assay returned a drop in the proportion of viable cells to 62% 
of control after 24 hours’ hypoxia  and both mRNA and protein expression for the  
amyloid precursor protein cleavage enzyme BACE1 were upregulated, suggesting a 
mechanistic link between hypoxia and the development of amyloid plaques in 
Alzheimer’s Disease (Li et al., 2010). 
  
1.7. N2a mouse cells as a model for evaluating neurotoxicity 
 
N2a cells were isolated from a brain neuroblastoma in a Strain A albino mouse by 
Klebe and Ruddle (1969). These cells have been used extensively in studies of 
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pesticide toxicity, due to their clear morphological change from an epitheloid 
structure to the expression of a predominance of single, long neurites when grown in 
induction media containing dibutyryl cyclic AMP (Shea et al., 1991; Flaskos et al., 
1998, 1999, 2007). It is widely reported to be easy to image and count, or measure the 
length of these singly-branched neurites. In 1998, Flaskos et al.  incubated N2a cells 
with the organophosphate pesticide tri-o-cresyl phosphate (1 µg/ml) for 24 hours then 
differentiated them for 2 days in serum-free media containing 0.3mM dibutyryl 
cAMP. At the end of this period a significant drop in the number of long (>2 cell 
bodies’) axonal outgrowths was observed in N2a cells that had been pre-treated with 
tri-o-cresyl phosphate compared to control, along with a reduction in the reactivity of 
neurofilament protein, involved in axonal stability. In 1999, Flaskos et al. found 
similar results with the pesticides carbaryl and trichlorphon. 
 
Lawton et al. (2007) investigated the toxicity of methylmercury chloride (1µM) to 
N2a cells, and found a significant (55%) reduction in the percentage of neurite 
outgrowths compared to control after methylmercury treatment for 4 hours during 
differentiation.  The oxon metabolite of the organophosphate pesticide diazinon 
(DZO) was found to reduce the number of axonal processes in N2a cells after 
24hours’differentiation in 0.3mM dibutyryl cAMP and co-treatment with 1, 5 and 
10µM DZO. The same concentrations of DZO reduced acetylcholinesterase activity in 
N2a cells by approximately 60% after 4 hours’ treatment, but this effect was not 
evident after 24 hours (Sidiropoulou et al., 2009).  
 
Importantly, the avermectin derivatives abamectin and doramectin inhibited the 
expression of mdr1a and cytoskeletal proteins, resulting in inhibition of neurite 
outgrowth after 48 hours’ exposure after induction with 0.3mM dibutyryl cAMP (Sun 
et al., 2010) 
 
It is notable that Bates and co-workers found that, while inducing cellular 
differentiation, retinoic acid caused up-regulation of MDR1 mRNA in SH-SY5Y cells 
over a 4-day period (Bates et al., 1989). In order to avoid any fluctuation in 
transporter expression that might be brought about by inducing differentiation, 
cellular assays of mRNA expression, transport and cell proliferation were all 
performed in undifferentiated SH-SY5Y and N2a cells in the current study.  
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1.8. Aims of the study 
 As a prerequisite to understanding the impact of the functional MDR1 
polymorphisms already identified, and those at novel sites to be characterised in 
future, it is important to identify similarities and differences between interactions of 
these avermectins with endogenous human MDR1 and mouse mdr1a, as well as other 
important CNS efflux transporters, to ascertain how useful data from murine models 
can be in predicting the consequences of human avermectin exposure.   
To this end, the current study proposes to test the hypothesis that, excepting the 
abnormal CF-1 and mdr1a-/- knockout mice, the kinetics of avermectin interactions in 
mdr1a- expressing mouse cells are similar to those in MDR1-expressing human cells, 
and data from mouse models can therefore be usefully applied in predictions of 
human CNS toxicity. The current work aimed to characterise transporter expression in 
SH-SY5Y cells to establish their utility cell models. The efflux activity of these cells 
was then compared upon exposure to a known substrate and known inhibitor for each 
transporter type, and the capability of avermectins to inhibit this transport was 
investigated using fluorescent dye retention assays. It was also of interest to quantify 
the toxic dose limits of avermectins for these neuroblastoma cells and to identify 
potential markers of exposure at subtoxic doses. 
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Chapter 2:  Methods 
2.1 Materials  
All plastics for cell culture were Costar by Corning Life Sciences, obtained from Fisher 
Scientific, Loughborough, UK. General cell culture reagents and ingredients for Krebs’ Buffer 
were from Sigma, Poole, UK. Abamectin and Emamectin benzoate were supplied as free 
samples by Syngenta, Bracknell, UK. Ivermectin was bought from ChemService, West Chester, 
PA. Antibodies and other individual reagents are mentioned where applicable in the methods. All 
other reagents were of the highest grade commercially available.   
2.2 Methods 
Cell Culture 
SH-SY5Y Human Neuroblastoma Cells 
SH-SY5Y cells were maintained in high glucose DMEM, supplemented with 2mM L-Glutamine 
(1%), 10% Foetal Calf Serum (FCS) and antibiotics; penicillin (10,000units/ml) and 
streptomycin (10,000µg/ml.) Fresh complete media was used within 4 weeks of being made up. 
Cells were sub cultured every 7 to 9 days. Cell media was removed and cell monolayers rinsed 
twice with a Ca
2+
-free phosphate buffered saline (PBS). Cell monolayers were then incubated in 
a small volume PBS with the addition of 0.02% Trypsin/EDTA for 5 minutes at 37
o
C. Detached 
cells were collected by centrifugation at 1500 rpm for 3 minutes; the pellet was re-suspended in 
media and passed x20 through a wide bore needle to generate a single cell suspension. Cell 
number was assessed using a Coulter Counter Z1™ (Beckman Coulter, Luton, UK.).  Cells were 
seeded onto 96-well plates (Costar) from this culture to achieve 80-90% confluence 3-4 days 
after seeding (approx 30,000 cells/well). Cells were also subcultured after each passage with 1.5 
million cells in a T75 Flask (Costar). Cells were incubated at 37°C in 5% CO2/95% air.  Cells 
were used from passage 29 – 39 and after these 20 passages the cells were replaced from frozen 
stock.  
 
N2a Mouse Neuroblastoma Cells 
N2a cells were maintained in high-glucose DMEM containing 2mM L-glutamine (1%), 10% 
Foetal Calf Serum (FCS), 1mM pyruvate, 0.1% v/v Non-essential amino acids and antibiotics; 
penicillin (10,000units/ml) and streptomycin (10,000µg/ml). Fresh complete media was used 
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within 4 weeks of being made up. Cells were subcultured every 4-6 days by washing twice with 
pre-warmed Ca
2+
-free Phosphate Buffered Saline (PBS), then 2ml of Trypsin/EDTA solution 
was added and incubated for 1-2 minutes.  The Trypsin/EDTA solution was neutralised with 
7.5ml complete growth media. Detached cells were collected by centrifugation at 1500 rpm for 3 
minutes; the pellet was re-suspended in media and passed x20 through a wide bore needle to 
generate a single cell suspension. Cells were counted using a Coulter Counter Z1
TM
 and seeded 
into a fresh flask at 40,000 cells/ cm
2
 (3 million per T75 flask). For each experiment, cells were 
seeded in 96-well plates to achieve 80-90% confluence 3-4 days after seeding (approx 20,000 
cells/well). Cells were incubated at 37°C in 5% CO2/95% air. Cells were used from passage 5-20 
and after these 15 passages the cells were replaced from frozen stock, to avoid overgrowth of the 
epitheloid subpopulation.   
 
Total RNA extraction  
For analysis of constitutive transporter mRNA expression (Chapter 3)  
Cells grown in complete media to subconfluence in T-75 Tissue Culture Flasks were processed 
with the RNeasy Midi Kit (Qiagen, Crawley, West Sussex, UK). RNA concentration was 
analysed and quality confirmed as RNA Integrity Number (RIN) ≥ 8.0 using an Agilent 2100 
bioanalyser for RNA and the RNA 6000 Nano Kit (Agilent Technologies, Cheshire, UK). 
 
For analysis of transporter mRNA expression in avermectin-treated cells (Chapter 6) 
Cells grown in complete media to 80% confluence over 4 days had media removed and replaced 
with media free from FCS, containing treatment solutions at concentrations described in the 
figure legends. Cells were incubated with treatments for 18 hours, after which RNA was 
extracted using the SV Total RNA Isolation System (Promega, Southampton, UK) as per 
manufacturer’s instructions, quantified and quality controlled with RIN ≥ 8.0 using an Agilent 
2100 Bioanalyser, and Agilent RNA 6000 Nano Kit.  
 
End-point and qRT-PCR 
Total RNA obtained from cells over 3 independent passages was reverse-transcribed with oligo 
dT primers and Omniscript RT-Kit (Qiagen, Crawley, UK) or RT enzyme (Promega, 
Southampton, UK) as available. End point PCR was performed to check identity of transporter 
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cDNA using GoTaq Green DNA polymerase and compatible buffers and dNTPs from Promega.  
Custom primers for both end point and qPCR were synthesized and purified by IDT (Glasgow, 
UK).  qRT-PCR experiments were performed using the LightCycler 480 II (Roche, West Sussex, 
UK) and SYBR Green Master Mix (Applied Biosystems, Paisley, UK) according to the 
manufacturer’s protocol. Sequences for gene-specific primers corresponding to PCR targets were 
obtained using Primer Design software (Invitrogen.com) and checked against corresponding 
sequences in the NCBI Genbank database (http://www.ncbi.nlm.nih.gov/genbank/).  Expression 
for individual genes was normalised to expression of the human/mouse GAPDH/gapdh 
housekeeping gene to account for differences in cDNA input concentrations. 
 
qPCR Arrays for endogenous expression of human drug transporters (Chapter 3) and changes 
in expression of selected chemokines in response to avermectin exposure (Chapter 6).  
Control or avermectin treated RNA samples, verified for RNA integrity ≥8.0, were transcribed to 
cDNA using the RT
2
 First Strand kit (SABiosciences). qPCR was performed as per 
manufacturer’s instructions on 2 independent RNA samples for each condition using array plates 
PAHS-070F (human drug transporters) and PAHS-022F (chemokines and receptors) and RT
2 
SYBR Green qPCR Master Mix with the Roche LightCycler 480 II.  
 
Immunocytochemical staining of cells for MDR1/mdr1a protein expression and 
BCRP/bcrp protein expression  
Cell monolayers were grown to confluence in 12-well plates on 13mm coverslips pretreated with 
0.1% poly-L-lysine (Sigma). When they reached 60% confluence, after 3-4 days in culture were 
washed 2x in PBS then fixed in a suitable medium according to the primary antibody used. The 
antibody for MDR1/mdr1a staining, MRK-16 (Kamiya Biomedical Company, USA), required 
fixing in 3% paraformaldehyde (PFA) for 15 min, to avoid disrupting MDR1 structure, whereas 
all other antibodies used (BXP21; BXP9 and C219; AbCam, Cambridge, UK) were suitable for 
fixation in 100% methanol for 5 min. Fixed cells were washed again 3x in PBS, and could be 
stored in PBS at 4ºC overnight. PBS storage buffer was removed from cells and, if cells were 
fixed in PFA, 0.1% Triton X-100 in water (400µl/well) was added. Cells were shaken for 15 
minutes to allow permeabilisation, then washed 3x in PBS.  400ul 3% goat serum diluted in 
sterile PBS was added and the plates shaken for 1 hour to block non-specific binding. 
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Primary antibody (MRK16, human monoclonal anti-MDR1 antibody) was diluted 1:20 or 1:50 in 
goat serum, or BXP-9 (anti- BCRP antibody) or BXP-21 (anti-mouse bcrp were diluted 1:20 or 
1:50 in horse serum) Laboratory parafilm was stretched across a new plate. 50uL primary 
antibody was pipetted onto parafilm for each allotted well then the cell layers on coverslips  were 
placed cell-side down into the antibody solution, in order to maximise binding of antibody in 
minimum volume. The coverslips were incubated overnight at 4ºC. Control coverslips with no 
primary antibody were set up for each condition to detect non-specific binding of the secondary 
antibody; these were incubated in goat serum overnight at 4ºC. 
 
After this time, all coverslips were transferred to fresh wells and washed 3x in PBS, gently 
rocking the plate to cover the cells. The last PBS wash was removed and 400ul 3% rabbit serum 
was added for 1 hour incubation at room temperature. The rabbit serum was then removed and 
coverslips were incubated in a solution of AlexaFluor 488-tagged rabbit-anti-mouse IgG 
secondary antibody against MRK-16 (1:100), or AlexaFluor488-tagged goat-anti-rat IgG 
antibody against BXP-9 and BXP-21 (1:100) and phalloidin (1:250) at 50µl per coverslip for 1hr 
at room temperature in the dark. Phalloidin was used to counterstain the cell membrane by 
binding to the actin cytoskeleton. At the end of this time, coverslips were transferred to new 
wells, washed 3x in PBS as previously and mounted onto slides using Vectashield mounting 
medium. Slides were wrapped in silver foil to protect them from light and stored at 4ºC for 
confocal imaging up to 24 hours later. 
 
The settings on the Leica TCS SP2 UV confocal microscope were FITC excitation 488nm, 
emission 500 - 545 nm; TRITC excitation 543nm, emission 550 – 600 nm. Magnification was 
achieved using a x63 0.5 NA oil immersion lens. Data was analysed using LCS 2.6.1 software 
(Leica Microsystems, GmbH, Heidelberg).  
 
 Assays for Transporter Activity  
Krebs’ Buffer used in Transport and MTT assays  
Krebs; mM: 137 NaCl, 5.4 KCl, 0.99 MgSO4.7H2O, 0.34 KH2.PO4, 0.30 NaH2PO4.2H2O, 10 
Glucose, 10 Hepes, 2.8 CaCl2.2H2O made up to pH 7.4 with Tris base, at 37°C.  
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Assay Principles 
The general principles of the fluorescence dye retention assays are summarized in Figure 2.1. 
Specific assays are described in individual sections. All concentrations of abamectin, emamectin 
benzoate and ivermectin used in the assays were calculated according to the molecular weights 
of the predominant B1a isoform.   
 
Figure 2.1 Principle of fluorescence dye efflux assays with substrate dyes H33342 for 
MDR1/mdr1 and BCRP/bcrp or CMFDA for MRP/mrp efflux transporters. In the absence 
of efflux transporters, dye diffuses through the cell membrane and establishes equilibrium. In an 
intracellular environment the dye becomes fluorescent, either by association with lipid (H33342; 
(Crissman & Steinkamp, 1987) or after cleavage by intracellular esterases and subsequent 
conjugation with gluathione (CMFDA; (Förster et al., 2008) (1). In the presence of functional 
effux transporters for which it is a substrate, fluorescent dye is actively effluxed and intracellular 
fluorescence decreases (2). With the introduction of a competitor, efflux of dye is reduced and 
intracellular fluorescence rises (3). Observed IC50 values are used to measure affinity of the 
receptor for the competitor. 
3 1 
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1 
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H33342 Dye Retention Assay Background (Chapter 4) 
 
The Hoechst 33342 dye retention assay was first used by Lalande, Ling and Miller (1981) as a 
flow cytometric assay, then used as an efflux assay by, among others, Goodell et al (1996) and 
Shapiro & Ling (1997). The Hoechst 33342 dye retention assay measures efflux activity by 
exploiting the affinity of Hoechst 33342 dye (Figure 2.3) for the “H”- binding site on MDR1 
(Shapiro & Ling, 1997). This dye diffuses easily through cell membranes, and in a lipid-rich 
environment inside cells, H33342 becomes fluorescent with excitation spectral maxima at 333nm 
(free dye), 367nm (H33342-dsDNA complex) and 360nm (H33342-poly[A] DNA) and broad 
emission spectra with maxima at  457 nm (free dye), 460nm ( H33342-dsDNA complex) to 
495nm (H33342-poly[A] DNA; Kapunski J. 1990).  In the absence of efflux transporters MDR1 
and BCRP, for both of which H33342 is a substrate, it establishes equilibrium between inter- and 
extracellular environments (Figure 4.1). If MDR1 or BCRP are present, H33342 is also actively 
effluxed from the cell by these transporters, causing a drop in intracellular fluorescence levels. 
This efflux can be inhibited by the introduction of any agent that interferes with the efflux 
activity of the transporters, resulting in an increase in intracellular fluorescence, whether the 
agent inhibits ATPase activity, or is a substrate or blocker of the binding sites (Műller et al, 
2007).     
 
H33342 Dye Retention Assay Method (Chapter 4)   
Cell monolayers grown on 96- well plates to 80-90% confluence were aspirated free from media 
and washed 2x in 200µL Krebs’ buffer warmed to 37ºC, pH 7.4. After removal of the final wash, 
200µL of the appropriate experimental solution was applied to each well. The composition of the 
experimental solution is detailed in the appropriate figure; all solutions within each experiment, 
including the control, contained the same concentration of solvent, ≤0.3%. Monolayers were 
incubated in the experimental solution at 37°C, for 30 minutes, protected from light. After this 
period, the experimental solution was aspirated off and replaced with 200 µl of the same solution, 
containing Hoechst 33342 at a final concentration detailed in the relevant figure legend. Cells 
were incubated with Hoechst 33342 at 37°C for 20 minutes in the absence of light, since 20 min 
was long enough for levels of intracellular H33342 to peak and plateau in two different cell lines 
(Morgan et al. 1989). At the end of this period, cell monolayers were washed 2x, in ice cold 
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Krebs’ buffer. The final wash was aspirated and 200µl Krebs buffer added for reading of cell 
monolayers in 96-well plates in either a Dynex MFX Microplate Fluorimeter (Dynex 
Technologies, Chantilly, VA) or a FLUOstar Omega plate reader (BMG Labtech), according to 
instrument availability. Fluorescence reads for 96-well plates in the Dynatech instrument were 
excitation wavelength 355 ± 20 nm; emission wavelength 460 ± 20 nm and in the Omega 
instrument excitation 355 ± 5 nm; emission 480 ± 5 nm. These were chosen following a study by 
Latt and Stetten (1976); spectral maxima for free H33342 / H33342-DNA were, respectively ex 
340/355 nm, em 510/465 nm.  
 
 
 
Figure 2.2 H33342 chemical structure (from Sigma-Aldrich website, product B2261). 
 
 
 The magnitude of the raw data obtained differed between instruments due to the differences in 
measurement parameters, i.e. halogen lamp in the Dynatech instrument versus xenon flash lamps 
in the Perkin-Elmer and Omega instruments, making it impossible to mean the raw data between 
experiments. See Figures 2.6 and 2.7 for a comparison of the same plate read in the Dynex and 
Omega fluorimeters; differences in signal magnitude between machines did not affect IC50 or Ki 
values obtained (IC50 = 0.22 ± 0.06 µM in Figure 2.5 and 0.20 ± 0.04 µM in Figure 2.6). The 
magnitude of the signal, (Vmax), is also dependent on the number of transporters present and 
therefore differed between experiments, but differences in Vmax should have no influence on Ki 
which is a measure of dissociation constant of the transporter-inhibitor complex and is 
independent of both transporter density and of substrate concentrations used  
(http://www.graphpad.com/curvefit/inhibitors.htm). Experimental solutions containing CSA or 
avermectins at maximal exposure concentrations were read on the instruments; these controls did 
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not quench the fluorescence signal of 1µM H33342 compared to Krebs buffer as a background.  
All solutions contained vehicle (DMSO and/or methanol) to a final vehicle concentration ≤ 0.3%, 
at a consistent concentration within each experiment, to ensure that measured differences in 
intracellular fluorescence were due to the test compounds, rather than solvent. 
  
H33342 dye retention assay data analysis  
Data are expressed as mean ± S.E.M., fitted to a non-linear least-squares regression curve (one-
site binding, hyperbola) to generate IC50 values. IC50 values were converted to Ki values 
according to the Cheng and Prusoff method (Cheng and Prusoff, 1973) using Equation 2.1 given  
below and the mean H33342 EC50 values for MDR1 and mdr1a (Table 4.1). Statistical 
differences were tested using Student’s unpaired t-test or a One-Way ANOVA with Dunnett’s 
post-hoc test as appropriate.  Statistical significance was assessed as or P < 0.05 or lower. 
Analysis was performed using Graphpad Prism 4 software (Graphpad, San Diego, CA, USA). 
 
 Adaptations to H33342 assay used in this study 
The H33342 assay used in this study was decided with reference to Müller et al (2007) after 
observations in the current study that, with three wash steps to remove dye, cells were flushed off 
the surface of the well at the required confluence of >80%. Müller et al (2007) observed that the 
dye retention of Hoechst is comparable whether the dye is added after incubation with putative 
inhibitors, then washed off, or whether it is added to a background well without cells and the 
background fluorescence is subtracted from the reading in the well containing cells, omitting the 
wash steps. Since the neuroblastoma cells used in this study were relatively loosely attached and 
washed off easily, eliminating an extra wash step from the assay prevented the loss of cells, and 
was an advantage; therefore a compromise was adopted. In the current study cells were washed 
twice to remove FCS proteins present in complete media, pre-incubated with inhibitors, then 
1µM H33342 was added for 20 min and washed off twice and the cell sample read, In contrast, 
in the original assay the cells are washed up to 3x and the inhibitor added with no dye, before 
H33342 dye is added and incubated, then a further 3 washes are performed (Műller et al. 2007; 
Goodell et al 1996). Removing a wash step did not significantly affect results in preliminary 
experiments in our laboratory and in experiments by Műller et al. (2007; Figure 2.3).  
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Figure 2.3 “ Concentration–response curves for XR9577 in A2780adr cells obtained with 
the standard Hoechst assay (open circles) and the new Hoechst assay (closed circles). In 
comparison to the standard Hoechst assay, the new Hoechst assay avoids three additional 
washing steps to remove extracellular Hoechst 33342. Data presented are average ± SE from one 
typical experiment with three replicates belonging to a series of three independent experiments: 
standard assay: pIC50 = 6.36 ± 0.07, nH = 2.27 ± 0.26, new assay: pIC50 = 6.49 ± 0.08, 
nH = 1.96 ± 0.53”. Figure and legend from Műller et al., (2007). 
 
Measures of transporter affinity for H33342 in the dye retention assay 
The assay chosen is a competition assay for binding of H33342 to transporters for efflux, with 
and without the presence of a competitor. The competitor used was either CSA or avermectin 
insecticides. The dye retention data was fitted to a One-site binding Hyperbola by nonlinear 
regression analyses and IC50 values were obtained. IC50 values give the concentration of 
competitor required to inhibit H33342 efflux by 50% of the maximum, and therefore cause 50% 
maximal increase in intracellular dye fluorescence. These results are better compared between 
different experiments as Ki (inhibition) values, which are measures of the affinity of the receptor 
for the competitor. Ki values account for differences in the affinity of the individual receptor for 
the substrate (in this case MDR1 and mdr1a) and also for differences in H33342 substrate 
concentration used throughout the test assays. Values representing the affinity of each transporter 
for H33342 are equilibrium dissociation constants, EC50 in Table 4.1 and equation 2.1 below. 
EC50 values give the concentration of H33342 substrate dye that resulted in 50% maximal 
increase in H33342 dye retention. Ki values were converted from IC50 values obtained for each 
competitor, using the Cheng & Prussoff equation (1973) (Equation 2.1 below).and Graphpad 
Prism’s online guide: 
 http://www.graphpad.com/curvefit/one_kind_of_receptor.htm. 
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Equation 2.1 Cheng & Prussoff’s equation (1973) for calculating Ki from EC50 values, to 
take account of differences in affinity for H33342 between transporters. EC50 values for each 
mdr1 receptor were taken from Table 4.1. EC50 is the concentration of substrate ligand required 
to produce 50% maximal increase in efflux transporter activity. IC50 is the concentration of 
inhibitor (for example, CSA or abamectin) required to inhibit this increase in efflux activity by 
50%, and thus cause 50% maximal increase in intracellular fluorescence. 
Inhibition of BCRP/bcrp- mediated H33342 efflux by KO-143  
Although CSA is a known substrate for MDR1, at higher concentrations it can also interact with 
other transporters and in using it as an internal standard in these dye retention experiments, it 
was necessary to identify any BCRP-dependent efflux of H33342 for further investigation. For 
these experiments the BCRP-specific inhibitor KO-143 was used. It is routinely used at 0.1µM 
for effective BCRP inhibition; it has relatively high affinity for inhibition of BCRP, with 90% 
inhibition (EC90) at approx. 25nM (Allen et al, 2002). In this study it was tested over a 
concentration range 0-5µM, including 5µM CSA as standard to compare MDR1 activity. 
 
CMFDA Assay Background (Chapter 5) 
 
CMFDA, 5-chloromethylfluorescein-diacetate, is a non-fluorescent, lipophilic derivative of 
fluorescein, which easily permeates across the cell membrane (Figure 2.4). Inside the cells it is 
cleaved by unspecific esterases forming the fluorescent intermediate 5-chloromethylfluorescein 
(CMF). CMF is hydrophilic and exhibits a very slow permeation across cell membranes. In a 
second step, the chloromethyl group reacts with intracellular thiol groups, predominantly 
glutathione. Glutathione methylfluorescein, GSMF, is produced, which  is much more 
hydrophilic. GSMF is a substrate for MRP2 and is actively excreted out of the cells. Interactions 
of test-compounds with MRP2 result in an increased intracellular fluorescence intensity (Förster 
et al., 2008). 
Ki = .      IC50          . 
    [ligand] .      
                 EC50 
1+ 
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Figure 2.4 Conversion of CMFDA to a fluorescent MRP/mrp substrate by esterases and 
conjugation with glutathione inside cells. Taken from Forster et al., (2008). 
 
 Unlike H33342, the chemical conversion of CMFDA and rapid excretion of GSMF means that 
intracellular fluorescence decays within a relatively short time period after CMFDA exposure; 
approx. 30 min (Forster et al. 2008). This two-step conversion process might explain why the 
relationship between CMFDA concentration and intracellular fluorescence was linear over the 
concentration ranges tested (0 - 1.5 µM in this study; 0 -10 µM by others in our laboratory), 
unlike for H33342 (0 -15 µM) where intracellular fluorescence had begun to plateau by 10 µM.   
 
CMFDA Retention Assay Method (Chapter 5) 
Cell monolayers grown on 96 well plates to 80-90% confluence were aspirated free from media 
and washed 2-3 times in Krebs’ buffer warmed to 37ºC, pH7.4. After removal of the final wash, 
200 µl of the appropriate experimental solution was applied to each well. The composition of the 
experimental solution is detailed in the appropriate figure. Monolayers were incubated in the 
experimental solution at 37°C, for 30 minutes, protected from light. After this period, the 
experimental solution was aspirated off and replaced with 200 µl of the same solution, 
containing CMFDA at a final concentration detailed in the relevant figure legend. Cells were 
incubated with CMFDA at 37°C for 30 minutes in the absence of light. At the end of this period, 
cell monolayers were washed 3 times, in ice cold Krebs’ buffer. The final wash was aspirated 
and 200µl Krebs buffer added for reading of cell monolayers in 96-well plates in a FLUOstar 
Omega plate reader (BMG Labtech, Aylesbury, UK), Fluorescence reads for CMFDA in the 
Omega instrument were excitation 480nm±5nm emission 520nm±5nm. The gain was set at the 
beginning of each experiment for the plate where highest fluorescence was expected and then 
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kept constant throughout the experiment. The gain was consistently set to 4500±250 units 
throughout all experiments. All experimental solutions were read on the instrument compared to 
water background and did not quench the fluorescence signal.  All solutions contained vehicle 
(DMSO and/or methanol) to a final vehicle concentration ≤ 0.3%, at a consistent concentration 
within each experiment, to ensure that measured differences in intracellular fluorescence were 
due to the test compounds, rather than solvent. 
 
CMFDA dye retention assay data analysis   
The readings for cells without dye were subtracted from the raw data and these data were 
normalised to the average of readings for the solvent control, which was taken to be 100%. 
Control (100%) was then substracted and the data were expressed as % increase above control. 
An analysis with nonlinear least squares regression (One-site binding, Hyperbola) was performed 
on Graphpad Prism 4 software up to 6 µM concentration of the avermectins. Above 6µM there 
was a consistent drop-off in intracellular fluorescence for all three avermectins tested, which is 
attributed to cellular toxicity at 7 and 10 µM (See Chapter 6). Hence these concentrations were 
excluded from the analysis, and the Vmax value of curves was constrained to 20% above the 
highest mean value, in order to define the plateau of the curve and obtain IC50 values. It was not 
possible to convert IC50 values for experiments with CMFDA to Ki values, since EC50 values for 
CMFDA were not obtainable due to the linear relationship between CMFDA concentration and 
intracellular fluorescence of GSMF.   
 
MTT Assay Background (Chapter 6) 
 
The MTT assay was initially described by Mossman in 1983 as a method of assessing cell 
viability after exposure to potential toxins. MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide) is a water soluble tetrazolium salt, which is converted to an 
insoluble purple formazan by cleavage of the tetrazolium ring by succinate dehydrogenase within 
the mitochondria. The formazan product is impermeable to the cell membranes and therefore it 
accumulates in healthy cells (Fotakis and Timbrell, 2006). The spectral maximum of the 
formazan salt is altered in the presence of media, so Denizot and Lang (1986) proposed the use 
of phenol red-free media for incubation, and removal of the media before reading the absorbance 
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of formazan produced. The current study avoids this change in spectral maxima altogether, since 
incubation for both the transporter and MTT assays can be performed in Krebs buffer. MTT 
conversion was found to be one of the more sensitive assays after short incubations of 3, 5 and 8 
hours (Fotakis and Timbrell, 2006) and it is also suitable to perform in situ where the cells are 
grown, with the solubilisation of formazan taking place at the end of the assay. As such, the 
MTT assay was chosen as a suitable assay of gross changes in cell proliferation after avermectin 
exposure.  
  
MTT Assay Method (Chapter 6) 
Cell monolayers at 80-90% confluence were aspirated free from growth media, and the 
monolayers were washed twice with 200 µl Krebs’ buffer for 96 well plates. (Krebs; mM: 137 
NaCl, 5.4 KCl, 0.99 MgSO4.7H2O, 0.34 KH2.PO4, 0.30 NaH2PO4.2H2O, 10 Glucose, 10 Hepes, 
2.8 CaCl2.2H2O made up to pH 7.4 with Tris base, at 37°C) To initiate the MTT assay,  Krebs’ 
buffer was removed from each well and replaced with experimengtal solutions dissolved in 
warm Krebs’ buffer; either 200 µl of experimental solution (96 well plates) or 1000 µl of 
experimental solution (24 well plates). Details of the experimental solutions are outlined in the 
appropriate figure legends. All control solutions included the appropriate amount of vehicle 
(DMSO and/or methanol). Total vehicle concentration never exceeded 0.3%. Monolayers were 
incubated with test reagents for 1 hour at 37°C in the absence of light.  
At the end of this period, the experimental solutions were aspirated and replaced with either 
100µl (for 96 well plates) or 750µl (for 24 well plates) of a 1mM MTT solution made up in 
warm Krebs buffer. Monolayers were then incubated in the presence of the MTT at 37°C, for 2 
hours in the absence of light.  
After 2 hours, the MTT solution was aspirated off, and replaced with either 100µl (for 96 well 
plates) or 250µl (for 24 well plates) 100% isopropanol (propan-2-ol). Plates were incubated on a 
shaker for 15 minutes. The formazan product, solubilized by the incubation with isopropanol, 
was quantified at 570 nm using a Dynatech MR5000 plate reader. 
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MTT cell proliferation assay data analysis 
Data are mean ± S.E.M. of n = 24 expressed as % control where solvent control = 100%   and 
analysed by One-Way ANOVA with Dunnett’s post-hoc test as above. Statistical significance 
was assessed as P < 0.05.    
 
Neurite Outgrowth Studies with N2a Cells (Chapter 6) 
 
To measure neurite outgrowth N2a cells were grown on poly-L- lysine coated cover slips n 6 
well plates. Polyglycine coated coverslips were prepared by sterilising glass coverslips with 70% 
ethanol.  After the ethanol evaporated off the coverslips, 200µl polyglycine was added to each 
well containing a cover slip and allowed to evaporate off. Cover slips were then gently washed 
with 200µl PBS. Coverslips were then seeded with N2a cells at a density of 40,000 cells/ well 
and allowed to adhere to the cover slip overnight. After this the cell media was replaced and the 
cells grown to approx 50-60% confluence. At this point the growth media was removed and 
induction media was added (DMEM containing 2mM L-glutamine, 1mM pyruvate, 0.1v/v 
NEAA and 0.3mM cAMP) for 24 hours or 48 hours. Induction media arrested cell proliferation 
and induced differentiation to neurite-expressing cells.    
 
To test the impact of test agents on neurite outgrowth, cells were incubated with the agent under 
test for 1hr at 37
0
C in induction media.  At the end of the test period, the media was removed, the 
cells were rinsed once with 1x PBS and fixed with 0.5ml/well of 100% methanol for 20 mins at -
20
0
C. To visualise neurite outgrowth, microtubules were stained using mouse monoclonal anti-
acetylated tubulin primary antibody (Sigma, Poole, UK) and Alexa Fluor® 488 rabbit anti-
mouse IgG (Invitrogen). Nuclei were visualised using propidium iodide to stain the DNA.   
 
   After cells were lysed with 100% methanol at -20°C, the cells were incubated for 1 hour in the 
presence of 5% BSA to block non specific binding. Cells were then washed three times with 
PBS-Tween buffer before being incubated with the primary antibody, mouse monoclonal anti 
acetylated tubulin antibody (1:1000, Sigma) The primary antibody solution was removed after 1 
hour and cells were washed with PBS-T 3x with intervals of 10 minutes for 30 minutes.  Cells 
were then exposed to the secondary antibody, 20µg/ml Alexa Fluor® 488 rabbit anti-mouse IgG 
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fluorescein isothiocyanate (FITC) for 1.5 hours. The secondary antibody solution was removed 
and the cells washed 3x in PBS-Tween buffer. Propidium Iodide staining was carried out for 30 
seconds at 1µg/ml diluted in PBS tween. Coverslips were then washed 3x in PBS-tween and 
mounted on glass slides using Vectashield (Vector Laboratories, Burlingame, CA) sealed with 
nail varnish and stored at -20°C overnight. 
Visualisation of neurites  
  2-3 fields per treatment were scanned with a Leica TCS SP2 UV confocal microscope using a 
63x 0.5 NA lens and 2CS 2.5 software (Leica Microsystems, GmbH, Heidelberg). An argon 
(488nm) laser was used to excite FITC. Emissions between 510-550nm were collected (FITC 
peak is 520nm). In experiments to assess the impact of avermectins upon neurite outgrowth, 
hydrogen peroxide at 0.1mM for 15 minutes was used a positive control for complete inhibition 
of neural outgrowth in N2a cells.  
SH-SY5Y cells were not suitable for neurite outgrowth analysis as they produced highly 
branched neurites after incubation with cAMP (data not shown).  
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Figure 2.5 Dose-response curve to CSA (0 – 5 µM) in N2a cells to compare reads 
between machines with H33342 dye kept constant at 1µM, read in MRX Fluorimeter. 
Data expressed as mean ± S.E.M. of 6 wells per concentration in a single experiment. Data 
were analysed with nonlinear least squares regression analysis. IC50 in the above experiment 
is 0.22 ± 0.06 µM.  
 
Figure 2.6 Dose-response curve to CSA (0 – 5 µM) in N2a cells to compare reads 
between machines with H33342 dye kept constant at 1µM, read in BMG Labtech 
Omega Multifunction Fluorimeter. Data expressed as mean ± S.E.M. of 6 wells per 
concentration in a single experiment. Data were analysed with nonlinear least squares 
regression analysis. IC50 in the above experiment is 0.20 ± 0.04 µM. 
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Chapter 3 Efflux transporter mRNA and protein expression in SH-SY5Y and N2a cells 
 
3.1 Summary 
 
This section of work aims to verify the selected cell lines as models for studying the effects 
of avermectin exposure by characterising efflux transporter mRNA and protein expression.  
 
I. SH-SY5Y cells were analysed for uptake- and efflux- transporter mRNA 
expression by PCR array, and found to express a panel of transporters similar to 
cells of the human blood-brain barrier and nigrostriatal tract, including the efflux 
transporters MDR1, MDR6 (a mitochondrial transporter), MRP1, MRP4 and 
MRP5, but the fluorescence signal for BCRP was not detected above background 
levels.  
II. In end-point PCR and real time qPCR assays over 3 independent passages, SH-
SY5Y cells expressed mRNA for MDR1 and MRP1, but signals for BCRP were 
not detected above background levels. 
III.  In end point PCR, N2a cells expressed mRNA for mdr1a but not bcrp. 
IV. At the protein level, SH-SY5Y cells immunostained positive for expression of the 
MDR1 protein with the anti-human MDR1 monoclonal antibody MRK-16 but did 
not stain for BCRP using the anti BCRP/bcrp antibody BXP-21.  
V. N2a cells immunostained stained positive for the presence of mdr1 protein with 
MRK-16 but not C219 but did not express bcrp as ascertained with the antibody 
BXP-21. 
 
3.2 Introduction 
 
Role of transporters in protection from neurotoxicity 
 
The efflux transporters MDR1 and mdr1a are important in protecting the human and mouse 
brain, respectively, from toxin exposure. Schinkel et al. demonstrated the essential role of 
mdr1 in protection from ivermectin exposure in 1994 with mdr1a/b (-/-) mice, who were 
much more susceptible to ivermectin toxicity than control mice, developing up to 60% higher 
ivermectin concentrations in the brain. Mdr1a/b knockout mice also accumulated higher 
concentrations of substrates such as vinblastine and digoxin (Schinkel et al. 1994). BCRP/ 
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bcrp is also expressed at the human and mouse blood-brain barrier, along with MRP 1 2, 4 
and 5 (Klaassen & Aleksunes, 2010 Review). Bcrp and mdr1a appear to have overlapping 
substrates, since bcrp expression is up-regulated 3-fold in the brain of mdr1a-/- mice 
(Cisternino et al. 2004).  Mrp1 is the most highly expressed multidrug resistance protein 
transporter in mouse brain, whereas MRP5 is one of the most highly expressed mRNAs in 
human brain (Klaassen & Aleksunes, 2010 Review). MRP5 transports both endogenous 
substrates such as cAMP, cGMP and folate (McAleer et al, 1999), as well as the anti-cancer 
drug methotrexate (Wijnholds et al. 2000). 
     
In mice, important uptake transporters include oct3 and oat3. Oct3 null mice exhibit more 
susceptibility to sodium depletion (Vialou et al., 2004). Also, oct3 null mice accumulate 
higher concentrations of extracellular dopamine in the brain and are more susceptible to 
striatal nerve damage after methamphetamine dosing (Cui et al. 2009 & Klaassen & 
Aleksunes, 2010 Review). Oat3 takes up xenobiotics from cerebrebrospinal fluid to the 
choroid plexus epithelium, and oat3 null mice accumulate lower concentrations of its 
substrate fluorescein (Sweet et al. 2002).  
       
The aim of this part of the study was to identify suitable model cell lines to compare the 
impact of CNS exposure to pesticides in mouse and man. To do this it was necessary to 
ascertain which transporters are expressed in SH-SY5Y and N2a cells, and how closely 
transporter expression in the cell lines resembles that of physiological tissue in the blood-
brain barrier and neurons within the brain.  
 
3.3 Methods 
 
RNA extractions and PCR 
     
For control RNA extractions, cells were grown to subconfluence and total RNA was 
extracted from three independent passages of each cell line after 6-7 days’ growth in SH-
SY5Y cells and 4-5 days’ growth in N2a cells. Samples were reverse transcribed to cDNA as 
described in methods and end-point PCR was performed with appropriate primers (see 
Appendix) to check for successful reverse transcription and presence of the target product 
MDR1/ mdr1a. Since cDNA is transcribed from mRNA and is therefore without introns, the 
two are equivalent, so the cDNA samples directly carry the “message” of expressed mRNA. 
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Primers were designed and verified using Invitrogen online primer design software and 
checked for specificity against sequences on the NCBI database. All positive control PCR 
products used in real-time PCR were identified from end-point PCR products by sequencing 
and alignment with their respective mRNA sequences on the NCBI database 
http://blast.ncbi.nlm.nih.gov/Blast.cgi (data not shown).   
 
Protein expression 
 
To investigate protein expression, cells were grown to 70-80% confluence on coverslips as 
described in methods Chapter 2, then fixed and treated with appropriate primary and 
secondary antibodies and phalloidin counterstain of the actin cytoskeleton.  Fixed and treated 
cells were always visualized within 48 hours to avoid decay of the fluorescent signal.  
 
3.4 Results 
 
To identify and quantitate the expression of MDR1 and other important transporters from 
messenger RNA, 2 strategies were employed. Two total RNA samples from independent 
passages of SH-SY5Y cells were applied to a preset real-time PCR array panel of 84 human 
drug transporters from SABiosciences. A similar panel for the mouse N2a cells was not 
available.  These samples were subsequently analysed for the expression mRNA of key efflux 
transporters by end point PCR then qPCR.   
 
qPCR Array 
 
Figure 3.1 is a series of bar graphs with expression levels of transporters expressed in SH-
SY5Y cells above background levels as detected in the qPCR array. Figure 3.1 A shows that, 
of the ABC binding cassette transporters, mRNA for MDR1 was expressed at the highest 
level, along with MDR6, which is expressed within the cell, on the mitochondrial membrane 
(Krishnamurthy et al. 2006). MRP1, MRP4 and MRP5 mRNA were also expressed. Figure 
3.1 G shows ABC transporters with an expression level below (2
-∆Ct 
) = 0.002 including 
MDR3, MRP3 and MRP6, but BCRP mRNA was not detected above threshold levels.  Other 
notable ABC transporters expressed in both passages above background levels in SH-SY5Y 
cells are ABCD3 and ABCA12.  
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Of drug-transporting members of the SLC family of uptake transporters, including the OAT 
and OATP series, SLC16A1, SLC19A2, SLC29A2, SLC38A2, SLC3A1, SLC7A6,  SLC7A7 
and GLUT1 (SLC2A1) mRNAs are expressed above background levels (Figures 3.1B (higher 
level expression) and 3.1H (low level expression. Of the OATs, only OAT4 is expressed at a 
low level (Figure 3.1H), whereas OATP1A2, OATP3A1 and OATP4A1 are all expressed 
above background levels (Figure 3.1C). Table 3.1 summarises transporter mRNAs expressed 
in the SH-SY5Y cells and how these compare with transporters found at the blood-brain 
barrier or intracerebral neurons.   
 
     
Constitutive efflux transporter expression in SH-SY5Y and N2a cells 
 
Using total RNA samples isolated from cells under normal growing conditions, the 
expression of the key efflux transporters MDR1, MRP1 and BCRP were further assayed in 
both cell lines, initially by end-point PCR and then by quantitative real-time PCR (qPCR).  
 
Figure 3.2 is a representative gel showing the results of end point PCR for MDR1 performed 
on the reverse-transcribed RNA samples from 5 independent extractions of total RNA from 
SH-SY5Y cells, at an annealing temperature of 58ºC, showing that mRNA for MDR1 was 
expressed in all reverse transcribed samples at the expected product size of 82bp. The identity 
of the end-point product of the MDR1 primers was confirmed by sequencing (data not 
shown). 
 
 Figure 3.3 is a representative gel showing the results of end point PCR for mdr1a performed 
on the reverse-transcribed RNA samples from 8 independent extractions of total RNA from 
N2a cells, at an annealing temperature of 55ºC, showing that mRNA for mdr1a was 
expressed in all reverse transcribed samples at the expected product size of 87bp. The identity 
of the end-point product of the mdr1a primers was confirmed by sequencing (data not 
shown). Figure 3.4A shows the results of end-point PCR assays performed with a positive 
cDNA sample from MDCKII-bcrp cells, and a bcrp-negative N2a sample, and Figure 3.4B 
shows a positive sample for gapdh, from mouse N2a- derived mRNA. Thus, both the bcrp 
and gapdh primers work in end-point PCR. The identity of the bcrp product was confirmed 
by sequencing.   
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Independent qPCR assays    
 
SH-SY5Y human cells 
The reverse transcribed control SH-SY5Y cDNA samples from 3 separate passages were 
assayed by qPCR using the BCRP, MDR1 and MRP1 primers, using DNA clones of the 
target product as positive controls (Summarised in Table 3.1). Samples were compared to 
GAPDH expression in parallel. In contrast to the MDR1, MRP1 and GAPDH samples, where 
the Ct values for positive samples are clearly lower than those of the negatives and the 
melting temperatures of the samples match the positive controls closely, the BCRP sample 
products returned high Ct values from 37.62-40.00, which did not differ from the negative 
controls at 37.66-40.00.  In contrast the BCRP clone was successfully detected over its 
standard curve, returning a consistent melting temperature of 75.81.  The BCRP product is 
not expressed above background levels, confirming the PCR array data.  
 
In contrast, mRNA for MDR1 and MRP1 are expressed consistently over the three passages 
tested in qPCR assays. These data have been expressed in Figure 3.5 (MDR1) and Figure 3.6 
(MRP1) as arbitrary concentration units normalized to GAPDH concentration. The Ct reading 
for each product was applied to a standard curve dilution series of 5 from DNA clones of the 
respective PCR products to generate concentration units. It should be emphasized that, since 
the arbitrary concentration values calculated depend on the absolute DNA concentration of 
each original clone, the absolute units for MDR1 are not comparable to those for MRP1; the 
expression of MRP1 is not definitively higher than MDR1, although the clones were diluted 
in the same way. Messenger RNA for both MDR1 and MRP1 is expressed consistently over 
all three control passages tested.    
 
N2a mouse cells 
Similar qPCR assays were conducted for the N2a samples with cDNA samples reverse 
transcribed on 2 independent occasions, using the primers from end-point PCR (Table 3.3).  
Samples assayed for mdr1a returned Ct values that did not differ from negative controls 
(24.61-26.90 versus 23.94 and 29.45, respectively). The same was true for the corresponding 
gapdh assay, so this qPCR was unsuccessful.    
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Protein Expression of MDR1/mdr1a and BCRP/bcrp 
 
Figure 3.7 A and B show live unfixed SH-SY5Y and N2a cells respectively, at x63 
magnification, their plasma membranes stained with FITC-conjugated wheatgerm agglutinin 
to show what the cells look like growing as a sub-confluent monolayer.  Wheatgerm 
agglutinin binds to cell membranes via oligosaccharides containing terminal N-
acetylglucosamine or chitobiose, structures which are common to many serum and membrane 
glycoproteins (Vector Labs product information) without fixation, making it a convenient 
way to visualize the cells in a state representative of that in which the antibody staining and 
transport assays were performed.  
 
 
MDR1 and mdr1 expression 
Figure 3.8 confirms expression of MDR1 protein in SH-SY5Y cells after fixation in 3% 
paraformaldehyde and staining with the anti-MDR1 antibody MRK-16 (1:50) and 
AlexaFluor488-conjugated rabbit anti-mouse IgG (1:250) since the fluorescence of secondary 
antibody bound to primary (A) is above the level of background control without the primary 
antibody (C). The actin cytoskeleton of cells is counterstained by phalloidin (1:450, B and 
D).   
 
MRK-16 was supposed to be human-specific and would not stain mouse mdr1 according to 
the product information, so the MDR1/mdr1 monoclonal antibody C219 was used as an 
alternative to stain N2a cells, since it had been used with success, albeit at relatively high 
concentrations (1:10 or 1:20), to stain mouse and human mdr1 and MDR1 proteins (Thiebaut 
et al. 1987).   
 
Figure 3.9 shows the results of staining N2a cells with C219 antibody (1:20) and AlexaFluor 
488-conjugated rabbit anti-mouse IgG (1:250) secondary. In this case there was no visible 
difference between the primary staining (A) and background control (C). Therefore MRK-16 
staining was used with on the mouse cells. Although there was a high level of non-specific 
background staining (Figure 3.10 C), at a 1:20 dilution MRK-16 returns brighter fluorescence 
than control, indicating expression of mdr1 protein in N2a cells (Figure 3.10A). This ties in 
with the positive end-point PCR results for mdr1a. 
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BCRP and bcrp expression 
Human and mouse BCRP were detected with the antibody BXP-21, reported to be active 
against BCRP/bcrp protein from both species. Since it was expected that the two cell lines 
may be negative for BCRP and bcrp protein, following the PCR results, it was necessary to 
confirm the reactivity of the anti-BCRP/bcrp antibody chosen.  To do this, MDCK-BCRP 
cells were stained with BXP-21 (Figure 3.11). Figure 3.11A shows that, at a 1:50 dilution, 
BXP-21 stained cells show much brighter fluorescence than the background control (Figure 
3.11 C). 
 
Figure 3.12A shows SH-SY5Y cells treated with anti-BCRP antibody BXP-21 (1:20) and 
AlexaFluor488-conjugated rabbit anti-mouse IgG (1:200) plus phalloidin (1:450) The 
fluorescence level of the BXP-21 stained cells appears very slightly above background 
control, suggestive of potentially very low level BCRP protein expression, however this 
would contradict the qPCR results and also, in Chapter 4,, the transport assay data. It is 
concluded that BCRP protein is expressed at a negligible level in SH-SY5Y cells. It is also 
noted that 1:20 is a very high dilution of the primary antibody to use and some non-specific 
binding may be expected.     
 
N2a cells were likewise stained with BXP21 (1:20), shown in Figure 3.13 (A). In accord with 
the findings for mRNA expression, fluorescent signal for BCRP protein was not detected 
above the signal for no primary antibody control (C).  
         
3.5 Discussion 
 
Expression of human drug transporters in qPCR array  
 
The expression of MDR1 and MDR6 in SH-SY5Y cells corresponds to transporters situated 
on the cell membrane (Shapiro and Ling, 1997) and mitochondria (Krishnamurthy et al. 
2006), respectively. The protein expression of MDR1 and MRP1 co-localized with mRNA 
detected in the PCR array. This data parallels results from an identical PCR array performed 
on the human blood-brain barrier cell line hCMEC/D3, which is a lentivirus-mediated co-
transfect of hTERT (human telomerase catalytic unit) and the SV40 T antigen of primary 
isolated human brain endothelial cells (Carl et al. 2010). The hCMEC/D3 cell line is 
considered a potential model of the blood brain barrier since it retains functional 
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characteristics of the human BBB including expression of MDR1, MRP1 and BCRP (Carl et 
al. 2010), similar to SH-SY5Y cells except for the lack of BCRP expression in the latter. 
BCRP is however a key transporter at the blood brain barrier (Carl et al. 2010; Klaassen and 
Aleksunes, 2010) and has been shown to interact with CSA (Gupta et al. 2006). Further to the 
qPCR array results, there was expression of MDR1 and MRP1 in SH-SY5Y cells and mdr1a 
in N2a cells. In contrast, BCRP was absent. The potential of BCRP to influence avermectin 
pesticide distribution needs to be investigated independently, therefore, and the hCMEC/D3 
cell line is a good prospect.  
 
With regard to other key transporters expressed in SH-SY5Y cells, the following have been 
identified: 
ABCD3 encodes a dimeric half-transporter responsible for import of fatty acids and fatty 
acyl-CoAs into the intracellular peroxisome (http://www.ncbi.nlm.nih.gov/gene/5825). 
ABCA12 is implicated in lipid transport; mutations in the gene are associated with the 
congenital skin disorder Harlequin Ichythosis (Kelsell et al. 2005). 
SLC16A1 is a monocarboxlate transporter responsible for the transfer of pyruvate and lactate 
across the plasma membrane. SLC16A2 encodes a transporter of thyroid hormones T3 and 
T4 and is essential to sufficiency of thyroid function 
(http://www.ncbi.nlm.nih.gov/gene/6567).  
SLC19A2 is a high affinity thiamine transporter, mutations in which are associated with 
thiamine deficiency disorder Roger’s syndrome (Guerrini et al. 2005). SLC38A2 codes for a 
high affinity glutamine transporter in neurons within the brain (Blot et al. 2009).  
SLC3A1 is an activator of cysteine, dibasic and neutral amino acid transport expressed in the 
intestine and renal tissue. Mutations are associated with cysteinuria, and several splice 
variants have been identified whose function is unknown (NCBI Gene database –updated 
27.08.2011)     
The SLC7A6 gene codes for a heterodimeric amino acid transporter known as y(+)LAT2, 
implicated in the release of arginine from  a wide variety of cell types in brain, heart, testis, 
kidney, small intestine and parotis (Bröer et al. 2000). 
 
The human Blood-Brain barrier cell line hCMEC/D3 has a very similar expression profile to 
the SH-SY5Y cells; it is noted that OCT1, OCT2 and OAT1-4 were not detected (Carl et al. 
2010), and only OAT4 was detected at low level in SH-SY5Y cells. OAT4 undertakes 
sodium-dependent excretion of toxic organic anions, mainly in the placenta (NCBI Gene 
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database), so its low-level expression in neuronal cell types is unexpected. This could be 
because the origin of the parent cells of SH-SY5Y was not brain but bone marrow (Ross et al. 
1983). 
 
Expression of efflux transporter proteins in SH-SY5Y and N2a cells 
Evidence for MDR1/ mdr1a and BCRP/bcrp mRNA expression is borne out by the protein 
staining, confirming that SH-SY5Y cells express MDR1 protein but not BCRP. N2a cells 
likewise express mRNA for mdr1a and mdr1 protein but not bcrp as ascertained with BXP-
21. Utilisation of the BCRP-transfected MDCKII-BCRP cell line confirmed that the BXP-21 
antibody successfully detected the presence of human BCRP. 
 
 MRK-16 has been used to identify MDR1 distribution in human tissues (Thiebaut et al. 
1987) and both MRK-16 and C219 were used with success to visualize the localization of 
mdr1 in primary and secondary cultures of rat astrocytes (Ronaldson et al. 2004). MRK-16 
was used at a 1:300 dilution, however, and C219 as high as 1:10. The fact that C219 needed 
to be so concentrated to obtain cell labelling is interesting and correlates with the lack of 
C219 cell staining at a 1:20 dilution in this study in mouse N2a cells. It worth noting that 
C219 returned a clear band in Western Blot at a dilution of 1:100 in the same study 
(Ronaldson et al. 2004) and may simply be unsuitable for immunocytochemistry.              
        
The evidence for expression of MRP transporters in SH-SY5Y cells is strong, both from the 
qPCR array and from the independent qPCR assays with primers designed for MRP1. It is 
still necessary to confirm the expression of MRP proteins as appropriate antibodies were not 
available during these studies.  
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 Table 3.1 (A) Summary of Drug Transporters in SH-SY5Y cells, CNS Neurons and the Human 
Blood-Brain Barrier.  
Expression of mRNA for key drug uptake and efflux transporters in SH-SY5Y cells obtained by PCR 
array compared to human CNS neurons and human Blood-Brain Barrier as reported in the literature. 
ND = not detected. 
 
 
 
PCR product SH-SY5Y  cells CNS neurons 
Blood-Brain 
Barrier 
MDR1 Present Present Present 
MDR6 Present ND ND 
MRP1 Present Present Present 
MRP2 ND Present Present 
MRP3 Present Present ND 
MRP4 Present ND Present 
MRP5 Present Present Present 
MRP6 ND ND Present 
OAT1 ND Present ND 
OAT2 ND ND ND 
OAT3 ND Present ND 
OAT4 Present Present ND 
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Table 3.1 (B) Summary of Drug Transporters in SH-SY5Y cells, CNS Neurons and the Human 
Blood-Brain Barrier.   
Expression of mRNA for key drug uptake and efflux transporters in SH-SY5Y cells obtained by PCR 
array compared to human CNS neurons and human Blood-Brain Barrier as reported in the literature. 
ND= not detected. 
 
PCR product SH-SY5Y  cells CNS neurons Blood-Brain 
Barrier 
OCT1 ND ND ND 
OCT2 ND ND ND 
OCT3 ND ND ND 
OATP1A2 Present ND Present 
OATP1B1 ND ND ND 
OATP1B3 ND ND ND 
OATP2A1 ND ND ND 
OATP2B1 ND Present Present 
OATP3A1 Present Present Present 
OATP4A1 Present Present Present 
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 _100bp 
   
   _50bp 
Figure 3.2 End point PCR of SH-SY5Y RNA samples expressing MDR1.  
Total RNA Samples 1-5 from 5 independent passages of SH-SY5Y cells were reverse transcribed to 
cDNA and end-point PCR was performed with MDR1 forward and reverse primers with an annealing 
temperature of 58ºC (see appendix for sequences). The expected product size was 82bp and the product 
identity was confirmed by sequencing (data not shown). Products were run on a 1% agarose gel in 1 x 
TBE at 120V for approximately 1 hour, with the expected PCR product alongside the RT enzyme 
negative control, expected blank (RT Negative). The second diffuse “band” at approx. 25bp is most likely 
a front of the loading gel. Lanes: 1 = Sample 1; 2 = Sample 1 RT negative; 3 = Sample 2; 4 = Sample 2 
RT  negative; 5 = Sample 3; 6 = Sample 3 RT negative; 7 = Sample 4; 8 = Sample 4 RT negative; 9 = 
Sample 5; 10 = Sample 5 RT negative; 11 = water blank; 12 = empty; 13 = empty; 14 = 100-1000bp 
marker. 
.  
 
 
 
 
 
 
 
Lane    1 2 3 4 5 6 7 8 9 10 11 12 13 14 
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Figure 3.3 End point PCR of N2a RNA samples expressing mdr1a. 
 Total RNA Samples 1-8 from 8 independent passages of N2a cells were reverse transcribed to cDNA 
and end-point PCR was performed with mdr1a forward and reverse primers with an annealing 
temperature of 55ºC (see appendix for sequences). Products were run on a 1% agarose gel in 1 x TBE 
at 120V for approximately 1 hour. The expected product size was 87bp and the product identity was 
confirmed by sequencing (data not shown). The additional bands running ahead are due to 
overloading. The sample product (expected 87bp) was run alongside the RT enzyme negative control 
(expected blank). Lanes: 1 =  1000bp marker; 2 = Sample 1 RT negative; 3 = Sample 1; 4 = Sample 2 
RT negative; 5 = Sample 2; 6 = Sample 3 RT negative; 7 = Sample 3; 8 = Sample 4 RT negative; 9 = 
Sample 4; 10 = water blank; 11 = empty; 12 = Sample 5 RT negative; 13 = Sample 5; 14 = Sample 6 
RT negative; 15 = Sample 6; 16 = Sample 7 RT negative; 17 = Sample 7; 18 = Sample 8 RT negative; 
19 = Sample 8.  
Lane    1    2    3    4    5   6   7   8   9 10 11 12 13 14 15 16 17 18 19 
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Figure 3.4 (A) End-point PCR for mouse bcrp with cDNA from MDCKII-bcrp cells and N2a 
cells. 
 Expected product size = 86bp. Figure 3.4A shows the results of end-point PCR assays performed 
with 2 positive cDNA  samples from separate passages of  MDCKII-bcrp cells, confirmed by 
sequencing (Lanes 2, 3), and a bcrp-negative N2a sample (Lane 6). RT negative (lane 5) is a no-
enzyme RT control, expected blank. This data confirms that the mouse bcrp primers are functional in 
end-point PCR, detecting the correct mouse bcrp product from bcrp-expressing cells, and that mouse 
N2a cells do not express this product in end-point PCR.See appendix for bcrp primer sequence.  Lane 
1 = water blank; 2 = MDCKII-brcp sample 1; 3 = MDCKII-bcrp sample 2; 4 = DNA Ladder; 5 = N2a 
sample 1 RT negative; 6 = N2a sample 1 cDNA.  
 
Figure 3.4 (B) End-point PCR for mouse gapdh with cDNA from mouse N2a cells. 
 Expected product size = 140bp using SABiosciences mouse primers for gapdh. Lane 1 = 1000bp 
DNA ladder; 2 = mouse gapdh-positive sample from mRNA isolated from N2a cells; 3 = N2a RT 
negative control, expected blank. As expected, mRNA for gapdh was expressed in the mouse sample 
therefore the chosen gapdh primers are functional in end-point PCR. 
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Figure 3.5 Expression of mRNA for MDR1 from total RNA of SH-SY5Y cells.  
Data shows MDR1 mRNA concentrations normalised to those of GAPDH, derived from the raw Ct 
data given in Table 3.2 and read off a standard curve from clones of GAPDH and MDR1. Samples 1-3 
are from 3 independent passages of cells and each sample was assayed in triplicate.    
 
Figure 3.6 Expression of mRNA for MRP1 in SH-SY5Y cells. 
Data shows MRP1 mRNA concentrations normalised to those of GAPDH, derived from the raw Ct 
data given in Table 3.2 and read off a standard curve from clones of GAPDH and MRP1. Samples 1-3 
are from 3 independent passages of cells and each sample was assayed in triplicate. 
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Figure 3.7 SH-SY5Y and N2a cells grown as an 80% confluent monolayer. 
(A) SH-SY5Y cells and (B) N2a cells, both live and unfixed, were stained with fluorescein-
conjugated wheatgerm agglutinin (1:250) and viewed under a Leica Confocal microscope at x63 
magnification. Wheatgerm agglutinin binds to cell membranes via oligosaccharides containing 
terminal N-acetylglucosamine or chitobiose, structures which are common to many serum and 
membrane glycoproteins (Vector Labs product information). The field chosen is representative of at 
least 3 different fields of view for each cell line. 
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Figure 3.8 SH-SY5Y cells stained for MDR1 protein with MRK-16 antibody. 
 SH-SY5Y cells, shown at x63 magnification, were fixed in 3% PFA, permeabilised in 0.1% Triton 
X-100 and stained for MDR1 protein with (A) MRK-16 anti-MDR1 monoclonal primary antibody 
(1:50) and AlexaFluor488 conjugated rabbit anti-mouse IgG secondary antibody (1:250) and (C) no 
primary antibody control. The actin cytoskeleton is counterstained with phalloidin at 1:450 dilution 
((B) and (D)). The field chosen is representative of at least 3 similar fields of view in each case. Cell 
samples from 3 separate passages were stained and visualised to confirm MDR1 expression status.  
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Figure 3.9 N2a cells stained for mdr1 protein with C219 antibody.  
N2a cells, shown at x63 magnification, were fixed and permeabilised in 100% methanol, then stained 
for mdr1 protein with (A) C219 anti-mdr1 monoclonal primary antibody (1:20) and Alexa-Fluor488 
conjugated rabbit anti-mouse IgG secondary antibody (1:250) and (C) no primary antibody control.  
The actin cytoskeleton of the cells is counterstained with red phalloidin at 1:450 dilution, (B) and (D). 
The field chosen is representative of at least 3 similar fields of view in each case. Cell samples from 3 
separate passages were stained and visualised to confirm mdr1 expression status. C219 antibody at 
1:20 did not stain N2a cells for mdr1.  
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Figure 3.10 N2a cells stained for mdr1 protein with MRK-16 antibody. 
 N2a cells (x20 magnification) were fixed in 3% PFA, permeabilised in 0.1% Triton X-100 and 
stained for mdr1 protein with (A) MRK-16 anti-MDR1 monoclonal primary antibody (1:20) and 
AlexaFluor488 conjugated rabbit anti-mouse IgG secondary antibody (1:250) or (C) no primary 
antibody control.  The actin cytoskeleton is counterstained with red phalloidin (1:450) ((B) and (D)). 
Since C219 antibody did not distinguish mouse mdr1, human MRK-16 antibody was used with some 
success, but non-specific binding was expected and is evident in panel C (no primary antibody). Cell 
samples from 3 separate passages were stained and visualised to confirm mdr1 expression status, and 
images are representative of at least 3 different fields of view in each case. 
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Figure 3.11 MDCKII-BCRP cells stained for BCRP protein by BXP-21 antibody. 
 MDCKII-BCRP cells (x63 magnification) were fixed and permeabilised in 100% methanol and 
stained for BCRP protein with (A) BXP-21 anti-BCRP/bcrp monoclonal primary antibody (1:50) and 
AlexaFluor488 conjugated rabbit anti-mouse IgG secondary antibody (1:250) or (C) no primary 
antibody control.  The actin cytoskeleton of cell membranes is counterstained with red phalloidin at 
1:450 dilution; (B) and (D). The field chosen is representative of at least 3 similar fields of view in 
each case. Cell samples from 3 separate passages were stained and visualised to confirm BCRP 
expression status.  This data confirms that the BXP-21 antibody is correctly detecting its target, in 
BCRP-expressing cells.  
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Figure 3.12 SH-SY5Y cells stained for BCRP protein by BXP-21 antibody. 
 BCRP protein expression in human SH-SY5Y cells was visualised by confocal microscopy at x63 
magnification.  Immunolocalisation of BCRP protein was determined by primary antibody BXP-21 
(1:20) and AlexaFluor488- conjugated rabbit anti-mouse IgG (1:250). BCRP-conjugated fluorescence 
appears slightly higher in test cells (A) than in background control (C), however 1:20 was a very high 
dilution of primary antibody and some non-specific binding may be expected. In agreement with the 
PCR/qPCR data, BCRP expression was detected as negligible or zero in SH-SY5Y cells.  Cell 
membranes were counterstained with red phalloidin diluted 1:450; (B) and (D). Cell samples from 3 
separate passages were stained and visualised to confirm BCRP expression status. 
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Figure 3.13 Mouse N2a cells stained for bcrp protein by BXP-21 antibody.   
Mouse bcrp protein expression in N2a cells was visualised by confocal microscopy at x63 
magnification. Cells were fixed and permeabilised in 100% methanol.  Immunolocalisation of bcrp 
protein was determined by the primary antibody BXP-21 (1:20) and AlexaFluor488- conjugated 
rabbit anti-mouse IgG (1:250). Mouse bcrp was not detected in the N2a cell sample (A) compared to 
no primary antibody background control (C). Cell membranes were counterstained with red 
phalloidin; 1:450, (B) and (D). The field chosen is representative of at least 3 similar fields of view in 
each case. Cell samples from 3 separate passages were stained and visualised to confirm bcrp 
expression status.  
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Summary Conclusions from Chapter 3 
The aim of this chapter was to characterise efflux transporter mRNA and protein expression 
in the chosen cell lines SH-SY5Y and N2a to validate the cells as models to study the effects 
of avermectin exposure. The presented results have shown that the SH-SY5Y cells used 
expressed MDR1 and MRP1 but not BCRP at the mRNA level, along with expression of 
related uptake and efflux transporters that mirror transporters at the human blood-brain 
barrier (BBB); accordingly they were a good model to study BBB transporters. SH-SY5Y 
cells also expressed MDR1 protein but not BCRP. N2a cells expressed mdr1a mRNA and 
protein but not mouse bcrp; they were therefore a good comparative model to study mdr1a 
function.    
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Chapter 4: Measurement of the interaction of avermectin insecticides 
with efflux transporters using the H33342 fluorescent dye retention 
assay 
4.1 Summary 
This section of work set out to characterise the dependence of intracellular accumulation 
of the MDR1 and BCRP substrate H33342 dye upon avermectin exposure and to 
compare kinetics in mouse and human cells for the interactions.    
 
I. Initial experiments demonstrated that both human and mouse neuroblastoma 
cell lines showed a saturable intracellular retention of the fluorescent dye 
H33342 (0-15µM).  In SH-SY5Y cells the Ka for H33342 dye retention was 
10.30 ± 3.12 µM.  In N2a cells the Ka for H33342 dye retention was 5.33 ± 
1.18 µM. Values are mean ± S.E.M. of 4 separate experiments. There were no 
significant differences in the EC50 values for H33342 dye retention between 
cell lines (P > 0.05).  
II. Competitive inhibition of H33342 efflux by Cyclosporin A (CSA, 0-10µM) 
was measured at an H33342 dye concentration of 1µM. Concentration-
dependent increases in intracellular dye retention were found which confirmed 
CSA-sensitive efflux activity in human SH-SY5Y and mouse N2a cells. Ki 
values for the ability of CSA to inhibit MDR1/mdr1a were 1.42 ± 0.29 µM 
(mean ± S.E.M. n = 5) in SH-SY5Y cells and 0.37 ± 0.10 µM (mean ± S.E.M. 
n = 4) in N2a cells (P < 0.05).  
III. Validation assays with the BCRP/bcrp-inhibitor Ko143 up to 1µM 
demonstrated no significant BCRP/bcrp activity above control in either SH-
SY5Y or N2a cell lines, while 5µM CSA confirmed activity of MDR1 and 
mdr1a. In contrast, MDCKII-BCRP transfected cell lines demonstrated 
concentration-dependent sensitivity to Ko143. 
IV. Dose-response curves were obtained for each of the avermectin pesticides 
over the concentration range 0-7µM, at an H33342 dye concentration of 1µM.  
Ki values for abamectin were 0.95 ± 0.08 µM in SH-SY5Y cells and 0.77 ± 
0.25 µM in N2a cells (P > 0.05).  Ki values for emamectin benzoate were 0.60 
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± 0.07 µM in SH-SY5Y and 0.56 ± 0.02 µM in N2a cells (P > 0.05).  Ki 
values for ivermectin were 0.24 ± 0.08 µM in SH-SY5Y cells and 0.18 ± 0.02 
µM in N2a cells (P > 0.05).  All values are mean ± S.E.M. of at least 4 
independent experiments, each experiment having n = 6 wells per condition. 
 
4.2 Introduction 
 
The aim of this section of work was to evaluate the interactions of abamectin, emamectin 
benzoate and ivermectin with efflux transporters expressed by human neuroblastoma SH-
SY5Y cells and mouse neuroblastoma N2a cells and to assess whether there are species 
differences in interactions of efflux transporters with these avermectins between human 
and mouse cell-lines. MDR1/mdr1a activity was measured as inhibition of Hoechst 
33342 (H33342) dye efflux from the cell by CSA.  BCRP/bcrp activity was assessed as 
the KO-143 sensitive component of H33342 dye efflux, since H33342 is also a substrate 
of BCRP/bcrp, and CSA can inhibit BCRP/bcrp activity as well as MDR1/mdr1 (Gupta et 
al, 2006; Matsson et al, 2009). In Chapter 5, the ability of MK-571 to inhibit CMFDA 
dye efflux was used to assess activity of the multidrug resistance proteins (MRP/mrp). 
  
In this chapter, transporter efflux activity was examined over a dye concentration range 
H33342 0-15µM. Dose response curves for the ability of CSA (0-10µM), or abamectin, 
emamectin benzoate and ivermectin (0-7µM) to inhibit H33342 dye efflux in each cell 
line were obtained with an H33342 concentration of 1µM. 5µM CSA was included in all 
experiments as an internal control for inhibition of dye efflux. Data were analysed to 
generate IC50 and Ki values as described in the methods section (Chapter 2).   
 
4.3 Results 
 
H33342 dose-response curves 
A single experiment, representative of three other similar experiments, is shown in Figure 
4.1, in which SH-SY5Y cells were exposed to a range of H33342 dye concentrations (0-
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15µM). There was a concentration-dependent increase in intracellular fluorescence which 
begins to plateau at 10µM H33342, with an EC50 of 9.00 ± 1.00 µM.   
Figure 4.2 depicts a single representative experiment in which N2a mouse cells were 
exposed to a range of H33342 dye concentrations (0-15µM). The concentration-
dependent increase in intracellular dye retention plateaus at 10µM H33342, with an EC50 
of 2.68 ± 0.34 µM.  
The EC50 value for H33342 in SH-SY5Y cells was 10.30 ± 3.11 µM (mean ± S.E.M. n = 
4). In N2a cells the EC50 value for H33342 was 5.33 ± 1.17 µM (mean± S.E.M. n = 4).  
There were no significant differences in mean EC50 values for H33342 dye retention (P > 
0.05) between human and mouse cell lines (Table 4.1 and 4.5). Cells were exposed to a 
range of H33342 dye concentrations to confirm dye efflux and to determine the lowest 
practical dye concentration to use to profile putative efflux inhibitors. 1µM H33342 was 
selected, as it was on the rising section of the curve, to ensure measurable sensitivity to 
inhibitors.  
 
Efflux modulation by Cyclosporin A (CSA) 
Preliminary experiments in SH-SY5Y cells revealed a significant (P < 0.01) 
concentration-dependent increase in intracellular fluorescence at 1µM and 10µM CSA 
treatments (42 + 8 % and 74 + 11 % higher than control, respectively, Figure 4.3). Dose-
response curves for the ability of CSA to increase intracellular H33342 dye retention 
were profiled over the concentration range 0-10µM, at a constant H33342 dye 
concentration of 1µM. Mean Ki values are given in Table 4.2. For IC50  and Ki values see 
Tables 4.6 and 4.7.  
Figures 4.4 and 4.5 show a representative experiment for the inhibition of transporter-
mediated dye efflux by CSA in SH-SY5Y cells. Dye retention by the cells shows 
saturation kinetics with an apparent IC50 of 0.42 ± 0.09 µM.   Analysis of the data from 5 
independent experiments gave an overall IC50 of 1.66 ± 0.33 µM. Conversion of the IC50 
values to Ki gave an apparent Ki of 1.42 ± 0.29 µM (mean ± S.E.M. n = 5). 
 
Figures 4.6 and 4.7 depict a representative experiment for the inhibition of transporter-
mediated dye efflux by CSA in N2a cells. Dye retention by the cells shows saturation 
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kinetics with an apparent IC50 of 0.36 ± 0.05 µM. Analysis of the data from 4 
independent experiments gave an overall IC50 of 0.44 ± 0.13 µM. Conversion of the IC50 
values to Ki gave an apparent Ki of 0.37 ± 0.10 µM (mean ± S.E.M. n = 4). 
Differences between the mean Ki values from each cell line, for dye efflux inhibition, by 
CSA were compared using Student’s t-test (Table 4.2). The Ki for inhibition of H33342 
dye efflux by CSA in mouse N2a cells (0.37 ± 0.10 µM) was significantly smaller than 
that for SH-SY5Y (1.42 ± 0.29 µM; P < 0.05).     
 
Inhibition of BCRP- and bcrp- mediated H33342 efflux by KO-143  
KO-143 was used as a BCRP-specific inhibitor in the H33342 efflux assay in both SH-
SY5Y and N2a cell lines over a concentration range 0-5mM. In four independent 
experiments, represented by the single experiments in Figures 4.8 and 4.9, there was no 
significant inhibition of H33342 efflux by KO-143 in either cell line up to 1µM. The 
apparent significance of the effect at 2.5mM and above in SH-SY5Y cells (P < 0.01) is 
likely due to non-specific inhibition at concentrations far above the Ki for KO-143, which 
is in the sub-micromolar range (Allen et al., 2002; Matsson et al., 2009). In contrast, 
inhibition by CSA (5µM) caused a significant increase in intracellular dye retention 
above control of 215 ± 17 %  and 297 ± 51 %  in SH-SY5Y and N2a cell lines 
respectively (both P < 0.01 versus control), demonstrating a high level of MDR1/mdr1a 
activity in both cell lines where there was no significant activity of BCRP/bcrp. 
  
As validation, MDCKII-BCRP transfected cells demonstrated concentration-dependent 
inhibition of dye efflux by Ko143, (P < 0.01 at 0.3µM Ko143 and above; Figure 4.10) Ki 
values obtained for inhibition of H33342 dye efflux in SH-SY5Y and N2a cells by CSA 
and avermectins therefore reflect MDR1/mdr1a activity rather than BCRP/bcrp activity. 
 
Functional Assay of MDR1 and mdr1a activity in SH-SY5Y and N2a cells exposed 
to avermectins  
 
Dose-response curves for the ability of selected avermectins to increase intracellular 
H33342 dye retention were profiled over the concentration range 0-7µM, at a constant 
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H33342 dye concentration of 1µM.  Mean Ki values were for each avermectin were 
compared between cell lines using Student’s t-test (Table 4.2). 
 
Abamectin 
Over a concentration range 0-7µM abamectin, there were significant concentration-
dependent increases in intracellular dye retention observed in both SH-SY5Y human and 
N2a mouse cell lines. (both P < 0.01  at 5µM abamectin and above).  
 
Figure 4.11 shows an individual experiment in SH-SY5Y human cells, representative of 6 
similar experiments, exposed to a range of abamectin concentrations (0-7µM). There is a 
dose-dependent increase in intracellular fluorescence (P < 0.01 versus control at 7µM 
abamectin). Figure 4.12 shows the same data as a dose-response curve with an IC50 of 
0.75 ± 0.12 µM.     
  
 Figure 4.13 shows a single experiment in N2a mouse cells exposed to a concentration 
range 0-7µM abamectin, representative of 6 similar experiments. There is a dose-
dependent increase in intracellular fluorescence (P < 0.01 versus control at 7µM 
abamectin). The same data is expressed as a dose-response curve in Figure 4.14 with an 
IC50 for abamectin of 1.29 ± 0.21 µM. 
 
In summary, abamectin inhibited H33342 efflux with a Mean Ki of 0.95 ± 0.08 µM for 
human SH-SY5Y cells and 0.77 ± 0.25 µM for mouse N2a cells (both mean ± S.E.M. n = 
6 experiments). There are no significant differences between the human and mouse cell 
lines in mean IC50 or Ki values for inhibition of H33342 efflux by abamectin (P > 0.05; 
Table 4.2). 
      
Emamectin benzoate 
Over a concentration range 0-7µM emamectin benzoate, there were significant 
concentration-dependent increases in intracellular dye retention observed in both SH-
SY5Y human and N2a mouse cell lines (both P < 0.01 at 5µM emamectin benzoate 
versus control). 
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A representative experiment performed in SH-SY5Y cells resulted in a concentration-
dependent increase in intracellular fluorescence (P < 0.01 at 5µM emamectin benzoate; 
Figure 4.15), with an IC50 of 0.65 ± 0.10 µM (Figure 4.16). Figures 4.17 and 4.18 depict a 
like experiment in N2a cells. The concentration-dependent increase in intracellular 
fluorescence reached P < 0.01 versus control at 5µM emamectin benzoate and above, 
giving an IC50 of 0.57 ± 0.08 µM.  
       
To summarise, emamectin benzoate inhibited H33342 efflux with a mean Ki of 0.60 ± 
0.07µM for human MDR1 in SH-SY5Y cells (mean ± S.E.M. n = 6) and 0.56 ± 0.02 µM 
for mdr1a in mouse N2a cells (mean ± S.E.M. n = 5).  There are no significant 
differences between the human and mouse cell lines in IC50 or Ki values for inhibition of 
H33342 efflux by emamectin benzoate (P > 0.05; Table 4.2). 
 
Ivermectin 
Over a concentration range 0-7µM ivermectin, there were significant concentration-
dependent increases in intracellular dye retention observed in both SH-SY5Y human and 
N2a mouse cell lines (both P < 0.01 at 5µM and above versus control).  
The individual experiment in Figure 4.19 shows a concentration-dependent increase in 
intracellular fluorescence in SH-SY5Y cells in the presence of ivermectin, (P < 0.01 at 
5µM ivermectin versus control). The IC50 for the same data in Figure 4.20 is 0.49 ± 0.07 
µM. A parallel experiment for ivermectin in N2a cells also resulted in a concentration-
dependent increase in intracellular fluorescence (P < 0.01 at 5µM ivermectin versus 
control, Figure 4.21). The IC50 for this data is 0.24 ± 0.05 µM (Figure 4.22).   
 
To summarise, ivermectin inhibited H33342 efflux with a Ki of 0.24 ± 0.06 µM in human 
SH-SY5Y cells (mean ± S.E.M. n = 4) and 0.18 ± 0.02 µM (mean ± S.E.M. n = 6) for 
mouse N2a cells. There are no significant differences between the human and mouse cell 
lines in IC50 or Ki values for inhibition of H33342 efflux by ivermectin (P > 0.05; Table 
4.2). 
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4.4 Discussion 
 
A main objective of this study was to ascertain how relevant data obtained in mouse 
models are to understanding the handling of avermectins in humans. Further to the 
positive data on mRNA and protein expression of MDR1/mdr1a in SH-SY5Y human and 
N2a mouse cells (Chapter 3), the data obtained here shows that both cell lines displayed 
sensitivity to the MDR1/mdr1 substrate CSA but not the BCRP/bcrp inhibitor Ko-143, 
and therefore had functionality of MDR1/mdr1a, making them suitable for comparison in 
this study.  
 
Abamectin, emamectin benzoate and ivermectin all inhibited MDR1-mediated H33342 
dye efflux in both SH-SY5Y and N2a cell lines, following Michaelis-Menten-like 
saturating kinetics, where low Ki values equate to high affinity of the inhibitor for the 
transporter. All avermectins had potencies in the low micromolar range, similar to the 
known MDR1 substrate CSA (Ki for CSA in SH-SY5Y cells 1.42 ± 0.29 µM; Ki in N2a 
cells 0.37 ± 0.10 µM). The order of affinities for MDR1 in human SH-SY5Y cells was 
ivermectin (Ki 0.24 ± 0.08 µM) ≥ emamectin benzoate (Ki 0.60 ± 0.07 µM) > abamectin 
(Ki 0.95 ± 0.08 µM). The order of affinities for mdr1a in mouse N2a cells followed a 
similar trend with ivermectin (Ki 0.18 ± 0.02 µM) > emamectin benzoate (Ki 0.56 ± 0.02 
µM) ≥ abamectin (Ki 0.77 ± 0.25 µM). Importantly the human SH-SY5Y and mouse N2a 
neuroblastoma cell lines did not differ significantly in their native MDR1 efflux transport 
profiles in response to exposure to abamectin, emamectin benzoate or ivermectin (P 
>0.05 for all comparisons, Table 4.2). These findings indicate that existing kinetic data 
obtained in mouse models expressing endogenous mdr1a is also applicable to humans. 
This is a useful observation in the light of the ongoing reliance on existing data obtained 
in mouse models such as mdr1a (-/-) or CF-1 mice to predict the effects of human 
exposure (Macdonald & Gledhill, 2007).  
  
Prior to the current work, observations in mouse models in vivo found that ivermectin and 
abamectin accumulate in mdr1-deficient tissues, suggesting that they may be substrates 
for mdr1 (Schinkel et al., 1994; Lankas et al., 1997).  These results suggested that mouse 
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brain was protected from exposure to ivermectin and vinblastine if MDR1 was present, 
but did not study the interaction of these compounds with MDR1 at the cellular level.  
 
Ivermectin was identified as a mdr1 substrate by Pouliot et al., (1997) and Schinkel et al., 
(1995). Pouliot and co-workers showed that the steady-state accumulation of [
3
H]-
ivermectin was lower in drug-resistant cells than drug-sensitive human lymphoma  cells 
in a similar manner to the known MDR1 substrate [
3
H]-vinblastine, that the efflux of both 
drugs was ATP-dependent, and that this efflux could be inhibited by the presence of 
cyclosporin A or unlabelled ivermectin in molar excess. Schinkel et al., (1995) provided 
evidence that MDR1-mediated transport of ivermectin, cyclosporin A and digoxin, in a 
basal to apical direction in bidirectional transfer experiments in porcine kidney epithelial 
cells transfected with human MDR1 or mouse mdr1a (Schinkel et al., 1995).  
 
 In the current study, abamectin, emamectin benzoate and ivermectin all inhibited the 
efflux of H33342 through MDR1 and mdr1a with potency in the low micromolar range, 
similar to that observed with the established MDR1 substrate and inhibitor CSA (Tsuji et 
al., 1993). The current data adds to other evidence that ivermectin is a potent MDR1 
inhibitor (Didier & Loor, 1996) and that ivermectin and the related compound selamectin 
are MDR1 substrates (Geyer et al., 2009). In another in vivo study, both CSA and 
ivermectin concentrations were found to increase in brains of mdr1a (-/-) CF-1 mice 
exposed to 0.2mg/kg ivermectin and 1mg/kg CSA by the oral and iv routes; CSA 
accumulated 10- and 15- fold greater after oral and iv dosing respectively in mdr1a(-/-) 
brains compared to mdr1a(+/+) brains, whereas ivermectin was 70-fold higher in mdr1a(-
/-) than in mdr1a(+/+) brains 24 hours after oral dosing (Kwei et al., 1999). These authors 
account for this difference in drug accumulation in mouse brain tissues as being due to 
the presence or absence of mdr1a at the blood-brain barrier. The in vitro data in the 
current study is in agreement with these observations. Mdr1-mediated H33342 efflux was 
modulated by both CSA and ivermectin in mouse neuroblastoma N2a cells. Similar data 
on the interaction of ivermectin and CSA with mdr1 were obtained in bovine brain 
microvessel endothelial cells, where 1µg/ml CSA or 50ng/ml ivermectin were both found 
to significantly enhance rhodamine-123 uptake compared to control, although the 
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inhibitory effect of ivermectin was prevented in the presence of serum (Rose et al., 1998). 
These authors conclude that “unbound ivermectin is at least an inhibitor” of mdr1 in 
bovine brain endothelial cells. 
 
 Data pertaining to the effect of ivermectin on human MDR1 was obtained by Brayden 
and Griffin (2008) in MDCKII wild-type monolayers or cells transfected with MDR1, 
MRP1 or MRP2.  Brayden and Griffin found an increase in basolateral-to-apical flux of 
tritiated ivermectin and selamectin across monolayers of MDCKII-MDR1 cells compared 
to the other cell lines, and this flux was significantly reduced by the bilateral addition of 
the MDR1 inhibitor verapamil (100µM). This data indicated that both avermectins 
interacted with human MDR1 in an overexpression cell model. However, flux of the 
avermectins across the MRP1-, MRP2- transfected and wild-type cell lines were also 
significantly reduced by the addition of 100µM verapamil, apparently due to the 
background expression of canine mdr1. The use of human cells expressing only 
endogenous levels of human MDR1 in the current study is an advantage since it should 
more closely resemble physiological expression of MDR1 and other ABC transporters in 
human brain cells over a limited number of passages and, because the cells are of human 
origin, background expression of transporters endogenous to a different species does not 
obscure the data obtained for human MDR1.  
 
The current study strengthens the existing evidence that avermectins are MDR1 inhibitors 
by adding emamectin benzoate to the list of likely inhibitors of both human MDR1 and 
mouse mdr1a, and extending the pre-existing data in favour of ivermectin and abamectin 
as inhibitors of human MDR1 (Didier & Loor, 1996; Lespine et al., 2007; Brayden & 
Griffin, 2008) and mouse mdr1a (Schinkel et al., 1994, 1996).    
 
In another in-vitro overexpression system, using the fluorescent MDR1 substrate dye 
rhodamine-123 (rho-123), Lespine et al., (2007) tested the avermectin insecticides 
ivermectin, abamectin, doramectin, eprinomectin, selamectin and the structurally related 
milbemycin moxidectin as putative inhibitors of dye efflux from porcine kidney epithelial 
cells transfected with either murine mdr1a or human MDR1. The IC50 values for 
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abamectin and ivermectin are similar to those obtained in the current study, at 
0.11±0.01µM and 0.44±0.07µM, respectively, proving them potent inhibitors of rho-123 
efflux. The other avermectins had similar effects, but the milbemycin Moxidectin was a  
weaker inhibitor with a IC50 of 4.4+0.6µM (Lespine et al., 2007). When comparing these 
values with the current study, it is noted that the H33342 substrate dye binds to a 
structurally distinct site on MDR1 from that of Rho-123 (Shapiro & Ling, 1997). Hence 
the assays should be regarded as qualitatively different, since the binding sites will likely 
have different affinities for their substrates, so the IC50 values are not directly comparable. 
Calculating Ki values takes account of differences in substrate affinities between 
transporters and different dyes, so overcoming this problem. 
 
Lespine et al., (2006) also used the CSA analogue Valspodar as a positive control to 
inhibit rhodamine-123 efflux in mdr1a-transfected but not untransfected cells with an 
IC50 of 0.11+0.03µM. All the avermectins tested inhibited transport of rhodamine 123 in 
mdr1a-transfected cells. abamectin inhibited transport by 83+2%, and ivermectin by 
86+2% of the effect of Valspodar. Similar trends were observed in the inhibition of 
MDR1 ATPase activity, with IC50 values for abamectin and ivermectin at 0.2 and 2.0µM 
for basal-, and 0.02 and 0.05µM for verapamil-stimulated ATPase activity, respectively. 
Abamectin and ivermectin were thus shown to be potent modulators of MDR1 activity in 
vitro in LLCK-PK1 mdr1a-transfected cells.  In LLCK-PK1 cells transfected with human 
MDR1, ivermectin inhibited rhodamine123 efflux with an IC50 of 1.0+0.2µM. 
  
Griffin et al., (2005) investigated transepithelial transport of ivermectin, selamectin and 
moxidectin across human intestinal epithelial Caco-2 cells. All three were transported 
preferentially in a basolateral to apical direction, although the milbemycin moxidectin 
was a weaker MDR1 substrate than the avermectins, since the secretory flux of both 
ivermectin and selamectin, but not moxidectin, was decreased in the presence of the 
MDR1 inhibitor verapamil (20µM). Ivermectin and selamectin were potent inhibitors of 
rhodamine-123 secretion, with IC50’s  of 0.1µM, whereas the IC50 for moxidectin of 
10.0µM indicates weaker inhibitory activity (Griffin et al, 2005).  
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In the current study, within each cell line there was an apparent rank order of affinities of 
the avermectins tested for inhibition of H33342 efflux through human MDR1 and mouse 
mdr1a. In human SH-SY5Y neuroblastoma cells, the order of affinities is ivermectin > 
emamectin benzoate > abamectin, whereas emamectin benzoate and ivermectin have 
significantly higher affinity than abamectin (P < 0.05 for emamectin and P < 0.01 for 
ivermectin in SH-SY5Y cells (Table 4.3). Affinities for mdr1a in mouse N2a 
neuroblastoma cells follow a similar trend, with ivermectin > emamectin benzoate (P < 
0.05) ≥ abamectin (Table 4.4). This is an interesting observation with respect to the 
neurotoxicities of ivermectin observed in animal models deficient in mdr1; if ivermectin 
is the most potent inhibitor of MDR1 of the three avermectins tested, it may also have the 
greatest impact upon cells when its function is inhibited or impaired. It is interesting to 
look at whether this relatively high affinity of ivermectin for MDR1 compared to 
emamectin benzoate or abamectin has any other impact on efflux transport or cell health. 
This idea has been explored in Chapter 6.     
 
Potential role of other transporters in avermectin handling 
  
Data obtained in this study on mRNA and protein expression of BCRP/bcrp (Chapter 3) 
indicates that it is not expressed in human SH-SY5Y or mouse N2a cells, and the absence 
of functional response to the BCRP/bcrp inhibitor KO-143 substantiates this observation. 
The expression of human BCRP and mouse bcrp at the blood-brain barrier of the 
respective species has been well documented (Eisenblätter et al., 2003; Cisternino et al., 
2004; Weksler et al., 2005; Ek et al., 2010), and bcrp protein expression was up-
regulated in the brain of mdr1a(-/-) knockout mice, indicating a potential compensatory 
mechanism (Cisternino et al., 2004).  CSA has been identified as an inhibitor but not a 
substrate for human BCRP in stably transfected HEK-293 cells (Gupta et al., 2006), with 
an IC50 value of 4.3±1.9µM, but Geyer et al (2008) found that bcrp(-/-) mice did not 
accumulate ivermectin or Selamectin in brain tissue in vivo compared to wild-type mice, 
whereas mdr1a/b(-/-) mouse brain accumulated 60x higher ivermectin concentrations; 
these authors suggest that bcrp is therefore not an important efflux carrier for ivermectin 
or Selamectin at the mouse blood-brain barrier in vivo compared to mdr1a. Conversely, 
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Jani et al., (2010) measured H33342 efflux in cells transfected with human BCRP and 
found that ivermectin inhibited cellular efflux and ATPase activities of BCRP with IC50 
values of  1.0- and 1.68µM respectively. Taken together this evidence is not conclusive 
as to the importance of BCRP/bcrp. It is possible that, in situations where P-gp activity is 
impaired, BCRP/bcrp efflux activity could become important in limiting avermectin 
accumulation.  Since human BCRP and mouse bcrp were not present in the cell lines 
studied, further work is still required to assess their contribution to the efflux of 
avermectin insecticides in the CNS in humans and in mice. 
 
In contrast to BCRP, mRNA level expression of MRP transporters by SH-SY5Y cells 
was observed in this study (Chapter 3) and there is existing evidence to suggest either 
that MRP transporters do interact with ivermectin (Lespine et al., 2006), or do not 
(Brayden & Griffin, 2008). As well as being a substrate for MDR1, Lespine et al., (2007) 
showed that ivermectin can inhibit the ATPase activity of MRPs 1, 2 and 3 with different 
affinities, and is transported by MRP1. They suggested that, as well as MDR1, the MRP 
efflux proteins may influence ivermectin transport. In contrast, Brayden and Griffin 
(2008) found significant basal to apical transport of ivermectin and selamectin, in both 
MDCK wild-type and MDCK-MDR1, -MRP1 and -MRP2 transfected cell lines. They 
concluded that background canine mdr1 expression in all four lines masked transport by 
the transfected proteins. Transport was indeed inhibited by the MDR1/mdr1 substrate 
verapamil, but not by MRP inhibitors. It was therefore claimed that the MRPs have 
negligible influence if MDR1 is expressed. An awareness of the influence of transporters 
other than MDR1 is essential though; SH-SY5Y human neuroblastoma cells used in our 
study are morphologically different from kidney. In the light of this conflict we set out to 
explore the function of MRP transporters in human and mouse cells in Chapter 5.           
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Figure 4.1 Hoechst 33342 dose-response curve (0 - 15 µM) in SH-SY5Y cells. 
 The data above are mean ± S.E.M. n = 6 wells per concentration from a single experiment 
representative of 4 experiments, analysed by nonlinear least squares regression with an EC50 of 9.00 ± 
1.00 µM (R2=0.98). The other individual experiments in SH-SY5Y cells generated EC50 values for 
H33342 retention of 18.30 ± 12.90 µM, 10.67 ± 1.98 µM, and 3.18 ± 0.48 µM, giving an EC50 of 
10.30 ± 3.11µM (mean ± S.E.M. n = 4).   
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Figure 4.2 Hoechst 33342 dose-response curve (0-15µM) in N2a cells.  
The data above are mean ± S.E.M. n = 6 wells per concentration from a single experiment 
representative of 4 experiments, analysed by nonlinear least squares regression with an EC50 of 2.68 ± 
0.34 µM (R2=0.95). The other individual experiments generated EC50 values for H33342 retention of 
6.97 ± 2.09 µM, 4.07 ± 1.48 µM and 7.60 ± 1.70 µM, giving an EC50 of 5.33 ± 1.17 µM (mean ± 
S.E.M. n = 4).   
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Figure 4.3 Hoechst 33342 dye efflux assay to determine CSA-sensitive transporter expression in 
SHSY5Y cells at least 1 day after seeding.  
Data is mean ± S.E.M. of n = 6 wells per concentration from a single experiment representative of 4 
independent experiments, analysed by One-Way ANOVA with Dunnett’s post-test; At 1µM CSA, the 
increase in intracellular fluorescence was 42 ± 8 % and at 10µM CSA was 74 ± 11 %; *P<0.05; 
**P<0.01 versus control.  
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Figure 4.4 Dose-response for the ability of CSA (0-10µM) to inhibit transporter-mediated efflux 
of 1µM H33342 in SH-SY5Y cells. 
Data are mean ± S.E.M. n = 6 wells per concentration from a single experiment, representative of 4 
independent experiments, analysed by One-Way ANOVA with Dunnett’s post-test; 
*P<0.05;**P<0.01 versus control. Owing to apparent, variable cytotoxicity at 7-10 µM CSA, 5µM 
CSA was used as a positive control standard in all further assays.  
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Figure 4.5 Dose-response curve for the ability of CSA (0-10µM) to inhibit transporter-mediated 
efflux of 1µM H33342 in SH-SY5Y cells. 
 Data are mean ±S.E.M. n = 6 wells per concentration from a single experiment representative of 4 
independent experiments, analysed with non-linear least-squares regression. The IC50 of the above 
curve is 0.42 ± 0.09 µM (R2=0.77). The other individual experiments generated IC50 values of 2.02 ± 
0.20 µM, 2.32 ± 0.30 µM, 1.82 ± 0.48 µM, and 1.73 ± 0.19 µM, giving a mean IC50 of 1.66 ± 0.33 
µM and Ki of 1.42 ± 0.29 µM (mean ± S.E.M. n  = 5).  
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Figure 4.6 Dose-response curve for the ability of CSA (0-10µM) to inhibit transporter-mediated 
efflux of 1µM H33342 efflux in N2a cells. 
 Data are mean ±S.E.M. n = 6 wells per concentration from a single experiment representative of 4 
independent experiments, analysed with One way ANOVA and Dunnett’s post test; * P<0.05, 
**P<0.01 versus control. Owing to apparent, variable cytotoxicity at 7-10 µM CSA, 5µM CSA was 
used as a positive control standard in all further assays.   
 Chapter 4: H33342 Efflux transporter assay: Figures                                       A M Dalzell 
87 
 
0.
0
2.
5
5.
0
7.
5
10
.0
0
10
20
30
CSAmM
H
3
3
3
4
2
 F
lu
o
re
s
c
e
n
c
e
 (
4
6
0
n
m
)
 
Figure 4.7 Dose-response curve for the ability of CSA (0-10µM) to inhibit transporter-mediated 
H33342 efflux in N2a cells, with an H33342 concentration of 1µM.  
Data are mean ±S.E.M. n = 6 wells per concentration from a single experiment representative of 4 
independent experiments, analysed with non-linear least-squares regression. The IC50 of the above 
curve is 0.36 ± 0.05 µM (R2 = 0.88). The other individual experiments generated IC50 values of 0.39 ± 
0.10 µM, 0.22 ± 0.06 µM and 0.80 ± 0.40 µM, giving a mean IC50 of 0.44 ± 0.13 µM and Ki of 0.37 ± 
0.10 µM (mean ± S.E.M. n = 4).   
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Figure 4.8 Dose-response curve for the ability of KO-143 (0-5µM) to inhibit BCRP-mediated 
efflux of 1µM H33342 in SH-SY5Y cells.  
Data are mean ±S.E.M. n = 6 wells per concentration from a single experiment representative of 4 
independent experiments. Data were analysed by One way ANOVA and Dunnett’s post test; * 
P<0.05; **P<0.01 versus control.  
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Figure 4.9 Dose-response curve for the ability of KO-143 (0-5µM) to inhibit bcrp-mediated 
efflux of 1µM H33342 in N2a cells. 
 Data are mean ±S.E.M. n = 6 wells per concentration from a single experiment representative of 4 
independent experiments, Data were analysed by One way ANOVA and Dunnett’s post test; * 
P<0.05; **P<0.01 versus control.  
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Figure 4.10 Dose-response curve for the ability of KO-143 (0-5µM) to inhibit BCRP-mediated 
efflux of 1µM H33342 in MDCKII-BCRP cells. 
 Data are mean ± S.E.M. n = 6 wells per concentration from a single experiment representative of 2 
independent experiments. Data were analysed by One way ANOVA and Dunnett’s post test; * 
P<0.05; **P<0.01 versus control.  
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Figure 4.11 Dose-response curve for the ability of abamectin (0-7µM) to inhibit MDR1-
mediated efflux of 1µM H33342 in SH-SY5Y cells. 
 Data are mean ±S.E.M. n = 6 wells per concentration from a single experiment representative of 4 
independent experiments, Data were analysed with One way ANOVA and Dunnett’s post test; * 
P<0.05, **P<0.01 versus control.   
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Figure 4.12 Dose-response curve for the ability of abamectin (0-7µM) to inhibit MDR1-
mediated efflux of 1µM H33342 in SH-SY5Y cells.  
Data are mean ±S.E.M. n = 6 wells per concentration from a single experiment representative of 4 
independent experiments, analysed with non-linear least-squares regression. The IC50 of the above 
curve is 0.77 ± 0.11 µM (R
2
 = 0.77). The other individual experiments generated IC50 values of 0.85 ± 
0.17 µM, 1.34 ± 0.32 µM, 0.95 ± 0.15 µM, 1.19 ± 0.25 µM and 1.18 ± 0.36 µM, giving a mean IC50 
of 1.05 ± 0.09 µM and  Ki of 0.95 ± 0.08 µM (mean ± S.E.M. n = 6).  
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Figure 4.13 Dose-response curve for the ability of abamectin (0-7µM) to inhibit mdr1a-mediated 
efflux of 1µM H33342 in N2a cells. 
 Data are mean ±S.E.M n = 6 wells per concentration from a single experiment representative of 4 
independent experiments, Data were analysed with One way ANOVA and Dunnett’s post test; * 
P<0.05, **P<0.01 versus control.  
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Figure 4.14 Dose-response curve for the ability of abamectin (0-7µM) to inhibit mdr1a-mediated 
efflux of 1µM H33342 in N2a cells. 
 Data are mean ± S.E.M. n = 6 wells per concentration from a single experiment representative of 4 
independent experiments, analysed with non-linear least-squares regression. The IC50 of the above 
curve is 1.29 ± 0.21 µM. (R²=0.87). The other individual experiments generated IC50 values of 1.35 ± 
0.39 µM, 0.21 ± 0.08 µM, 1.94 ± 0.60 µM, 0.43 ± 0.12 µM and 0.23 ± 0.10 µM giving a mean IC50 of 
0.91 ± 0.29 µM and Ki of 0.77 ± 0.25 µM (mean ± S.E.M. n = 6).  
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Figure 4.15 Dose-response curve for the ability of emamectin benzoate (0-7µM) to inhibit 
MDR1-mediated efflux of 1µM H33342 in SH-SY5Y cells. 
 Data are mean ± S.E.M.  n = 6 wells per concentration from a single experiment representative of 4 
independent experiments, analysed with One way ANOVA and Dunnett’s post test; * P<0.05, 
**P<0.01 versus control.   
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Figure 4.16 Dose-response curve for the ability of emamectin benzoate (0-7µM) to inhibit 
MDR1-mediated efflux of 1µM H33342 in SH-SY5Y cells.  
Data are mean ± S.E.M. n = 6 wells per concentration from a single experiment representative of 4 
independent experiments, analysed with non-linear least-squares regression. The IC50 of the above 
curve is 0.65 ± 0.10 µM (R2 = 0.87). The other individual experiments generated IC50 values of 0.75 ± 
0.09 µM, 0.78 ± 0.11 µM, 0.38 ± 0.09 µM, 0.86 ± 0.31 µM and 0.51 ± 0.12 µM, giving a mean IC50 
of 0.66 ± 0.07 µM and  Ki of 0.60 ± 0.07 µM (mean ± S.E.M. n = 6).  
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Figure 4.17 Dose-response curve for the ability of emamectin benzoate (0-7µM) to inhibit 
mdr1a-mediated efflux of 1µM H33342 in N2a cells.  
Data are mean ± S.E.M. n = 6 wells per concentration from a single experiment representative of 4 
independent experiments, analysed with One way ANOVA and Dunnett’s post test; * P<0.05, 
**P<0.01 versus control.   
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Figure 4.18 Dose-response curve for the ability of emamectin benzoate (0-7µM) to inhibit 
mdr1a-mediated efflux of 1µM H33342 in N2a cells. 
 Data are mean ± S.E.M. n = 6 wells per concentration from a single experiment representative of 4 
independent experiments, analysed with non-linear least-squares regression. The IC50 of the above 
curve is 0.57 ± 0.08 µM (R2=0.92). The other individual experiments generated IC50 values of 0.68 ± 
0.16 µM, 0.72 ± 0.22 µM, 0.64 ± 0.28 µM and 0.70 ± 0.26 µM, giving a mean IC50 of 0.66 ± 0.03 µM 
and Ki of 0.56 ± 0.02 µM (mean ± S.E.M. n = 5).  
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Figure 4.19 Dose-response curve for the ability of ivermectin (0-7µM) to inhibit MDR1-
mediated efflux of 1µM H33342 in SH-SY5Y cells. 
 Data are mean ±S.E.M. n = 6 wells per concentration from a single experiment representative of 4 
independent experiments, analysed with One way ANOVA and Dunnett’s post test; * P<0.05, 
**P<0.01 versus control.   
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Figure 4.20 Dose-response curve for the ability of ivermectin (0-7µM) to inhibit MDR1-
mediated efflux of 1µM H33342 in SH-SY5Y cells.  
Data are mean ±S.E.M. n = 6 wells per concentration from a single experiment representative of 4 
independent experiments, analysed with non-linear least-squares regression. The IC50 of the above 
curve is 0.50 ± 0.07 µM (R2=0.88). The other individual experiments generated IC50 values of 0.22 ± 
0.05 µM, 0.23 ± 0.08 µM and 0.11 ± 0.05 µM, giving a mean IC50 of 0.27 ± 0.08µM and Ki of 0.24 ± 
0.08 µM (mean ± S.E.M. n = 4).  
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Figure 4.21 Dose-response curve for the ability of ivermectin (0-7µM) to inhibit mdr1a-
mediated efflux of 1µM H33342 in N2a cells.  
Data are mean ±S.E.M. n = 6 wells per concentration from a single experiment representative of 4 
independent experiments, analysed with One way ANOVA and Dunnett’s post test; * P<0.05, 
**P<0.01 versus control.   
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Figure 4.22 Dose-response curve for the ability of ivermectin (0-7µM) to inhibit mdr1a-
mediated efflux of 1µM H33342 in N2a cells. 
Data are mean ± S.E.M. n = 6 wells per concentration from a single experiment representative of 4 
independent experiments, analysed with non-linear least-squares regression. The IC50 of the above 
curve is 0.24 ± 0.05 µM (R2=0.82). The other individual experiments generated IC50 values of  
0.15 ± 0.07 µM, 0.15 ± 0.09 µM and 0.26 ± 0.05 µM, 0.17 ± 0.05 µM and  0.31 ± 0.07 µM giving a 
mean IC50 of 0.21 ± 0.03 µM and Ki of 0.18 ± 0.02 µM (mean ± S.E.M. n  = 6).  
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Table 4.1 Affinity constants (EC50 values) for H33342 in human SH-SY5Y and mouse N2a 
neuroblastoma cells. 
EC50 values measure the affinities of the MDR1 and mdr1a transporters for H33342. Data are mean ± 
S.E.M.  n = 4 independent experiments, analysed with Student’s two-tailed T-test (P>0.05 between 
cell lines). 
 
Mean EC50 
values/ µM 
SH-SY5Y N2a  
 Mean SEM N Mean SEM N P value 
H33342 10.30 3.12 4 5.33 1.18 4 0.18 
 
Table 4.2 Ki values for avermectin treatments in human and mouse neuroblastoma cells. 
 Data is Ki from IC50 via Cheng &Prusoff’s equation (1973) (See Chapter 2 and Tables 4.6 and 4.7), 
mean ± S.E.M. n ≥ 4 independent experiments, analysed with Student’s two-tailed T-test. 
 
Mean Ki 
values/µM 
 
SH-SY5Y 
 
 
N2a 
  
 Mean SEM N Mean SEM N P value 
CSA 1.42 0.29 5 0.37 0.10 4 P<0.05 
abamectin 0.95 0.08 6 0.77 0.25 6 P>0.05 
emamectin 
benzoate 
0.60 0.07 6 0.56 0.02 5 P>0.05 
ivermectin 0.24 0.08 4 0.18 0.02 6 P>0.05 
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Table 4.3 Mean Ki values of avermectins for MDR1-mediated efflux of H33342 in SH-SY5Y 
cells, analysed by One-Way ANOVA with Dunnett’s post test. 
The order of affinities is ivermectin ≥ emamectin benzoate > abamectin. 
 
SH-SY5Y 
Ki/ µM 
Mean SEM N P value 
abamectin 0.95 0.08 6 ---- 
emamectin 
benzoate 
0.60 0.07 6 P<0.01 
ivermectin 0.24 0.08 4 P<0.01 
 
Table 4.4 Mean Ki values of avermectins for mdr1a-mediated efflux of H33342 in N2a cells, 
from n ≥ 4 independent experiments, analysed by One-Way ANOVA with Dunnett’s post test. 
The order of affinities is ivermectin > emamectin benzoate ≥ abamectin.  
 
N2a 
Ki/ µM 
Mean SEM N P value 
abamectin 0.77 0.25 6 ---- 
emamectin 
benzoate 
0.56 0.02 5 P>0.05 
ivermectin 0.18 0.02 6 P<0.05 
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Summary Conclusions 
This aims of this work were to characterise the dependence of intracellular accumulation of 
H33342 dye, a fluorescent MDR1 and BCRP substrate, upon avermectin exposure. We set 
out to compare kinetics in mouse and human cells for the transporter interactions. Abamectin, 
emamectin benzoate and ivermectin all interacted with human MDR1 and mouse mdr1a. 
Ivermectin had the highest affinity for this interaction with both MDR1 and mdr1a. The order 
of affinities for MDR1 in human SH-SY5Y cells was ivermectin (Ki 0.24 ± 0.08 µM) ≥ 
emamectin benzoate (Ki 0.60 ± 0.07 µM) > abamectin (Ki 0.95 ± 0.08 µM). The order of 
affinities for mdr1a in mouse N2a cells followed a similar trend with ivermectin (Ki 0.18 ± 
0.02 µM) > emamectin benzoate (Ki 0.56 ± 0.02 µM) ≥ abamectin (Ki 0.77 ± 0.25 µM). 
Importantly, there were no significant differences in affinities for abamectin, emamectin 
benzoate or ivermectin between cell lines (P>0.05). These findings indicate that existing 
kinetic data obtained in mouse models relating to endogenous mdr1a is applicable to humans, 
who express MDR1.  Both cell lines were insensitive to Ko-143, indicating that BCRP and 
bcrp were not functionally expressed in human SH-SY5Y or mouse N2a cells.      
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Chapter 5 Measurement of the interaction of avermectin insecticides with multidrug 
resistance proteins using a CMFDA fluorescence dye retention assay 
 
5.1 Summary 
In view of the comparability of MDR1 kinetics with those of mdr1a demonstrated in Chapter 
4, and the pre-existing conflict of opinion as to whether avermectins inhibit MRP/mrp 
transporter activity, this study aimed to characterise avermectin interaction with the MRP 
proteins.   
 
I. Initial experiments measured intracellular retention of the fluorescent MRP/mrp substrate 
dye GSMF, an intracellular metabolic product of CMFDA. Intracellular GSMF retention 
increased significantly above background readings in the absence of dye (P < 0.01) with 
CMFDA concentrations up to 1.5µM. In both cell lines, exposure to MK571 (10µM) caused 
an increase in intracellular fluorescence above dye-only controls, which was significant at 
CMFDA concentrations above 0.2µM in SH-SY5Y cells and above 0.4µM in N2a cells 
(P<0.001 versus control).         
II. In MK-571 concentration-dependence assays up to 15µM with a constant CMFDA 
concentration of 1µM, significant inhibition of  GSMF efflux was observed at 5µM MK-571 
and above in SH-SY5Y cells (P < 0.01) and at 1µM and above (P < 0.01) in N2a cells 
compared to 1µM CMFDA alone. 
III. Inhibition of GSMF efflux through MRP and mrp transporters by 5µM abamectin, 5µM 
CSA and 10µM MK-571 were all of comparable magnitude (all P < 0.01 versus 1µM 
CMFDA only).  
IV. Dose-response curves were performed for selected avermectins (0-7µM) with 1µM 
CMFDA.  Abamectin inhibited GSMF efflux with an IC50 of 2.25 ± <0.01 µM (n = 30) in 
SH-SY5Y cells and 1.68 ± 0.63 µM (n = 24) in N2a cells;  emamectin benzoate with an IC50 
of 1.87 ± 0.57 µM (n = 36) in SH-SY5Y cells and 2.74 ± 1.01 µM (n = 24) in N2a cells; and  
ivermectin with a mean IC50 of 1.58 ± 0.51 µM (n = 24) in SH-SY5Y cells and 1.94 ± 0.72 
µM (n = 24) in N2a cells.  There were no significant differences in IC50 values between cell 
lines (P > 0.05) for each avermectin tested. There were also no significant differences in IC50 
values between abamectin, emamectin benzoate and ivermectin in either SH-SY5Y or in N2a 
cell lines (all P > 0.05).      
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 5.2 Introduction         
 In this study it was of interest to assess whether MRP/mrp transporters interacted with 
avermectins in a similar way to MDR1 and mdr1a in the same model cell lines. Human 
MRP1 is highly expressed in neuroblastoma cell lines including undifferentiated SH-SY5Y 
cells similar to those used in this study (Bordow et al., 1994).  
CMFDA dye was used initially in flow cytometry to measure intracellular glutathione content 
in melanoma cells (Coates & Tripp, 1995) and to identify inflammatory cells based on its 
intracellular conjugation with glutathione. Its metabolic product GSMF was identified as a 
substrate of MRP transporter proteins and used in a fluorescence efflux assay to profile MRP 
transporter activity by Roelofsen et al. (1997). CMFDA diffuses across the cell membrane 
and is cleaved by non-specific intracellular esterases into CMF which slowly permeates the 
cell membrane. CMF reacts with intracellular thiol groups including those on glutathione, 
forming GSMF which is a high-affinity substrate for efflux by MRP transporters (Leier et al., 
2000; Lespine et al., 2007; Förster et al., 2008). The CMFDA assay has been used as a 
fluorescence assay to profile human MRP2 activity in MDCKII-MRP2 transfected cells, 
using MK-571 as a MRP2 inhibitor at 20µM to significantly increase intracellular CMF 
retention (P < 0.01 compared to control; Lindenmaier et al. 2005)  with an IC50 of 
21.2±1.1µM in the same cells (Förster et al., 2008).  Förster and co-workers showed that 
inhibition of native BCRP and P-gp had no effect on intracellular fluorescence levels, 
indicating that the intracellular metabolite of CMFDA, GSMF, is a specific substrate for 
MRP family members.  In the current study, GSMF was used as a substrate for the multidrug 
resistance proteins human MRP and mouse mrp, in a dye retention assay similar to the 
H33342 assay in Chapter 4 (See Methods Chapter 2). Transport kinetics were assessed as cis-
inhibition of efflux of GSMF, through MRP/mrp transporters by MK-571 or selected 
avermectin insecticides.  
 MK-571 has been shown to selectively inhibit human multidrug resistance proteins at 
concentrations of the order of 10µM (Leier et al., 2000; Lespine et al., 2006).  In the current 
study, MRP/mrp efflux activity was examined over a dye concentration range CMFDA 0-
1.5µM, in the presence and absence of the MRP/mrp inhibitor MK571 (10µM). 
Concentration-dependence assays over a range of concentrations of MK-571 (0-50µM) were 
then obtained in each cell line at an external CMFDA concentration of 1µM. 10µM MK571 
Chapter 5 CMFDA efflux transporter assay A M Dalzell 
102 
 
was included in all assays to confirm function of MRP/mrp transporters. Since CSA was used 
as a control inhibitor of MDR1/mdr1a in Chapter 4, and it is reported to inhibit the activity of 
multidrug resistance proteins as well (Matsson et al., 2009), 5µM CSA was tested in the 
CMFDA assay to investigate the specificity of its inhibition of efflux transporters. To assess 
the interaction of avermectins with the MRP/mrp efflux transporters that are endogenously 
expressed in these neuroblastoma cells, dose response curves for abamectin, emamectin 
benzoate and ivermectin (0-7µM) were obtained with external CMFDA concentration set at 
1µM.  
   
 5.3 Results 
 
CMFDA dose-response curves 
The human and mouse cell lines were exposed to a range of CMFDA concentrations in the 
presence and absence of the multidrug resistance protein inhibitor MK571 (10µM) and 
intracellular GSMF fluorescence was measured. Incubation of cells with 0-1.5µM CMFDA 
resulted in a significant increase in fluorescence compared with cells not exposed to CMFDA 
(P < 0.01). The increase in GSMF retention was a linear function of the external CMFDA 
concentration over the concentration range tested. Concentrations higher than 1.5 µM 
resulted in cellular toxicity, so it was not possible to achieve saturation and obtain EC50 
values for GSMF efflux; hence Ki values could not be calculated from IC50 values for putative 
inhibitors. In the presence of MK571 (10µM), intracellular retention of fluorescent GSMF 
was significantly higher than in the absence of MK571 at a given concentration of CMFDA.   
 Figure 5.1 shows mean data from 4 experiments (in total n = 12) in which SH-SY5Y cells 
were exposed to a range of CMFDA dye concentrations (0 - 1.5µM) in the presence or 
absence of 10µM MK571. Data are normalised to background fluorescence (100%). At 1µM 
CMFDA there is an increase of 3500 ± 310% above background (cells without dye). In the 
presence of MK571 (10µM) intracellular fluorescence is significantly higher - 11040 ± 
369%; P<0.001 compared to 1µM CMFDA alone. MRP-mediated efflux of GSMF is 
therefore significantly inhibited by MK571 in SH-SY5Y cells. 
Figure 5.2 shows mean data, normalised to background fluorescence (100%), from 4 
experiments (in total n = 12) in which N2a cells were exposed to a range of CMFDA dye 
concentrations (0 - 1.5µM) in the presence or absence of 10µM MK571. At 1µM CMFDA 
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alone the intracellular GSMF fluorescence signal was 3745 ± 478% higher than background 
in the absence of dye, which is similar to the response of SH-SY5Y cells. After the addition 
of MK571 (10µM) intracellular fluorescence is significantly higher -11540 ± 729 %; P<0.001 
compared to 1µM CMFDA alone, which demonstrates that efflux of GSMF mediated by mrp 
transporters was significantly inhibited by MK571 in N2a cells. 
In summary, cells were exposed to a range of CMFDA concentrations to profile MRP and 
mrp efflux function in human and mouse cell lines and to determine the lowest practical 
CMFDA dye concentration to use for each cell line to give a measurable distinction in 
intracellular fluorescence levels between control and inhibitor. Human SH-SY5Y and mouse 
N2a neuroblastoma cells were both susceptible to inhibition of GSMF efflux by 10µM 
MK571 and responded with increases in intracellular GSMF fluorescence of comparable 
magnitude; 3.08- and 3.15-fold, respectively (P > 0.05). 1µM CMFDA was chosen as a 
suitable concentration for all further assays in both cell lines. 
Efflux modulation by MK571 and CSA 
The concentration dependence of intracellular GSMF fluorescence upon exposure to MK571 
was assessed over a concentration range 0 – 50 µM MK571 using 1µM CMFDA. Due to 
cellular toxicity in both cell lines at 25 and 50 µM (data not shown) the analyses were 
restricted to 0 - 15 µM MK571. Figures 5.3 and 5.4 show mean data from 4 experiments in 
SH-SY5Y cells and N2a cells, respectively, normalised to control (n = 24). In both sets of 
experiments there were significant increases in intracellular fluorescence above control at 5, 
10 and 15 µM in SH-SY5Y cells (P <0.01) and at 1µM and above in N2a cells (P <0.01). The 
IC50 for inhibition of GSMF efflux through mrp transporters in N2a cells was 2.67 ± 0.91 µM 
(Figure 5.4). A saturable curve was not obtainable for SH-SY5Y cells in these experiments 
(Figure 5.3). 10µM MK571 was included in all subsequent experiments as an internal control 
to confirm functional inhibition of MRP/mrp transporters.  
 
 To test the specificity of transporter inhibition for the different compounds used, 5µM CSA 
was compared with 10µM MK571, 5µM abamectin, or control. 10µM MK571 and 5µM CSA 
both inhibit CMFDA dye efflux through MRP/ mrp transporters to a similar degree in SH-
SY5Y cells (both P < 0.01 versus 1µM CMFDA only; Figure 5.5) and in N2a cells (both P < 
0.01 versus 1µM CMFDA only; Figure 5.6).  
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Functional inhibition of CMFDA efflux through MRP and mrp transporters by 
avermectins   
 
Abamectin, emamectin benzoate and ivermectin were all tested over a concentration range 0 
– 7 µM in SH-SY5Y and N2a cell lines at a constant CMFDA concentration of 1µM to 
generate dose-response curves, in which data were normalised to solvent only control (0µM 
avermectin, 100%) and then 100% control was subtracted and data expressed as % 
fluorescence increase above control. MK-571 (10µM) was included in all assays with 
avermectins as an internal control, where it consistently inhibited CMFDA efflux 
significantly compared to control (P < 0.01 in all experiments). Significant concentration-
dependent increases in intracellular dye retention were observed for all insecticides tested in 
both cell lines (P < 0.01 at 5µM and above). Dose-response curves generated were analysed 
by non-linear least-squares regression to generate IC50 values (summarised in Tables 5.1, 5.2 
and 5.3). A drop-off in intracellular fluorescence levels was observed for all three 
avermectins in both cell lines above 6µM, so dose-response curves are shown over the 
concentration range 0 – 6 µM only.  
 
Abamectin 
SH-SY5Y human cells were exposed to a range of abamectin concentrations (0 – 6 µM) and 
fluorescent GSMF retained inside cells was quantified at 520 ± 2.5 nm. Mean data from 5 
independent experiments (total n = 30) are normalised to % control as above and shown as a 
dose response curve (Figure 5.7). The IC50 from nonlinear regression analysis for inhibition 
of GSMF efflux by abamectin in SH-SY5Y cells was 2.25 ± <0.01 µM.  
 Figure 5.8 shows mean data normalised to % control from 4 independent experiments (n = 
24), performed in parallel in N2a mouse cells exposed to a range of abamectin concentrations 
(0 -6 µM). Analysis by non-linear regression returned an IC50 for abamectin of 1.68 ± 0.63 
µM for inhibition of GSMF efflux in N2a cells.   
To summarise, mean IC50 values were 2.25 ± <0.01 µM for abamectin in human SH-SY5Y 
cells and 1.68 ± 0.63 µM for mouse N2a cells. There are no significant differences for 
inhibition of GSMF efflux by abamectin between the SH-SY5Y human and N2a mouse cell 
lines (two-tailed t-test; P = 0.32, Table 5.1). 
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Emamectin benzoate 
SH-SY5Y human cells were exposed to a range of concentrations of emamectin benzoate (0 - 
6 µM). Data from 6 independent experiments (total n = 36) are expressed as mean ± S.E.M. 
normalised to % control (Figure 5.9). Analysis by nonlinear least squares regression gave a 
dose-response curve with an IC50 for inhibition of GSMF efflux through human MRP 
transporters by emamectin benzoate of 1.87 ± 0.57 µM.   
 Figure 5.10 shows mean data, normalised to % control, from 4 independent experiments 
(total n = 24) performed in parallel in N2a mouse cells which were exposed to a range of 0 – 
6 µM emamectin benzoate concentrations. Nonlinear regression analysis generated an IC50 
for inhibition of GSMF efflux through mouse mrp transporters by emamectin benzoate of 
2.74 ± 1.01 µM. 
 Emamectin benzoate inhibited H33342 efflux with a Mean IC50 of 1.87 ± 0.57 µM for 
human SH-SY5Y cells and 2.74 ± 1.01 µM for mouse N2a cells. There are no significant 
differences between the human and mouse cell lines in Mean IC50 values for inhibition of 
CMFDA efflux by emamectin benzoate (two-tailed t-test; P = 0.42, Table 5.1). 
 
Ivermectin 
SH-SY5Y human cells were exposed to a range of ivermectin concentrations (0 - 6 µM). 
Figure 5.11 shows mean data from 4 individual experiments (n = 24), normalised to % 
control. Data were analysed by nonlinear regression to generate an IC50 of 1.58 ± 0.51 µM for 
the ability of ivermectin to inhibit GSMF efflux through human MRP transporters.   
 Figure 5.12 shows mean data from 4 independent experiments (total n = 24), normalised to 
% control, in N2a mouse cells exposed to a range of ivermectin concentrations (0 – 6 µM). 
Nonlinear regression analysis of the dose-response curve gave an IC50 of 1.94 ± 0.72 µM for 
inhibition of GSMF efflux through mouse mrp transporters by ivermectin.  
In summary, ivermectin inhibited H33342 efflux with a mean IC50 of 1.58 ± 0.51 µM for 
human SH-SY5Y cells and 1.94 ± 0.72 µM for mouse N2a cells. There are no significant 
differences between the human and mouse cell lines in Mean IC50 values for inhibition of 
CMFDA efflux by ivermectin (two-tailed T-test; P = 0.69, Table 5.1). 
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Data obtained in this chapter for the interaction of abamectin, emamectin benzoate and 
ivermectin with MRPs  expressed in the neuroblastoma cell line SH-SY5Y, of human origin, 
and with mrps expressed in N2a cells of mouse origin, indicates that all three avermectins 
tested significantly inhibit the efflux of CMFDA through both MRP and mrp transporters (P 
< 0.01 vs solvent only control at 5µM and above of each avermectin) , and that there are no 
significant species differences in this interaction. Similar data was obtained for MDR1 and 
mdr1a in Chapter 4.  
 
5.5 Discussion 
Human MRP2 activity was measured in MDCKII-MRP2 transfected cells by Lindenmaier et 
al., (2005) using 20µM MK571 as a positive control inhibitor to test the interaction of 
selected progestins with MRP2 in the CMFDA assay. Förster et al. (2008) found that MK-
571 had an IC50 of 21.2 ± 1.1 µM as a MRP2 inhibitor in MDCKII-MRP2 cells using the 
CMFDA intracellular metabolite GSMF as an MRP substrate. In the current study, there were 
significant increases in intracellular GSMF fluorescence at 5µM MK571 and above in SH-
SY5Y cells and 1µM MK571 and above in N2a cells, in four independent experiments (all P 
< 0.01 versus 1µM CMFDA only). The IC50 from these experiments for inhibition of GSMF 
efflux through mrp transporters in N2a cells was 2.67 ± 0.91 µM. An IC50 value was not 
obtainable for SH-SY5Y cells because the cells did not achieve saturation with GSMF. 
Experiments by others in our lab on the HK2 cell line have yielded similar results (data not 
shown). 
 
 Further support for MK571 as an effective inhibitor of MRP transporters comes from Leier 
et al (2000), who report specific inhibition of PAH efflux by MK-571 with an IC50 of 4 µM 
in HEK293-MRP2 cells. MK-571 also inhibited human MRP1 in an HL60-MRP1 transfected 
cell line at concentrations up to 30µM with an IC50 of 2µM in a retention assay using 
Calcein-AM (Lespine et al, 2006). It is apparent that IC50 values differ according to the efflux 
substrate and cell line used, however the value of 2.67 ± 0.91 µM obtained for N2a cells in 
this study is in agreement with above values obtained in transfected cells using Calcein-AM 
or PAH (2 and 4 µM, respectively; Lespine et al., 2006 and Leier et al., 2000). Experiments 
using 1µM CMFDA with MK571 over a concentration range 0 – 15 µM need to be repeated 
to obtain a corresponding IC50 for SH-SY5Y cells.          
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In the current study, abamectin, emamectin benzoate and ivermectin all inhibited efflux of the 
CMFDA metabolite GSMF through MRP transporters in human SH-SY5Y neuroblastoma 
cells with respective mean IC50 values of 2.25 ± <0.01 µM, 1.87 ± 0.57 µM and 1.58 ± 0.51 
µM; all three avermectins also inhibited GSMF efflux through mrp transporters in N2a 
neuroblastoma cells with respective mean IC50 values of 1.68 ± 0.63 µM, 2.74 ± 1.01 µM and 
1.94 ± 0.75 µM. There were no significant differences in affinities of abamectin (P=0.32), 
emamectin benzoate (P=0.42) or ivermectin (P=0.69) for MRP or mrp transporters between 
human SH-SY5Y or mouse N2a cells (Table 5.1). Likewise affinities of the avermectins for 
MDR1 or mdr1a did not differ significantly between the two cell lines (Chapter 4). All 
avermectins tested had affinities in the low micromolar range for inhibition of efflux of the 
CMFDA metabolite GSMF through MRP/mrp transporters, similar to the affinities measured 
for H33342 efflux inhibition through MDR1/mdr1a in Chapter 4. This is an important finding 
in the light of conflicting reports as to the role of MRP/mrp transporters in ivermectin efflux 
(Lespine et al., 2006; Brayden & Griffin, 2008). 
 
Brayden and Griffin (2008) suggested that ivermectin and selamectin did not undergo flux 
through MRP2, since the avermectins apparently did not inhibit the flux of the MRP2-
specific substrate sulforhodamine 101 through MDCKII-MRP2 cells (data not shown). These 
authors performed basal-apical and apical-basal flux studies in MDCK II-MDR1, MDCKII-
MRP1 and MDCKII-MRP2 transfected cells, as well as MDCKII wild-type cells. Fluxes of 
radiolabelled ivermectin and selamectin were polarised in the basolateral to apical direction 
in MDCKII-MDR1 cells. Ivermectin and selamectin were also found to inhibit the flux of 
Rhodamine-123, an MDR1/mdr1 substrate (Matsson et al., 2009). The validity of transport 
assays on MRP- expressing cell lines was limited by two factors; the constitutive expression 
of functional mdr1 (most likely canine) across all cell types, and the lack of an MRP1-
specific substrate.  
Conversely, Lespine et al., (2006) present evidence which supports the data for ivermectin 
obtained in the current study. These researchers conducted transport assays in two different 
cell lines in which MRP1 expression is high, using two different dyes. In A459 cells the 
apparent IC50 for ivermectin with Calcein-AM was 1µM, and 2.5µM with BCECF; in HL60-
MRP1 cells the IC50 for ivermectin was 3.8µM with Calcein-AM only. The IC50 values for 
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inhibition of dye efflux by ivermectin in the current study using CMFDA are similar to that 
for Calcein-AM in A459 cells (1µM), at 1.58 ± 0.51 µM; however this is for all MRP 
transporters expressed in the cells, not necessarily reflecting solely MRP1 activity. It should 
be noted that IC50 values obtained using different substrate dyes are not directly comparable; 
this would require Ki values, however the similar findings in the two assay types by Lespine 
and co-workers (2007) and in the current study together provide strong support that 
ivermectin inhibits one or more human MRP transporters, including MRP1. Evidence 
suggesting interaction of ivermectin with other human MRP transporters indicates lower 
affinity, with inhibition of the ATPase activity of MRP2 and MRP3 returning IC50 values of 
18 ± 5 µM and 40 ± 21 µM respectively, compared to MDR1 (IC50 = 2.5 ± 2µM) and MRP1 
(IC50 = 9 ± 4 µM) (Lespine et al. 2006). The current study has extended this evidence by 
showing functional activity of MRP- and mrp- type transporters in human and mouse 
neuronal cells, respectively. This functional activity was likewise inhibited by ivermectin but 
also by abamectin and emamectin benzoate. 
Contrary to the findings for human MDR1 and mouse mdr1a, there were no significant 
differences between affinities of abamectin, emamectin benzoate or ivermectin for MRP 
transporters (Table 5.2) or mrp transporters (Table 5.3) in either human SH-SY5Y or in 
mouse N2a cells (all P > 0.05 compared to abamectin). In contrast, the order of affinities for 
human MDR1 was ivermectin > emamectin benzoate > abamectin, and for mouse mdr1a was 
ivermectin > emamectin benzoate ≥ abamectin. Brayden and Griffin (2008) suggest that, 
where there is background expression of MDR1, substrate efflux by MRP proteins is not 
significant. The similarity of avermectin affinities for MDR1/mdr1a as for MRP/mrp 
transporters found in this study suggests that MRP/mrp proteins may have a complementary 
interaction with avermectins. The fact that they are inhibited with similar affinity means that 
the avermectins could affect the efflux of MRP/mrp substrates that are transported less 
efficiently by MDR1/mdr1a, such as unconjugated bilirubin (Corich et al. 2009). 
   
There are reports elsewhere of substrate overlap, e.g. Calcein-AM and rhodamine-123 are 
transported by both MDR1 and MRP-type proteins (McAleer et al, 1999; Brayden & Griffin, 
2008); indeed if the substrates are multispecific the presence of multiple transporters may 
mask the source of observable effects. Due to the use of distinct dyes and specific inhibitors, 
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substrate overlap was not considered a problem in this study, however. Metabolites of 
CMFDA are specific substrates for MRP-/mrp- transporters (McAleer et al., 1999; Luna-
Tortós et al., 2009; Förster et al., 2008), H33342 is selective for MDR1/mdr1 and BCRP/bcrp 
at appropriate concentrations (Matsson et al., 2009), and the transporters were responsive to 
their respective specific inhibitors  (Ko-143 for BCRP/bcrp and MK-571 for MRP/mrp) in 
this study. Accordingly the IC50 values obtained should relate to the specific transporter types 
under investigation in each assay, MDR1/mdr1 or MRP/mrp. 
It is important that, in the current study, 5µM CSA was found to inhibit CMFDA efflux 
significantly compared to control (P < 0.01), consistently comparable with inhibition by 
10µM MK-571. This observation is in agreement with another study which reports that CSA 
is a multi-specific inhibitor of MDR1, BCRP and MRP2 (Matsson et al 2009). CSA is also 
capable of inhibiting human BCRP in transfected HEK-BCRP cells with an IC50 of 
4.3±1.9µM where there is little endogenous expression of MDR1 or MRP1/MRP2 (Gupta et 
al., 2006). 
In order to clarify the specificity of the two model inhibitors CSA and MK571, dose-response 
curves should be performed in the model cell lines with the CMFDA assay for MRP/mrp 
transporters simultaneously with H33342 as an MDR1/mdr1a substrate to quantify relative 
inhibition of each of the transporter types. The same assays should be performed with the 
avermectins, since the importance of the two transporter types in avermectin handing will 
depend not only on the affinity of the interactions, which are similar, but also upon absolute 
expression and activity levels, which can best be compared in a simultaneous assay. The 
excitation and emission wavelengths (355nm excitation and 480nm emission for H33342, and 
480nm excitation and 520nm emission for CMFDA) are distinct enough that signal overlap 
was not a problem. 
The experiments in the current studies were not flux assays, so although they have identified 
inhibitory interactions for abamectin, emamectin benzoate and ivermectin with MDR1/mdr1a 
as well as MRP/mrp transporters, they do not address whether or not these proteins mediate 
efflux of the avermectins. To address this question, further work is required to ascertain 
intracellular avermectin concentrations after treatment, using HPLC/MS. Assessment of 
intracellular concentrations under the same conditions with individual transporters knocked 
out would then determine which transporters are involved in avermectin efflux.          
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Figure 5.1 Concentration dependence of intracellular GSMF fluorescence after 
treatment with CMFDA (0-1.5µM) in SH-SY5Y cells ± 10µM MK-571. The data 
above are mean ± S.E.M. n = 12 wells per concentration from 4 experiments, analysed by 
One-way ANOVA with Dunnett’s post-test; ** P<0.01; At 0.2µM CMFDA and above, 
the increases in intracellular fluorescence in the presence of 10µM MK571 was 
significant compared to the corresponding control (P<0.001 by Bonferroni’s post-test, not 
shown). 
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Figure 5.2 Concentration dependence of intracellular GSMF fluorescence after 
treatment with CMFDA (0-1.5µM) in N2a cells ± 10µM MK-571. Data are mean ± 
S.E.M. n = 12 wells per concentration from 4 experiments, analysed by One-way 
ANOVA with Dunnett’s post-test; * P<0.05; ** P<0.01. At 0.4µM CMFDA and above, 
the increase in intracellular fluorescence in the presence of 10µM MK571 was significant 
compared to the corresponding control (P<0.001 by Bonferroni’s post-test, not shown). 
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Figure 5.3 Concentration-dependence of MK-571 (0-15µM) for the ability of to 
inhibit transporter-mediated efflux of 1µM CMFDA in SH-SY5Y cells. Data are 
mean ± S.E.M. n = 24 from 4 independent experiments, analysed by One-Way ANOVA 
with Dunnett’s post-test; *P<0.05;**P<0.01 versus control.  
 
Figure 5.4 Concentration dependence of MK-571 (0-15µM) for ability to inhibit 
transporter-mediated efflux of 1µM CMFDA in N2a cells. Data are mean ± S.E.M. of 
n = 24 from 4 independent experiments, analysed by nonlinear least-squares regression, 
One-site binding, Hyperbola.  The mean IC50 for MK571 from the above curve is 2.67 ± 
0.91 µM in N2a cells.   
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Figure 5.5 Inhibition of transporter-mediated efflux of 1µM CMFDA efflux by 5µM 
abamectin, 10µM MK571 or 5µM CSA in SH-SY5Y cells compared to control. Data 
are mean ± S.E.M. n = 6 wells from 2 independent experiments, analysed by One-way 
ANOVA and Dunnett’s post test; * P<0.05, **P<0.01 versus control.  
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Figure 5.6 Inhibition of transporter-mediated efflux of 1µM CMFDA efflux by 5µM 
abamectin, 10µM MK571 or 5µM CSA in N2a cells compared to control. Data are 
mean ± S.E.M. n = 6 wells from 2 independent experiments, analysed by One-way 
ANOVA and Dunnett’s post test; * P<0.05, **P<0.01 versus control.  
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Figure 5.7 Dose-response curve for the ability of abamectin (0-6µM) to inhibit MRP-
mediated efflux of 1µM CMFDA in SH-SY5Y cells. Data are mean ± S.E.M. n = 30 
from 5 independent experiments, each n = 6 wells per concentration, analysed with non-
linear least-squares regression. The IC50 of the above curve is 2.25 ± <0.01 µM.   
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Figure 5.8 Dose-response curve for the ability of abamectin (0-6µM) to inhibit MRP-
mediated efflux of 1µM CMFDA in N2a cells. Data are mean ± S.E.M. n = 24 from 4 
independent experiments, analysed with non-linear least-squares regression. The IC50 of 
the above curve is 1.68 ± 0.63 µM.  
 
 
Chapter 5: CMFDA efflux transporter assay figures                                       A M Dalzell 
  
114 
 
0.
0
1.
0
2.
0
3.
0
4.
0
5.
0
6.
0
0
100
200
300
400
500
Emamectin benzoate mM
%
 I
n
c
re
a
s
e
d
 G
S
M
F
F
lu
o
re
s
c
e
n
c
e
(5
2
0
n
m
)
 
Figure 5.9 Dose-response curve for the ability of emamectin benzoate (0-6µM) to 
inhibit MRP-mediated efflux of 1µM CMFDA in SH-SY5Y cells. Data are mean ± 
S.E.M. n = 36 from 6 independent experiments, analysed with non-linear least-squares 
regression. The IC50 of the above curve is 1.87 ± 0.57 µM.  
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Figure 5.10 Dose-response curve for the ability of emamectin benzoate (0-6µM) to 
inhibit mrp-mediated efflux of 1µM CMFDA in N2a cells. Data are mean ± S.E.M. n 
= 24 from 4 independent experiments, analysed with non-linear least-squares regression. 
The IC50 of the above curve is 2.74 ± 1.01 µM. 
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Figure 5.11 Dose-response curve for the ability of ivermectin (0-6µM) to inhibit 
MRP-mediated efflux of 1µM CMFDA in SH-SY5Y cells. Data are mean ± S.E.M. n = 
24 from 4 independent experiments, analysed with non-linear least-squares regression. 
The IC50 of the above curve is 1.58 ± 0.51 µM.  
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Figure 5.12 Dose-response curve for the ability of ivermectin (0-6µM) to inhibit 
mrp-mediated efflux of 1µM CMFDA in N2a cells. Data are mean ± S.E.M. n = 24 
from 4 independent experiments, analysed with non-linear least-squares regression. The 
IC50 of the above curve is 1.94 ± 0.72 µM.  
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Summary Conclusions 
To investigate the relevance of MRP/ mrp transporters to avermectin exposure, this study 
aimed to characterise avermectin interactions with the MRP and mrp transporter proteins. 
Kinetic data obtained for MDR1 and mdr1a in Chapter 4 could then be placed in the 
context of other transporters. CMFDA dye retention experiments confirmed the 
functionality of MRP and mrp transporters and sensitivity to MK-571 in SH-SY5Y and 
N2a cell lines. Dose response curves with 1µM CMFDA and either abamectin, 
emamectin benzoate and ivermectin at 0-7µM returned IC50 values that were comparable 
between cell lines (P>0.05) and avermectin compounds (P>0.05), ranging from 1.58 ± 
0.51 µM (ivermectin, SH-SY5Y cells) to 2.74 ± 1.01 µM (emamectin benzoate, N2a 
cells). These values do not differ significantly from affinities for MDR1 and mdr1a, and 
thus abamectin, emamectin benzoate and ivermectin all have important interactions with 
MDR1 and MRP and their mouse counterparts in human SH-SY5Y and mouse N2a cell 
lines.           
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Chapter 6: Cell Viability and Markers of Avermectin Exposure 
 
6.1 Summary 
This section of work explores the effects of avermectin exposure upon cell viability, and 
potential early markers of exposure, such as changes in chemokine gene expression, neurite 
outgrowth and the expression of transporter genes.    
I. Abamectin and ivermectin exposure for 1 hour up to 10µM caused no significant 
decreases in mitochondrial dehydrogenase activity compared to control in either SH-
SY5Y or N2a cell lines using the MTT assay of cell viability (P > 0.05). 
II. Exposure of cells to emamectin benzoate up to 5µM for 1 hour caused no significant 
changes in mitochondrial activity in either cell line (P > 0.05 compared to control). 
At 7-10µM emamectin benzoate in SH-SY5Y cells there was a significant decrease 
in conversion of MTT to formazan compared to control (P < 0.01), but this did not 
apply to N2a cells.   
III.  From a qPCR array panel of 84 genes, expression of the BDNF, AIMP1, CX3CL1 
and the chemokine-related factor SDF2 genes were identified as potential markers of 
exposure which increased or decreased expression more than 3-fold compared to 
control after exposure to 1µM emamectin benzoate or 1µM ivermectin.  
IV. An acute 1 hour exposure to 1µM abamectin, emamectin benzoate or ivermectin 
post-differentiation made no apparent qualitative difference to neurite expression in 
N2a cells compared with the positive control 0.1mM hydrogen peroxide, in 
preliminary experiments which need further investigation. 
V. Exposure of SH-SY5Y cells to 1µM abamectin, emamectin benzoate or ivermectin 
for 1 hour brought about no significant changes expression levels for the MDR1 or 
MRP1 gene compared to solvent control (P > 0.05 for both genes). 
 
6.2 Introduction 
MTT Assay of cell viability 
The MTT assay has been used successfully as a measure of pesticide-induced damage of SH-
SY5Y cells and other drug resistant cell lines (Hu et al., 2009; Gao et al., 2010) and N2a cells 
(Sul et al., 2009). Hu and co-workers studied the cytotoxic effect of 100nM rotenone on SH-
SY5Y cells in the presence and absence of a donor of hydrogen sulphide, which was found to 
Chapter 6: Cell Viability and Markers of Avermectin Exposure A M Dalzell  
120 
 
protect against rotenone-induced damage. Gao et al., (2010) assessed the intrinsic 
cytotoxicity of the macrocyclic lactone sister compounds doramectin and nemadectin to the 
human breast carcinoma adriamycin-resistant cell line MCF7/adr, and found IC50 values of 
14μM and 19.7μM, respectively. 8µM of either compound was insufficient to cause 15% cell 
death. At concentrations of 1 – 8 µM, though, both compounds were effective at reversing 
resistance to adriamycin in a concentration-dependent manner.  8µM doramectin rendered 
these cells up to 50-fold more sensitive to adriamycin, and 8µM nemadectin brought about a 
24-fold reversal in adriamycin resistance (Gao et al., 2010). N2a cells were evaluated for 
their sensitivity to the neurotoxicant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) from 0 - 
1000 nM over 24 hour exposure using MTT by Sul et al., (2009) who found that 100-
1000nM TCDD brought about a significant decrease in mitochondrial activity (P < 0.05).  
Since the MTT method is thus a proven assay for pesticide toxicity in the test cell lines, it 
was used to measure gross changes in cell viability in response to avermectin exposure in the 
current study. 
Chemokines in the CNS 
Chemokines are constitutively expressed in a variety of brain cells including neurons, 
astrocytes and glial cells and are important in normal brain homeostasis and development; for 
example SDF1 and its receptor CXCR4 mediate neuronal migration during development 
(Bajetto et al., 1999; Zhu et al., 2009). Brain-derived neurotrophic factor, BDNF, is involved 
in regulating dopamine uptake and release in mouse brain (Bosse et al., 2011). Chemokines 
have the potential to be useful markers of exposure because they are induced under 
conditions of cell damage e.g. ischemia during stroke, or viral infection and inflammation 
(Bajetto et al. 2001 Review).    
Neurite outgrowth 
Recently neurite outgrowth in mouse neuroblastoma N2a cells has proved to be a sensitive 
assay of damage in response to pesticide exposure.  Both mouse N2a and human SHSY5Y 
cells can be induced to produce neurite outgrowths. Differentiated N2a and SH-SY5Y cells 
have both been used successfully in experiments on pesticide exposure and viral infection 
(Vesanen et al. 1994; Kume et al. 2008; Miglio et al. 2009; Cheung et al 2009; Sun et al. 
2010). Since differentiation of the cells affects expression levels of MDR1 (Bates et al., 
1989), it stands independently of the transport assays, which were all performed with 
undifferentiated cells. It is however of burgeoning interest as a quantitative marker of early 
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effects on cell growth and maintenance and is worth investigating for the avermectins in this 
study.     
 Modulation of MDR1 and MRP1 expression by avermectins 
Both MDR1 (Bates et al., 1989) and MRP1 (Bordow et al., 1994; Corich et al., 2009) are 
inducible genes, and both genes have been reported to interact avermectins (Lespine et al., 
2006). Furthermore, the related macrocyclic lactone compounds doramectin and nemadectin 
have been reported to down-regulate MDR1 mRNA and protein expression (Gao et al., 
2010). Hence it was of interest to see if the expression of these genes was affected by acute 
exposure to avermectins.   
Aims 
This study set out to ascertain the effect of acute avermectin exposure upon cell viability, 
measured by the MTT assay of mitochondrial dehydrogenase activity. The avermectin 
concentration range and length of exposure paralleled that of the transporter assays in 
Chapters 4 and 5. Potential markers of avermectin exposure were also of interest, preferably 
ones that can be identified earlier in time or at lower avermectin concentrations than those 
that might affect cell viability.    
6.3 Results 
MTT Assay 
The MTT assay of cell proliferation was used in parallel to the transport assays, to measure 
the effect of avermectin exposure upon on cell monolayer integrity. The assay was first 
validated by dosing the cells with a range of concentrations of Triton-X100, which is a 
detergent that brings about cell lysis. Example experiments are shown in Figures 6.1 and 6.2 
in SH-SY5Y and N2a cells respectively. From these validation experiments, 0.01% Triton-
X100 was used as a positive control in all experiments to achieve 100% cell lysis with an 
exposure time of 15 minutes.   Figure 6.3 displays the results from SH-SY5Y cells exposed to 
abamectin 0-10µM for 1 hour. In 4 independent assays after exposure to abamectin up to 
10µM there were no significant differences in the percentage of cells capable of metabolising 
MTT to formazan compared to control (P > 0.05, n = 4 experiments, each n = 6 wells per 
concentration). The same was true for N2a cells (Figure 6.4; P > 0.05, n = 4 experiments).   
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Emamectin Benzoate was used to dose cells from 0-10µM for 1 hour. The results in Figure 
6.5 for SH-SY5Y show that at 7 and 10µM there were significant decreases in viable cell 
number compared to control (P < 0.05 and P < 0.01 respectively, n = 5 experiments). To 
compare the sensitivity of N2a cells as compared to SH-SY5Y cells, cells were exposed to 
emamectin benzoate for 1 hour in the MTT assay. The mean data is presented and analysed in 
Figure 6.6. There was no significant trend in cell viability changes in response to any of the 
treatments compared to control in 4 independent experiments (P > 0.05, n = 4 experiments, 
each n = 6 wells per concentration), suggesting that the N2a cells may be less sensitive than 
SH-SY5Y cells to low µM concentrations of this pesticide.  
Figures 6.7 and 6.8 show MTT assays performed on SHSY5Y and N2a cells respectively, 
performed in parallel to the transporter experiments, to determine the effect of ivermectin 
upon cell proliferation. Cell viability for all ivermectin concentrations tested (up to 10µM) 
does not vary significantly from control after 1 hour exposure for either SH-SY5Y or N2a 
cells (P > 0.05, n = 4 experiments, each n = 6 wells per concentration).  
Chemokine and receptor gene expression after avermectin exposure 
Figures 6.7 A-D show mRNA for chemokines, chemokine receptors and chemokine-like 
factors expressed at a Ct value > 35 in SH-SY5Y cells exposed to 1µM emamectin benzoate 
(Figure 6.7 A & B) or ivermectin (Figure 6.7 C & D) for 18 hours, plotted against  
corresponding gene expression in solvent control samples. The 84-gene qPCR array panel 
used was SABiosciences PAHS-022. Notable expressed genes are shown in red; these are 
BDNF (Figure 6.7 C), which increased its expression level above control after treatment with 
Ivermectin; AIMP1 (Figure 6.7 C) whose expression increased approximately 2-fold above 
control after treatment with both ivermectin and emamectin benzoate. There was decreased 
mRNA expression of the ligand CX3CL1 after exposure to both emamectin benzoate and 
ivermectin (Figure 6.7 -B, -C and -D). Of particular interest is SDF2 as a potential marker of 
exposure, since its expression decreased approximately 6-fold compared to control after 
exposure to both emamectin benzoate and ivermectin (1µM) (Figure 6.7 A & 6.7 C). The 
data obtained in the current study cannot be conclusive as to a potential, as some of the data 
conflicts and there were insufficient chemokine array plates available to increase the n 
number of the data, hence results are plotted individually for each of the two independent 
samples for each condition against its control; however, BDNF, AIMP1, CX3CL1 and SDF2 
are all candidates for further study.      
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Neurite outgrowth 
There are two different approaches to assessing neurite outgrowth, which measure different 
aspects of neurite health. The first method is to expose the cells to the putative toxin during 
differentiation. The second is to pre-differentiate the cells, then expose them to toxin post-
differentiation, which is a measure of the maintenance of neurite integrity in mature cells. 
This latter was the method adopted in the current study. 
 N2a cells were induced to express neurites for 24 hours, then treated with either solvent 
control (Figure 6.8A), 0.1mM hydrogen peroxide (B) or 1µM abamectin(C, D), emamectin 
benzoate (E) or ivermectin (F) and antibody-stained as detailed in the methods section and 
figure legends. The cells were then visualised using a x63 oil immersion lens on a Leica 
TCS-NT confocal microscope, scanned with argon laser at 488 (FITC) and 568 (TRITC) with 
4-6 sections in the xy plane (Figure 6.8 A-F). Each figure shown is representative of 6 similar 
fields for each condition. Qualitatively, treatment with the selected avermectins for 1 hour 
post neurite induction did not bring about significant reduction neurite expression by N2a 
cells. Acute exposure of neurite-induced N2a cells to 1µM abamectin, emamectin benzoate or 
ivermectin had no qualitative effect upon neurite expression as assessed in 2-3 independent 
experiments. The standard accepted for quantitation is 100 neurites per condition when 
measuring cell length and 100 neurites in control cells when counting neurite number. The 
current experiments produced too few neurites to meaningfully quantitate the results either by 
number or length, and these preliminary observations require further work. 
Modulation of MDR1 and MRP1 expression by avermectins 
To investigate the effect of avermectin exposure upon MDR1 and MRP1 mRNA expression, 
three independent passages of SH-SY5Y cells were dosed with 1µM abamectin, emamectin 
benzoate or ivermectin for 18 hours in the absence of serum. RNA samples from the cells 
were assayed by qPCR in triplicate, so that data are mean ± S.E.M. of n = 9. No significant 
changes in MDR1 mRNA expression were found in SH-SY5Y cells (P > 0.05; Figure 6.9), or 
in expression levels of MRP1 mRNA (P > 0.05; Figure 6.10). 
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6.4 Discussion 
MTT assay  
As one of a number of measures of toxicity, we initially focussed on the MTT assay as a 
broad measure of cell proliferation and monolayer integrity in parallel to the transporter 
assays. The methodology was validated by looking at the impact of a short 1 hour exposure to 
Triton X100 upon the viability of SH-SY5Y and N2a cells. Triton X 100 proved to be a very 
effective method of inducing damage with maximal cell death occurring with Triton X100 
concentrations as low as 0.01%. Avermectins were much less toxic to both cell lines. In a 
series of experiments repeated 4-5 times for each avermectin, we found no significant loss of 
cell viability as measured by MTT after 1 hour exposure of SH-SY5Y cells or N2a cells to 
either 10µM abamectin or ivermectin. In contrast, when the concentration dependence of 
emamectin benzoate induced cell damage was measured, exposure of SH-SY5Y cells to 
10µM was associated with significant (P < 0.01) decrease in cell viability. The data indicate 
that exposure for 1 hour to emamectin benzoate concentrations of 7µM and above resulted in 
≥ 50% cell death. It is noted that it was difficult to obtain data points above 6µM for 
emamectin benzoate in the H33342 assay in Chapter 4; this can now be attributed to cellular 
toxicity at concentrations above 6µM. For comparison, circulating plasma concentrations of 
avermectins detected in animal models are ~ 22 - 70nM/L (Alvinerie et al., 1999; Gokbulut et 
al., 2010). 
 
Chemokines and receptors as potential biomarkers of avermectin exposure    
Of all the chemokines and receptors whose expression was assayed in the array, the genes of 
particular interest as potential markers of avermectin exposure are BDNF, AIMP1 and SDF-
2. BDNF (Brain-Derived Neurotrophic Factor) increased its mRNA expression levels 
compared to control in response to treatment with 1µM ivermectin. The expression of BDNF 
is induced by cortical neurons and it is necessary for the survival of striatal neurons in the 
human brain (NCBI Gene database, Dec 2008).The AIMP1 gene is specifically induced 
during apoptosis, and is likely to be responsible for modulating the activity of tRNA 
synthetase in normal cells, but renders vasculature sensitive to tumour necrosis factor during 
inflammation. (NCBI Gene Database, information dated Dec. 2008). AIMP1 increased its 
expression compared to control after treatment with both emamectin benzoate and ivermectin 
(Figure 6.9C) in 1 out of 2 samples and is worth further investigation as a potential marker.  
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CX3CL1 also decreased its expression in response to exposure to both avermectins tested 
(Figures 6.9 B, C & D) and  has been found to suppress the activation of microglia in 
Parkinson’s Disease, after insult with 6-hydroxydopamine (6-OHDA) and thus protect 
against neuronal cell damage; its expression is constitutively suppressed but low doses of 
3ng/day to Sprague-Dawley rats resulted in neuroprotection (Pabon et al., 2011). Also, 
CX3CL1 knockout mice are susceptible to autonomous neurotoxicity caused by microglial 
activation (Cardona et al., 2006).   
 
In contrast, the mRNA expression level of SDF-2 decreased compared to control after 18hr 
exposure to both avermectins. SDF2 (stromal-cell derived factor 2) is a secretory protein 
induced in the endoplasmic reticulum under stressed conditions, highly conserved in animals 
and plants. Mutations result in abortive growth and seedling development in the Aribidopsis 
thaliana plant, as it promotes the accumulation of unfolded proteins to facilitate growth and 
development (Schott et al. 2010). The data obtained in the current study cannot be conclusive 
as to a potential, as some of the data conflicts and there were insufficient chemokine array 
plates available to increase the n number of the data, however, BDNF, AIMP1, CX3CL1 and 
SDF2 are all candidates for further study.      
Neurite outgrowth 
Although there are a number of reports of successful quantitative measurement of neurite 
outgrowth in N2a cells and in SH-SY5Y cells, either by length or by number, it proved 
difficult to induce neurites in either cell line on a sufficiently large scale to obtain meaningful 
quantitative data (n ≥ 100 neurites per condition). SH-SY5Y cells were a particularly difficult 
cell type to induce neurite expression in, since they tended to produce short, highly branched 
neurites, and the outgrowth of these was inhibited upon contact with the adjacent cells (data 
not shown). Different densities and time profiles were tested, but further work is required 
with other differentiation agents in order to make this data quantifiable and to compare both 
cell lines. The N2a cells tended to clump when seeded at a suitable density for neurite 
outgrowth, and unsuccessful variations in cell seeding density, this problem was overcome by 
low-level sonication of the cells in suspension for 30 seconds before seeding. It is important 
to note that this procedure may have had an effect upon transporter expression, itself, since it 
may have subjected the cells to mild stress, but this was not ascertained.  
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It is pertinent to compare the results of Sun et al., (2010) who did quantitate a dose-dependent 
decrease in neurite expression with abamectin and the related compound doramectin in N2a 
cells at concentrations as low as 0.5µM up to 4µM. This was achieved by co-incubation of 
the avermectin compounds with the differentiation agent dibutyryl cAMP for 48hr, which is a 
much longer exposure time than that tested in this study. The measurements are also 
different; the work of Sun et al., (2010) looked at the effects of avermectin exposure upon 
initiating differentiation, where as the current study looked at the maintenance of established 
neurites after an acute 1hr exposure. The longer exposure during differentiation is of interest 
and should be investigated in further work.     
Modulation of MDR1 and MRP1 mRNA expression by avermectins 
Exposure to abamectin, emamectin benzoate or ivermectin at 1µM for 18 hours resulted in no 
significant changes to the expression levels of mRNA for either MDR1 or MRP1 over 3 
independent passages of SH-SY5Y cells. 18 hours is a short exposure time for the turnover of 
mRNA to protein and it is of interest to extend the time-span of these experiments to 24 and 
48 hours. It would also be illuminating to incubate cells with a specific inhibitor of MDR1 or 
the MRP transporters, e.g. MK571, and assess whether exposure to avermectins brought 
about modulation of gene and protein expression of the transporter type whose activity was 
not inhibited. This would shed light on whether or not other transporters can compensate for 
loss of efflux function of the avermectins by a given transporter.    
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Figure 6.1 SH-SY5Y cells were exposed to a range of concentrations of Triton-X100. 
Data in the above experiment is mean± S.E.M. n  = 8 , representative of 3 similar 
experiments at different concentrations of detergent within the range 0 – 1.0 %. ** P < 0.01.   
 
Figure 6.2 N2a cells were exposed to a range of concentrations of Triton-X100. Data in 
the above experiment is mean± S.E.M. n  = 8 , representative of 3 similar experiments at 
different concentrations of detergent within the range 0 – 1.0 % **P < 0.01.   
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Figure 6.3 SH-SY5Y cells grown to a sub-confluent monolayer were exposed to 
abamectin at a concentration range 0-10µM for 1 hr, or to 0.01% triton-X-100 for 15 
minutes and then incubated in the dark with MTT reagent dissolved in Krebs buffer for 2 
hours at 37 ºC, after which absorbance of intracellular formazan, solubilised in 100% DMSO, 
was read at 575 ± 5nm, against a background of cells exposed to 100% DMSO but not MTT. 
The background absorbance was substracted, and the readings were normalised to 100% for 
cells exposed to solvent control and MTT reagent. Data are mean ± S.E.M. n = 4 
experiments, each n = 6 wells per concentration. Data are analysed by One-Way ANOVA 
with Dunnett’s post test compared to solvent control; ** P < 0.01. 
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Figure 6.4 N2a cells grown to a sub-confluent monolayer were exposed to abamectin at 
a concentration range 0-10µM for 1 hr, or to 0.01% triton-X-100 for 15 minutes and then 
incubated in the dark with MTT reagent dissolved in Krebs buffer for 2 hours at 37 ºC, after 
which absorbance of intracellular formazan, solubilised in 100% DMSO, was read at 575 ± 
5nm, against a background of cells exposed to 100% DMSO but not MTT. The background 
absorbance was substracted, and the readings were normalised to 100% for cells exposed to 
solvent control and MTT reagent. Data are mean ± S.E.M. n = 4 independent experiments, 
each n = 6 wells per concentration. Data are analysed by One-Way ANOVA with Dunnett’s 
post test compared to solvent control; ** P < 0.01. 
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Figure 6.5 SH-SY5Y cells grown to a sub-confluent monolayer were exposed to 
emamectin benzoate at a concentration range 0-10µM for 1hr or to 0.01% triton-X-100 
for 15 minutes and then incubated with MTT reagent for 2 hours, after which absorbance of 
intracellular formazan, solubilised in 100% DMSO was read at 575nm against a background 
of cells without MTT exposed to the solubilisation agent DMSO (100%). The background 
absorbance was substracted, and the readings were normalised to that for cells exposed to 
solvent control then MTT reagent. Data are mean ± S.E.M.  n = 5 independent experiments, 
each n = 6 wells per concentration. Data are analysed by One-Way ANOVA with Dunnett’s 
post test compared to solvent control; *P < 0.05, **P < 0.01, ***P < 0.001 
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Figure 6.6 N2a cells grown to a sub-confluent monolayer were exposed to emamectin 
benzoate at a concentration range 0-10µM for 1hr or to 0.01% triton-X-100 for 15 
minutes and then incubated with MTT reagent for 2 hours, after which absorbance of 
intracellular formazan, solubilised in 100% DMSO was read at 575nm against a background 
of cells without MTT exposed to the solubilisation agent DMSO (100%). The background 
absorbance was substracted, and the readings were normalised to that for cells exposed to 
solvent control then MTT reagent. Data are mean ± S.E.M. of n = 4 independent experiments, 
each n = 6 wells per concentration. Data are analysed by One-Way ANOVA with Dunnett’s 
post test compared to solvent control; ** P < 0.01.  
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Figure 6.7 SH-SY5Y cells grown to a sub-confluent monolayer were exposed to 
ivermectin at a concentration range 0-10µM for 1hr or to 0.01% triton-X-100 for 15 
minutes and then incubated with MTT reagent for 2 hours, after which absorbance of 
intracellular formazan, solubilised in 100% DMSO was read at 575nm against a background 
of cells without MTT exposed to the solubilisation agent DMSO (100%). The background 
absorbance was substracted, and the readings were normalised to that for cells exposed to 
solvent control then MTT reagent. Data are mean ± S.E.M n = 4 independent experiments, 
each n = 6 wells per concentration. Data are analysed by One-Way ANOVA with Dunnett’s 
post test compared to solvent control; ** P < 0.01. 
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Figure 6.8 N2a cells grown to a sub-confluent monolayer were exposed to ivermectin at 
a concentration range 0-10µM for 1hr or to 0.01% triton-X-100 for 15 minutes and then 
incubated with MTT reagent for 2 hours, after which absorbance of intracellular formazan, 
solubilised in 100% DMSO was read at 575nm against a background of cells without MTT 
exposed to the solubilisation agent DMSO (100%). The background absorbance was 
substracted, and the readings were normalised to that for cells exposed to solvent control then 
MTT reagent. Data are mean ± S.E.M. of n = 4 independent experiments, each n = 6 wells 
per concentration. Data are analysed by One-Way ANOVA with Dunnett’s post test 
compared to solvent control; ** P < 0.01.  
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Figure 6.9 A Emamectin benzoate Sample 1  
Chemokine and chemokine receptor mRNA expression was detected in a 96 well qPCR 
array (SABiosciences PAHS-022) after exposure of independent SH-SY5Y cells samples 
to SH-SY5Y cells to 1µM emamectin benzoate, 1µM ivermectin or solvent control for 18 
hours in the absence of serum. Figure 6.7 A and B show gene expression for 2 independent 
RNA samples from cells exposed to emamectin benzoate versus control. Genes that returned 
a Ct <35 are expressed as log (2
-∆Ct
). Housekeeping gene expression is included for 
comparison. Of interest as potential markers of emamectin benzoate and ivermectin exposure 
are BDNF (Brain-Derived Neurotrophic Factor), AIMP1 (aminoacyl tRNA synthetase 
complex-interacting multifunctional protein 1), CX3CL1 (chemokine (C-X3-C motif) ligand 
1)  and SDF2 (stromal cell-derived factor 2), whose data points are highlighted in red.   
 
-4 
-3.5 
-3 
-2.5 
-2 
-1.5 
-1 
-0.5 
0 
0.5 
1 
-4 -3.5 -3 -2.5 -2 -1.5 -1 -0.5 0 0.5 1 
E
m
a
m
e
ct
in
 B
e
n
zo
a
te
 l
o
g
 (
2
-Δ
C
t )
 
 
Control log (2-ΔCt) 
 
SDF2 
CXC3L1 
GAPDH 
AIMP1 
BDNF 
Chapter 6: Cell viability and markers of avermectin exposure: figures A M Dalzell 
135 
 
 
Figure 6.9 B Emamectin benzoate Sample 2  
Chemokine and chemokine receptor mRNA expression was detected in a 96 well qPCR 
array (SABiosciences PAHS-022) after exposure of independent SH-SY5Y cells samples 
to SH-SY5Y cells to 1µM emamectin benzoate, 1µM ivermectin or solvent control for 18 
hours in the absence of serum. Figure 6.7 A and B show gene expression for 2 independent 
RNA samples from cells exposed to emamectin benzoate versus control Genes that returned a 
Ct <35 are expressed as log (2
-∆Ct
). Housekeeping gene expression is included for 
comparison. Of interest as potential markers of emamectin benzoate and ivermectin exposure 
are BDNF (Brain-Derived Neurotrophic Factor), AIMP1 (aminoacyl tRNA synthetase 
complex-interacting multifunctional protein 1), CX3CL1 (chemokine (C-X3-C motif) ligand 
1)  and SDF2 (stromal cell-derived factor 2), whose data points are highlighted in red.   
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Figure 6.9 C Ivermectin Sample 1  
Chemokine and chemokine receptor mRNA expression was detected in a 96 well qPCR 
array (SABiosciences PAHS-022) after exposure of independent SH-SY5Y cells samples 
to SH-SY5Y cells to 1µM emamectin benzoate 1µM ivermectin or solvent control for 18 
hours in the absence of serum. Figure 6.7 C and D show gene expression for 2 independent 
RNA samples from cells exposed to ivermectin versus control. Genes that returned a Ct <35 
are expressed as log (2
-∆Ct
). Housekeeping gene expression is included for comparison. Of 
interest as potential markers of emamectin benzoate and ivermectin exposure are BDNF 
(Brain-Derived Neurotrophic Factor), AIMP1 (aminoacyl tRNA synthetase complex-
interacting multifunctional protein 1), CX3CL1 (chemokine (C-X3-C motif) ligand 1)  and 
SDF2 (stromal cell-derived factor 2), whose data points are highlighted in red.   
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Figure 6.9 D Ivermectin Sample 2  
Figure 6.9 Chemokine and chemokine receptor mRNA expression was detected in a 96 
well qPCR array (SABiosciences PAHS-022) after exposure of independent SH-SY5Y 
cells samples to SH-SY5Y cells to 1µM emamectin benzoate, 1µM ivermectin or solvent 
control for 18 hours in the absence of serum. Figure 6.7 C and D show gene expression for 
2 independent RNA samples from cells exposed to ivermectin versus control. Genes that 
returned a Ct <35 are expressed as log (2
-∆Ct
). Housekeeping gene expression is included for 
comparison. Of interest as potential markers of emamectin benzoate and ivermectin exposure 
are BDNF (Brain-Derived Neurotrophic Factor), AIMP1 (aminoacyl tRNA synthetase 
complex-interacting multifunctional protein 1), CX3CL1 (chemokine (C-X3-C motif) ligand 
1)  and SDF2 (stromal cell-derived factor 2), whose data points are highlighted in red.   
 
 
 
 
 
-3.5 
-3 
-2.5 
-2 
-1.5 
-1 
-0.5 
0 
0.5 
1 
-3.5 -3 -2.5 -2 -1.5 -1 -0.5 0 0.5 1 
Iv
e
rm
e
ct
in
 l
o
g
 (
2
-Δ
C
t )
 
Control log (2-ΔCt) 
 
BDNF 
AIMP1 
CX3CL1 
SDF2 
GAPDH 
Chapter 6: Cell viability and markers of avermectin exposure: figures A M Dalzell 
138 
 
  
Figure 6.10 Neurite outgrowths in N2a cells visualised by confocal microscopy (A-D) 
and light contrast microscopy (E-F) at x63 magnification. Cells were stained with anti-α-
tubulin antibody and FITC conjugated rabbit anti-mouse IgG as described in methods (A-D). 
Alternatively cells were viewed under a light contrast microscope (Leica) as live cells 
without fixation or staining (E-F). Test conditions prior to visualisation were 60 min exposure 
to: solvent control (A); 0.01M hydrogen peroxide (positive control for ablation of neurite 
outgrowth -B); 1µM abamectin (C); 1µM abamectin (D); 1µM emamectin benzoate (E); 1µM 
ivermectin (F). The images are representative of 6 similar fields in each experiment and the 
experiments were replicated 3 times.  
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Figure 6.11 MDR1 mRNA expression in SH-SY5Y cells after exposure to 1µM 
abamectin, emamectin benzoate, ivermectin or solvent control for 18 hours in the 
absence of serum, normalised to GAPDH expression. Data are mean ±S.E.M. n = 9 using 
total RNA from  3 independent passages of cells, each performed in triplicate, tested for 
statistical significance by One-Way ANOVA with Dunnett’s post-test. There were no 
significant differences between treatments (P > 0.05) 
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.  
Figure 6.12 Expression of MRP1 mRNA in SH-SY5Y cells after exposure to 1µM 
abamectin, emamectin benzoate, ivermectin or solvent control for 18 hours in the 
absence of serum, normalised to GAPDH expression. Data are mean ±S.E.M. n = 9, using 
RNA from 3 independent passages of cells, each performed in triplicate. Data were tested for 
statistical significance using One-Way ANOVA with Dunnett’s post-test. There were no 
significant differences between treatments (P > 0.05). 
 
Summary Conclusions 
There were no gross effects on cell viability, assessed using the MTT assay, for abamectin or 
emamectin benzoate up to 10µM  in SH-SY5Y or N2a cells exposed for 1 hour, conditions 
comparable to the transport assays in Chapters 4 and 5. Emamectin benzoate at 7µM and 
above caused a 50% decrease in SH-SY5Y cell viability (P<0.01) but not for N2a cells. 
Neurite outgrowth did not qualitatively change after 1hr exposure to 1µM abamectin, 
emamectin benzoate or ivermectin in N2a cells.  Expression of MDR1 and MRP1 transporter 
mRNA was not significantly changed compared to control over 3 passages of SH-SY5Y cells 
after 18hr exposure to 1µM concentrations of abamectin, emamectin benzoate or ivermectin. 
The chemokine genes BDNF, AIMP1 CX3CL1 and SDF2 either increased or decreased 
mRNA expression versus control after 18hr exposure to emamectin benzoate or ivermectin at 
1µM and therefore were all identified as candidate markers of emamectin benzoate and 
ivermectin exposure. BDNF and SDF2 are important chemokines in neural cells. 
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Chapter 7: General Discussion, Conclusions and Future Work 
 
This study has shown that the macrocyclic lactone insecticides abamectin, emamectin 
benzoate and ivermectin interact with both MDR1 and MRP transporters in both human and 
mouse neuroblastoma cells SH-SY5Y and N2a.  It has explored the quantitative aspects of 
this interaction and discovered that the avermectins tested inhibit the efflux of substrate dyes 
through the MDR1/mdr1a and MRP/mrp transporters with similar affinities in the low µM 
range. It is yet to be determined whether the insecticides themselves are substrates for these 
transporters, but it is likely that they compete for efflux as the interaction does not increase 
toxicity. The concentrations used are well in excess of the peak plasma concentrations found 
for ivermectin in cattle after therapeutic doses (20ng/mL = 22nM/L) (Alvinerie et al., 1999). 
As insecticides the avermectins have very low application rates on crops (e.g. 6g per hectare), 
as well as short half-lives under conditions of light and moisture, so occupational exposure 
would result in lower plasma concentrations.  
  
SH-SY5Y cells have already proven a useful model for investigating neurotoxicity. Although 
their origin is from peripheral bone marrow, PCR array studies showed that they expressed a 
similar array of uptake and efflux transporters to that in the blood-brain barrier, except that 
BCRP was not expressed. Functional expression of the key efflux transporters MDR1 and 
MRP1 was maintained over three sequential passages. Uptake and efflux transporter 
expression in SH-SY5Y cells was similar to that at the BBB and also closely resembles 
transporter expression in other CNS cell models such as the endothelial cell line hCMEC/D3 
(Carl et al., 2010). N2a cells also sustained the expression of mRNA for mdr1a but not for 
bcrp over three passages, although the full profile of mouse transporters was not investigated.   
 
Until now, transporter affinity data has mostly been obtained in cell lines into which the 
transporter of interest was transfected, resulting in overexpression, e.g. (Griffin et al., 2005; 
Lespine et al., 2007; Brayden & Griffin, 2008; Geyer et al., 2009). Arguably these studies 
may skew the results, returning a higher affinity for the overexpressed transporter than that 
measurable when the transporter is constitutively expressed. The current study is the first to 
compare the interaction of avermectins with endogenously expressed transporters in both 
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human and mouse neuroblastoma cell lines. Data obtained in the current study indicates that 
the affinity profiles for the two efflux transporter types MDR1 and mdr1a as well as MRP 
and mrp are similar between cell lines. This confirms the usefulness of data from mouse 
model cell lines to predict human exposure and suggests that affinity data from in vivo mouse 
models expressing functional mdr1 may be used to draw useful comparisons too.  
 
MDR1 dye retention assays performed in the current study confirmed the existing evidence 
indicating that ivermectin and abamectin are inhibitors of MDR1-mediated substrate dye 
efflux and show that emamectin benzoate was also an inhibitor. All three avermectins 
returned Ki values for MDR1 and mdr1a inhibition in the low µM range but ivermectin was 
the most potent MDR1 inhibitor. In MRP dye retention assays that all three avermectins also 
inhibited human MRP- and mouse mrp transporter efflux activity with affinities in the low 
µM range that were similar to those for MDR1 and mdr1a, and avermectin affinities for MRP 
versus mrp transporters were similar for all three compounds. The interaction of MRP 
transporters with avermectins has been in dispute due to the conflicting findings of Lespine et 
al (2006) and Brayden and Griffin (2008), but the data in the current study has confirmed that 
abamectin, emamectin benzoate and ivermectin inhibit MRP- and mrp-mediated efflux.  
However, their importance in avermectin disposition relative to MDR1 or mdr1a was not 
determined, and is dependent upon absolute protein expression levels as well as affinities. 
 
Interspecies variation in mRNA expression of efflux transporters has been reported, with 
MRP5 being most highly expressed in human BMECs but MRP4 detected at the highest level 
in mouse, and mRNA levels of BCRP being higher in mouse than human. However mRNA 
MDR1 was expressed at equally high levels in all species examined (Warren et al., 2009). It 
is important to note that Warren and colleagues did not conclusively quantitate transporter 
protein expression levels. To investigate the functional consequences of differences in 
absolute transporter expression levels between human and mouse brain cells, it will be 
necessary to perform simultaneous assays of MDR1 and mdr1a in our model cell lines 
alongside the MRP and mrp transporters. The dyes H33342 and CMFDA should be used 
simultaneously in the presence and absence of specific inhibitors (see future work).  
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Avermectins exhibited low toxicity to SH-SY5Y and N2a neuroblastoma cells in culture.  
Toxicity only occurred for emamectin above 6µM; this is 100-fold higher than concentrations 
of ivermectin observed after administration of doses within the therapeutic range (Alvinerie 
et al., 1999). It is important to explore whether toxicity can be increased by exposing the cells 
to mixtures of therapeutic drugs such as cyclosporin and avermectins at therapeutic 
concentrations. 
 
Chemokine genes are induced in the CNS under conditions of chemical stress. Induction of 
these genes might be an early marker of CNS exposure and were explored in cells exposed to 
avermectins. Although the studies produced inconclusive results because of low sample size, 
SDF2, BDNF and AIMP1 were the chemokine genes most affected and these emerge as 
candidates for further study as biomarkers, using a larger sample size and perhaps longer 
avermectin exposure times than 18 hours.  
 
18 hours’ acute exposure to abamectin, emamectin benzoate and ivermectin did not result in 
changes to MDR1 or mrp1 mRNA expression levels in the current study, however  the related 
compounds doramectin and nemadectin have been shown to reverse adriamycin resistance by 
7-fold and 3-fold, respectively, at 1µM. They also significantly down-regulated MDR1 
mRNA protein and protein after 24 hours’ exposure by 30-40% at concentrations of 5µM 
(Gao et al., 2010). In future studies, it would be of interest to increase the exposure to 
avermectins by lengthening the exposure times, increasing the concentrations or repeat 
dosing, to assess the effect on expression of these transporter genes. It would also be of 
interest to expose the cells to avermectins and simultaneously inhibit or silence MDR1 using 
siRNA to see whether MRP1, or other transporters, up-regulate their gene and protein 
expression levels in response.         
 
SH-SY5Y cells and N2a cells are both neuronal precursor cell types that exist in a relatively 
stable state. It is possible to induce neurite expression in both cell types as they begin to 
differentiate into neural cells, by the application of differentiation agents including retinoic 
acid, dibutyryl cAMP and sodium butyrate. All of these agents may be expected to have an 
influence upon efflux transporter expression levels; retinoic acid treatment has been reported 
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to increase MDR1 expression in SH-SY5Y cells (Bates et al. 1989). For this reason the cells 
were maintained in an undifferentiated state throughout the transporter and proliferation 
experiments (Chapters 3-5) but the potential to assess neurite outgrowth as a quantitative 
marker of avermectin exposure was worth exploiting independently here, since differentiated 
N2a and SH-SY5Y cells have both been used successfully in experiments on pesticide 
exposure and viral infection (Vesanen et al. 1994; Kume et al. 2008; Miglio et al. 2009; 
Cheung et al 2009; Sun et al. 2010).         
 
Assays of neurite outgrowth in differentiated cells suggest that the cells maintain outgrowths 
after 1 hours’ exposure to 1µM avermectins. Further work is necessary to quantitate effects of 
avermectin exposure on neurite length and rate of growth;  it would be worth exploring 
differences in their response when they are cultured with avermectins during or after 
differentiation. The reversibility of any effects on neurite outgrowth should be investigated.     
 
Other avermectins and the milbemycins 
The new generation avermectins and milbemycins are all derivatives of ivermectin. They 
may take over eventually due to better potency and/or lower toxicity in veterinary or human 
uses (e.g. selamectin) but for the foreseeable future the natural compound abamectin and its 
semi-synthetic derivatives emamectin benzoate and ivermectin are in use and will remain of 
global importance, so a greater understanding of mechanisms of avermectin exposure is 
pertinent.     
Conclusions 
These studies have confirmed that avermectins are substrates for efflux pumps MDR1 and 
MRP, and that the counterpart mouse transporters have similar kinetics to human. Variation 
in expression of the efflux pumps between cells in the CNS and between individuals may 
contribute to variation in levels of exposure. Although the molecules are relatively non-toxic 
at therapeutic doses, reduced efflux from the CNS has lead to toxicity in mdr1 knockout 
animals. It is unlikely that such non-functional MDR1 polymorphisms will be identified in 
humans, but variability in the transport of individual substrates due to SNPs, or competition 
with other efflux inhibitors or substrate drugs such as CSA or adriamycin (Gao et al., 2010)  
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might still occur in humans; indeed the effects of some polymorphisms are substrate-specific 
in animals (Shilling et al., 2006).  
Future work 
1. Measure intracellular avermectin levels by HPLC after experiments with inhibitors to 
establish whether or not MDR1/mdr1a and MRP/mrp efflux the avermectins directly 
(e.g. Sams et al., 1993). 
2. Assay transporter activity with both H33342 and CMFDA simultaneously, in the 
presence of avermectins with and without inhibitors, to explore the relative 
contributions of the two transporter types MDR1/mdr1a and MRP/mrp when both are 
present and functional. 
3. Conduct assays with avermectins in a BCRP-expressing cell line e.g.hMEC/D3 cells 
to explore the contributions of BCRP/ bcrp not studied here but important at the 
blood-brain barrier.  
4. Further investigate changes in chemokine expression for SDF2, AIMP1 and BDNF.  
5. Perform siRNA knockdown to confirm importance of individual transporter types.   
6. The co-culture of SH-SY5Y and N2a cells with astrocytes may more closely 
approximate physiology of CNS barrier sites. 
7. Assay the influence of polymorphisms upon avermectin exposure in a suitable cell 
type e.g. HEK293.    
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NCBI Reference Sequence: NM_000927.3 
Homo sapiens ATP-binding cassette, sub-family B (MDR/TAP), 
member 1 (ABCB1), mRNA 
ORIGIN       
        1 tattcagata ttctccagat tcctaaagat tagagatcat ttctcattct cctaggagta 
       61 ctcacttcag gaagcaacca gataaaagag aggtgcaacg gaagccagaa cattcctcct 
      121 ggaaattcaa cctgtttcgc agtttctcga ggaatcagca ttcagtcaat ccgggccggg 
      181 agcagtcatc tgtggtgagg ctgattggct gggcaggaac agcgccgggg cgtgggctga 
      241 gcacagccgc ttcgctctct ttgccacagg aagcctgagc tcattcgagt agcggctctt 
      301 ccaagctcaa agaagcagag gccgctgttc gtttccttta ggtctttcca ctaaagtcgg 
      361 agtatcttct tccaaaattt cacgtcttgg tggccgttcc aaggagcgcg aggtcggaat 
      421 ggatcttgaa ggggaccgca atggaggagc aaagaagaag aactttttta aactgaacaa 
      481 taaaagtgaa aaagataaga aggaaaagaa accaactgtc agtgtatttt caatgtttcg 
      541 ctattcaaat tggcttgaca agttgtatat ggtggtggga actttggctg ccatcatcca 
      601 tggggctgga cttcctctca tgatgctggt gtttggagaa atgacagata tctttgcaaa 
      661 tgcaggaaat ttagaagatc tgatgtcaaa catcactaat agaagtgata tcaatgatac 
      721 agggttcttc atgaatctgg aggaagacat gaccaggtat gcctattatt acagtggaat 
      781 tggtgctggg gtgctggttg ctgcttacat tcaggtttca ttttggtgcc tggcagctgg 
      841 aagacaaata cacaaaatta gaaaacagtt ttttcatgct ataatgcgac aggagatagg 
      901 ctggtttgat gtgcacgatg ttggggagct taacacccga cttacagatg atgtctccaa 
      961 gattaatgaa ggaattggtg acaaaattgg aatgttcttt cagtcaatgg caacattttt 
     1021 cactgggttt atagtaggat ttacacgtgg ttggaagcta acccttgtga ttttggccat 
     1081 cagtcctgtt cttggactgt cagctgctgt ctgggcaaag atactatctt catttactga 
     1141 taaagaactc ttagcgtatg caaaagctgg agcagtagct gaagaggtct tggcagcaat 
     1201 tagaactgtg attgcatttg gaggacaaaa gaaagaactt gaaaggtaca acaaaaattt 
     1261 agaagaagct aaaagaattg ggataaagaa agctattaca gccaatattt ctataggtgc 
     1321 tgctttcctg ctgatctatg catcttatgc tctggccttc tggtatggga ccaccttggt 
     1381 cctctcaggg gaatattcta ttggacaagt actcactgta ttcttttctg tattaattgg 
     1441 ggcttttagt gttggacagg catctccaag cattgaagca tttgcaaatg caagaggagc 
     1501 agcttatgaa atcttcaaga taattgataa taagccaagt attgacagct attcgaagag 
     1561 tgggcacaaa ccagataata ttaagggaaa tttggaattc agaaatgttc acttcagtta 
     1621 cccatctcga aaagaagtta agatcttgaa gggtctgaac ctgaaggtgc agagtgggca 
     1681 gacggtggcc ctggttggaa acagtggctg tgggaagagc acaacagtcc agctgatgca 
     1741 gaggctctat gaccccacag aggggatggt cagtgttgat ggacaggata ttaggaccat 
     1801 aaatgtaagg tttctacggg aaatcattgg tgtggtgagt caggaacctg tattgtttgc 
     1861 caccacgata gctgaaaaca ttcgctatgg ccgtgaaaat gtcaccatgg atgagattga 
     1921 gaaagctgtc aaggaagcca atgcctatga ctttatcatg aaactgcctc ataaatttga 
     1981 caccctggtt ggagagagag gggcccagtt gagtggtggg cagaagcaga ggatcgccat 
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     2041 tgcacgtgcc ctggttcgca accccaagat cctcctgctg gatgaggcca cgtcagcctt 
     2101 ggacacagaa agcgaagcag tggttcaggt ggctctggat aaggccagaa aaggtcggac 
     2161 caccattgtg atagctcatc gtttgtctac agttcgtaat gctgacgtca tcgctggttt 
     2221 cgatgatgga gtcattgtgg agaaaggaaa tcatgatgaa ctcatgaaag agaaaggcat 
     2281 ttacttcaaa cttgtcacaa tgcagacagc aggaaatgaa gttgaattag aaaatgcagc 
     2341 tgatgaatcc aaaagtgaaa ttgatgcctt ggaaatgtct tcaaatgatt caagatccag 
     2401 tctaataaga aaaagatcaa ctcgtaggag tgtccgtgga tcacaagccc aagacagaaa 
     2461 gcttagtacc aaagaggctc tggatgaaag tatacctcca gtttcctttt ggaggattat 
     2521 gaagctaaat ttaactgaat ggccttattt tgttgttggt gtattttgtg ccattataaa 
     2581 tggaggcctg caaccagcat ttgcaataat attttcaaag attatagggg tttttacaag 
     2641 aattgatgat cctgaaacaa aacgacagaa tagtaacttg ttttcactat tgtttctagc 
     2701 ccttggaatt atttctttta ttacattttt ccttcagggt ttcacatttg gcaaagctgg 
     2761 agagatcctc accaagcggc tccgatacat ggttttccga tccatgctca gacaggatgt 
     2821 gagttggttt gatgacccta aaaacaccac tggagcattg actaccaggc tcgccaatga 
     2881 tgctgctcaa gttaaagggg ctataggttc caggcttgct gtaattaccc agaatatagc 
     2941 aaatcttggg acaggaataa ttatatcctt catctatggt tggcaactaa cactgttact 
     3001 cttagcaatt gtacccatca ttgcaatagc aggagttgtt gaaatgaaaa tgttgtctgg 
     3061 acaagcactg aaagataaga aagaactaga aggttctggg aagatcgcta ctgaagcaat 
     3121 agaaaacttc cgaaccgttg tttctttgac tcaggagcag aagtttgaac atatgtatgc 
     3181 tcagagtttg caggtaccat acagaaactc tttgaggaaa gcacacatct ttggaattac 
     3241 attttccttc acccaggcaa tgatgtattt ttcctatgct ggatgtttcc ggtttggagc 
     3301 ctacttggtg gcacataaac tcatgagctt tgaggatgtt ctgttagtat tttcagctgt 
     3361 tgtctttggt gccatggccg tggggcaagt cagttcattt gctcctgact atgccaaagc 
     3421 caaaatatca gcagcccaca tcatcatgat cattgaaaaa acccctttga ttgacagcta 
     3481 cagcacggaa ggcctaatgc cgaacacatt ggaaggaaat gtcacatttg gtgaagttgt 
     3541 attcaactat cccacccgac cggacatccc agtgcttcag ggactgagcc tggaggtgaa 
     3601 gaagggccag acgctggctc tggtgggcag cagtggctgt gggaagagca cagtggtcca 
     3661 gctcctggag cggttctacg accccttggc agggaaagtg ctgcttgatg gcaaagaaat 
     3721 aaagcgactg aatgttcagt ggctccgagc acacctgggc atcgtgtccc aggagcccat 
     3781 cctgtttgac tgcagcattg ctgagaacat tgcctatgga gacaacagcc gggtggtgtc 
     3841 acaggaagag attgtgaggg cagcaaagga ggccaacata catgccttca tcgagtcact 
     3901 gcctaataaa tatagcacta aagtaggaga caaaggaact cagctctctg gtggccagaa 
     3961 acaacgcatt gccatagctc gtgcccttgt tagacagcct catattttgc ttttggatga 
     4021 agccacgtca gctctggata cagaaagtga aaaggttgtc caagaagccc tggacaaagc 
     4081 cagagaaggc cgcacctgca ttgtgattgc tcaccgcctg tccaccatcc agaatgcaga 
     4141 cttaatagtg gtgtttcaga atggcagagt caaggagcat ggcacgcatc agcagctgct 
     4201 ggcacagaaa ggcatctatt tttcaatggt cagtgtccag gctggaacaa agcgccagtg 
     4261 aactctgact gtatgagatg ttaaatactt tttaatattt gtttagatat gacatttatt 
     4321 caaagttaaa agcaaacact tacagaatta tgaagaggta tctgtttaac atttcctcag 
     4381 tcaagttcag agtcttcaga gacttcgtaa ttaaaggaac agagtgagag acatcatcaa 
     4441 gtggagagaa atcatagttt aaactgcatt ataaatttta taacagaatt aaagtagatt 
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     4501 ttaaaagata aaatgtgtaa ttttgtttat attttcccat ttggactgta actgactgcc 
     4561 ttgctaaaag attatagaag tagcaaaaag tattgaaatg tttgcataaa gtgtctataa 
     4621 taaaactaaa ctttcatgtg actggagtca tcttgtccaa actgcctgtg aatatatctt 
     4681 ctctcaattg gaatattgta gataacttct gctttaaaaa agttttcttt aaatatacct 
     4741 actcattttt gtgggaatgg ttaagcagtt taaataattc ctgttgtata tgtctattca 
     4801 cattgggtct tacagaacca tctggcttca ttcttcttgg acttgatcct gctgattctt 
     4861 gcatttccac at 
// 
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Homo sapiens ATP-binding cassette, sub-family G (WHITE), member 2 
(ABCG2), mRNA 
NCBI Reference Sequence: NM_004827.2 
ORIGIN       
        1 gtcagcgctg cctgagctcg tcccctggat gtccgggtct ccccaggcgg ccacccgccg 
       61 gctcccatcg tgacctccag ccgcagcgcc tcccacgccg gccgccgcgc gaggggagcg 
      121 ctcgggcgcg ccgggtgtgg ttgggggaag gggttgtgcc gcgcgcgggc tgcgtgctgt 
      181 gcccactcaa aaggttccgg gcgcgcagga gggaagaggc agtgcccgcc actcccactg 
      241 agattgagag acgcggcaag gaggcagcct gtggaggaac tgggtaggat ttaggaacgc 
      301 accgtgcaca tgcttggtgg tcttgttaag tggaaactgc tgctttagag tttgtttgga 
      361 aggtccgggt gactcatccc aacatttaca tccttaattg ttaaagcgct gcctccgagc 
      421 gcacgcatcc tgagatcctg agcctttggt taagaccgag ctctattaag ctgaaaagat 
      481 aaaaactctc cagatgtctt ccagtaatgt cgaagttttt atcccagtgt cacaaggaaa 
      541 caccaatggc ttccccgcga cagcttccaa tgacctgaag gcatttactg aaggagctgt 
      601 gttaagtttt cataacatct gctatcgagt aaaactgaag agtggctttc taccttgtcg 
      661 aaaaccagtt gagaaagaaa tattatcgaa tatcaatggg atcatgaaac ctggtctcaa 
      721 cgccatcctg ggacccacag gtggaggcaa atcttcgtta ttagatgtct tagctgcaag 
      781 gaaagatcca agtggattat ctggagatgt tctgataaat ggagcaccgc gacctgccaa 
      841 tttcaaatgt aattcaggtt acgtggtaca agatgatgtt gtgatgggca ctctgacggt 
      901 gagagaaaac ttacagttct cagcagctct tcggcttgca acaactatga cgaatcatga 
      961 aaaaaacgaa cggattaaca gggtcattca agagttaggt ctggataaag tggcagactc 
     1021 caaggttgga actcagttta tccgtggtgt gtctggagga gaaagaaaaa ggactagtat 
     1081 aggaatggag cttatcactg atccttccat cttgttcttg gatgagccta caactggctt 
     1141 agactcaagc acagcaaatg ctgtcctttt gctcctgaaa aggatgtcta agcagggacg 
     1201 aacaatcatc ttctccattc atcagcctcg atattccatc ttcaagttgt ttgatagcct 
     1261 caccttattg gcctcaggaa gacttatgtt ccacgggcct gctcaggagg ccttgggata 
     1321 ctttgaatca gctggttatc actgtgaggc ctataataac cctgcagact tcttcttgga 
     1381 catcattaat ggagattcca ctgctgtggc attaaacaga gaagaagact ttaaagccac 
     1441 agagatcata gagccttcca agcaggataa gccactcata gaaaaattag cggagattta 
     1501 tgtcaactcc tccttctaca aagagacaaa agctgaatta catcaacttt ccgggggtga 
     1561 gaagaagaag aagatcacag tcttcaagga gatcagctac accacctcct tctgtcatca 
     1621 actcagatgg gtttccaagc gttcattcaa aaacttgctg ggtaatcccc aggcctctat 
     1681 agctcagatc attgtcacag tcgtactggg actggttata ggtgccattt actttgggct 
     1741 aaaaaatgat tctactggaa tccagaacag agctggggtt ctcttcttcc tgacgaccaa 
     1801 ccagtgtttc agcagtgttt cagccgtgga actctttgtg gtagagaaga agctcttcat 
     1861 acatgaatac atcagcggat actacagagt gtcatcttat ttccttggaa aactgttatc 
     1921 tgatttatta cccatgagga tgttaccaag tattatattt acctgtatag tgtacttcat 
     1981 gttaggattg aagccaaagg cagatgcctt cttcgttatg atgtttaccc ttatgatggt 
     2041 ggcttattca gccagttcca tggcactggc catagcagca ggtcagagtg tggtttctgt 
     2101 agcaacactt ctcatgacca tctgttttgt gtttatgatg attttttcag gtctgttggt 
     2161 caatctcaca accattgcat cttggctgtc atggcttcag tacttcagca ttccacgata 
     2221 tggatttacg gctttgcagc ataatgaatt tttgggacaa aacttctgcc caggactcaa 
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     2281 tgcaacagga aacaatcctt gtaactatgc aacatgtact ggcgaagaat atttggtaaa 
     2341 gcagggcatc gatctctcac cctggggctt gtggaagaat cacgtggcct tggcttgtat 
     2401 gattgttatt ttcctcacaa ttgcctacct gaaattgtta tttcttaaaa aatattctta 
     2461 aatttcccct taattcagta tgatttatcc tcacataaaa aagaagcact ttgattgaag 
     2521 tattcaatca agtttttttg ttgttttctg ttcccttgcc atcacactgt tgcacagcag 
     2581 caattgtttt aaagagatac atttttagaa atcacaacaa actgaattaa acatgaaaga 
     2641 acccaagaca tcatgtatcg catattagtt aatctcctca gacagtaacc atggggaaga 
     2701 aatctggtct aatttattaa tctaaaaaag gagaattgaa ttctggaaac tcctgacaag 
     2761 ttattactgt ctctggcatt tgtttcctca tctttaaaat gaataggtag gttagtagcc 
     2821 cttcagtctt aatactttat gatgctatgg tttgccatta tttaataaat gacaaatgta 
     2881 ttaatgctat actggaaatg taaaattgaa aatatgttgg aaaaaagatt ctgtcttata 
     2941 gggtaaaaaa agccaccgtg atagaaaaaa aatctttttg ataagcacat taaagttaat 
     3001 agaacttact gatattcctg tctagtggta taatatctca ggaatcttgg ctgagggttt 
     3061 ggaactgtgg gtagagtaga gggccaggag tccagtaata gaattcttgc accatttctg 
     3121 gaacattcta gctctgggag gtcacgtaac cttcttgggg tagttcagtg gtttagtggt 
     3181 ttataatcca ggtgtgcgtc agaatcatct gaggaacttt gctaaaatac aaaaatctgg 
     3241 cctaagtagc tccagatcta ccttcataaa ggaatctgac cactcctgga tttggtaatt 
     3301 tccaagttct gaaaatttta cttaggattt aataactatt aacatctgtc cctacatagg 
     3361 ttttctttcc tacttatata ccttatgttc tcttcattct aaccttcatc agtaataggg 
     3421 aaatgtttta attttatttt tttagttgaa gggtaatgta ccaaaaaata tagttcagtg 
     3481 aattaaaatg aacacacatg tgcaaccatc aattcaggtc aagaaataga agattgtagc 
     3541 acacaaaagc ctactcagcc attctcccag tcactacttc cttccttacc cctgggttat 
     3601 ttttgaaatg acacttgatg tatttccctc tgttgctgtt atgagaacat tgctacagcc 
     3661 aagtgttgtg tttctgtgtg cataggttga tacttaatta tctccccact ttttaataaa 
     3721 cttttaattt ggaaataatt ttagattgac agaaaagttg caaagatagt gaggaaagtt 
     3781 cctgtctact ctttgctcag cttcccttaa tgttaacatt ttatatagca agatgcattt 
     3841 gtcaaagcta acaagttaac attggtacaa tcactgttaa ttaaactgca cacaatattc 
     3901 agatttcacc acttttccac taatattctt tcattgttct aggattcaat tcaggagacc 
     3961 acatttcatc tagccctctt ttttaaaagt aaatactttt cagcacttac aggagttaac 
     4021 tgagctgggg catcatggtg tatagacgcc ctgacactgg tcatcttgga attcatttag 
     4081 tttgtcagtg ggtgccctga cattctgtca caacatcaat ttgggaacat ggcattatat 
     4141 ttttatcttt gaactttttt ctttttggat gacatttgat taatgcgtca tcttggaaca 
     4201 cattatcttt tttcttggtt atgtgatcag gaagattaat cagtttttcc tgttcttggt 
     4261 ataattcctg cttttcacat acctgtccct tacagttctc tatatatacc cttcccttat 
     4321 tacacagaga gaaatatcta tctatacttt ttacacaaaa tatacttcaa aagaaacaaa 
     4381 acagccacaa ttattaactt tttaaataaa tgagaattta attatatcct aaaaaaaaaa 
     4441 aaaaa 
// 
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Homo sapiens ATP-binding cassette, sub-family C (CFTR/MRP), member 
1 (ABCC1), transcript variant 1, mRNA 
NCBI Reference Sequence: NM_004996.3 
ORIGIN       
        1 ccaggcggcg ttgcggcccc ggccccggct ccctgcgccg ccgccgccgc cgccgccagc 
       61 gctagcgcca gcagccgggc ccgatcaccc gccgcccggt gcccgccgcc gcccgcgcca 
      121 gcaaccgggc ccgatcaccc gccgcccggt gcccgccgcc gcccgcgcca ccggcatggc 
      181 gctccggggc ttctgcagcg ccgatggctc cgacccgctc tgggactgga atgtcacgtg 
      241 gaataccagc aaccccgact tcaccaagtg ctttcagaac acggtcctcg tgtgggtgcc 
      301 ttgtttttac ctctgggcct gtttcccctt ctacttcctc tatctctccc gacatgaccg 
      361 aggctacatt cagatgacac ctctcaacaa aaccaaaact gccttgggat ttttgctgtg 
      421 gatcgtctgc tgggcagacc tcttctactc tttctgggaa agaagtcggg gcatattcct 
      481 ggccccagtg tttctggtca gcccaactct cttgggcatc accatgctgc ttgctacctt 
      541 tttaattcag ctggagagga ggaagggagt tcagtcttca gggatcatgc tcactttctg 
      601 gctggtagcc ctagtgtgtg ccctagccat cctgagatcc aaaattatga cagccttaaa 
      661 agaggatgcc caggtggacc tgtttcgtga catcactttc tacgtctact tttccctctt 
      721 actcattcag ctcgtcttgt cctgtttctc agatcgctca cccctgttct cggaaaccat 
      781 ccacgaccct aatccctgcc cagagtccag cgcttccttc ctgtcgagga tcaccttctg 
      841 gtggatcaca gggttgattg tccggggcta ccgccagccc ctggagggca gtgacctctg 
      901 gtccttaaac aaggaggaca cgtcggaaca agtcgtgcct gttttggtaa agaactggaa 
      961 gaaggaatgc gccaagacta ggaagcagcc ggtgaaggtt gtgtactcct ccaaggatcc 
     1021 tgcccagccg aaagagagtt ccaaggtgga tgcgaatgag gaggtggagg ctttgatcgt 
     1081 caagtcccca cagaaggagt ggaacccctc tctgtttaag gtgttataca agacctttgg 
     1141 gccctacttc ctcatgagct tcttcttcaa ggccatccac gacctgatga tgttttccgg 
     1201 gccgcagatc ttaaagttgc tcatcaagtt cgtgaatgac acgaaggccc cagactggca 
     1261 gggctacttc tacaccgtgc tgctgtttgt cactgcctgc ctgcagaccc tcgtgctgca 
     1321 ccagtacttc cacatctgct tcgtcagtgg catgaggatc aagaccgctg tcattggggc 
     1381 tgtctatcgg aaggccctgg tgatcaccaa ttcagccaga aaatcctcca cggtcgggga 
     1441 gattgtcaac ctcatgtctg tggacgctca gaggttcatg gacttggcca cgtacattaa 
     1501 catgatctgg tcagcccccc tgcaagtcat ccttgctctc tacctcctgt ggctgaatct 
     1561 gggcccttcc gtcctggctg gagtggcggt gatggtcctc atggtgcccg tcaatgctgt 
     1621 gatggcgatg aagaccaaga cgtatcaggt ggcccacatg aagagcaaag acaatcggat 
     1681 caagctgatg aacgaaattc tcaatgggat caaagtgcta aagctttatg cctgggagct 
     1741 ggcattcaag gacaaggtgc tggccatcag gcaggaggag ctgaaggtgc tgaagaagtc 
     1801 tgcctacctg tcagccgtgg gcaccttcac ctgggtctgc acgccctttc tggtggcctt 
     1861 gtgcacattt gccgtctacg tgaccattga cgagaacaac atcctggatg cccagacagc 
     1921 cttcgtgtct ttggccttgt tcaacatcct ccggtttccc ctgaacattc tccccatggt 
     1981 catcagcagc atcgtgcagg cgagtgtctc cctcaaacgc ctgaggatct ttctctccca 
     2041 tgaggagctg gaacctgaca gcatcgagcg acggcctgtc aaagacggcg ggggcacgaa 
     2101 cagcatcacc gtgaggaatg ccacattcac ctgggccagg agcgaccctc ccacactgaa 
     2161 tggcatcacc ttctccatcc ccgaaggtgc tttggtggcc gtggtgggcc aggtgggctg 
     2221 cggaaagtcg tccctgctct cagccctctt ggctgagatg gacaaagtgg aggggcacgt 
     2281 ggctatcaag ggctccgtgg cctatgtgcc acagcaggcc tggattcaga atgattctct 
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     2341 ccgagaaaac atcctttttg gatgtcagct ggaggaacca tattacaggt ccgtgataca 
     2401 ggcctgtgcc ctcctcccag acctggaaat cctgcccagt ggggatcgga cagagattgg 
     2461 cgagaagggc gtgaacctgt ctgggggcca gaagcagcgc gtgagcctgg cccgggccgt 
     2521 gtactccaac gctgacattt acctcttcga tgatcccctc tcagcagtgg atgcccatgt 
     2581 gggaaaacac atctttgaaa atgtgattgg ccccaagggg atgctgaaga acaagacgcg 
     2641 gatcttggtc acgcacagca tgagctactt gccgcaggtg gacgtcatca tcgtcatgag 
     2701 tggcggcaag atctctgaga tgggctccta ccaggagctg ctggctcgag acggcgcctt 
     2761 cgctgagttc ctgcgtacct atgccagcac agagcaggag caggatgcag aggagaacgg 
     2821 ggtcacgggc gtcagcggtc cagggaagga agcaaagcaa atggagaatg gcatgctggt 
     2881 gacggacagt gcagggaagc aactgcagag acagctcagc agctcctcct cctatagtgg 
     2941 ggacatcagc aggcaccaca acagcaccgc agaactgcag aaagctgagg ccaagaagga 
     3001 ggagacctgg aagctgatgg aggctgacaa ggcgcagaca gggcaggtca agctttccgt 
     3061 gtactgggac tacatgaagg ccatcggact cttcatctcc ttcctcagca tcttcctttt 
     3121 catgtgtaac catgtgtccg cgctggcttc caactattgg ctcagcctct ggactgatga 
     3181 ccccatcgtc aacgggactc aggagcacac gaaagtccgg ctgagcgtct atggagccct 
     3241 gggcatttca caagggatcg ccgtgtttgg ctactccatg gccgtgtcca tcggggggat 
     3301 cttggcttcc cgctgtctgc acgtggacct gctgcacagc atcctgcggt cacccatgag 
     3361 cttctttgag cggaccccca gtgggaacct ggtgaaccgc ttctccaagg agctggacac 
     3421 agtggactcc atgatcccgg aggtcatcaa gatgttcatg ggctccctgt tcaacgtcat 
     3481 tggtgcctgc atcgttatcc tgctggccac gcccatcgcc gccatcatca tcccgcccct 
     3541 tggcctcatc tacttcttcg tccagaggtt ctacgtggct tcctcccggc agctgaagcg 
     3601 cctcgagtcg gtcagccgct ccccggtcta ttcccatttc aacgagacct tgctgggggt 
     3661 cagcgtcatt cgagccttcg aggagcagga gcgcttcatc caccagagtg acctgaaggt 
     3721 ggacgagaac cagaaggcct attaccccag catcgtggcc aacaggtggc tggccgtgcg 
     3781 gctggagtgt gtgggcaact gcatcgttct gtttgctgcc ctgtttgcgg tgatctccag 
     3841 gcacagcctc agtgctggct tggtgggcct ctcagtgtct tactcattgc aggtcaccac 
     3901 gtacttgaac tggctggttc ggatgtcatc tgaaatggaa accaacatcg tggccgtgga 
     3961 gaggctcaag gagtattcag agactgagaa ggaggcgccc tggcaaatcc aggagacagc 
     4021 tccgcccagc agctggcccc aggtgggccg agtggaattc cggaactact gcctgcgcta 
     4081 ccgagaggac ctggacttcg ttctcaggca catcaatgtc acgatcaatg ggggagaaaa 
     4141 ggtcggcatc gtggggcgga cgggagctgg gaagtcgtcc ctgaccctgg gcttatttcg 
     4201 gatcaacgag tctgccgaag gagagatcat catcgatggc atcaacatcg ccaagatcgg 
     4261 cctgcacgac ctccgcttca agatcaccat catcccccag gaccctgttt tgttttcggg 
     4321 ttccctccga atgaacctgg acccattcag ccagtactcg gatgaagaag tctggacgtc 
     4381 cctggagctg gcccacctga aggacttcgt gtcagccctt cctgacaagc tagaccatga 
     4441 atgtgcagaa ggcggggaga acctcagtgt cgggcagcgc cagcttgtgt gcctagcccg 
     4501 ggccctgctg aggaagacga agatccttgt gttggatgag gccacggcag ccgtggacct 
     4561 ggaaacggac gacctcatcc agtccaccat ccggacacag ttcgaggact gcaccgtcct 
     4621 caccatcgcc caccggctca acaccatcat ggactacaca agggtgatcg tcttggacaa 
     4681 aggagaaatc caggagtacg gcgccccatc ggacctcctg cagcagagag gtcttttcta 
     4741 cagcatggcc aaagacgccg gcttggtgtg agccccagag ctggcatatc tggtcagaac 
     4801 tgcagggcct atatgccagc gcccagggag gagtcagtac ccctggtaaa ccaagcctcc 
     4861 cacactgaaa ccaaaacata aaaaccaaac ccagacaacc aaaacatatt caaagcagca 
     4921 gccaccgcca tccggtcccc tgcctggaac tggctgtgaa gacccaggag agacagagat 
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     4981 gcgaaccacc caaaacacgc acaccctgcc cctggtgccc tgagacagac acacagcctc 
     5041 acgcccccag gaatgcaagt ggtttcctgg tgcttcccac ggaggagttt tggcagccag 
     5101 acttctggag gaattggttg tatagaagat cctagtgacc aaattcagcc tactgcctcg 
     5161 gatctctcca gccgaagtct gtggactgca agtctttgag atgcttctgg ctcccatcac 
     5221 ctctaacatc cttgtctggg tctaccagga acgcttcatt tccttggggc tgcagttttg 
     5281 tggttgaggg gcctggagaa aatcattttc tccccttggc agtgtcccag ggccctggat 
     5341 ggtcctctta ccaacatctg gtcttccagg cactcaaaag ctgggaacca gcatctcagc 
     5401 gccagctcta ccagttctcg ttttgggcca gaggcagcct ctgcactccc acgcctgtcc 
     5461 tcctggaagg gacctggttg gactaacggc taacctggac ctggaactgt agggccaggg 
     5521 gattgtctca gggccgacgt tccacctggg gcttccctcc ccacccaccc cgactccagg 
     5581 ctttcccttt tttcttttgt tcaacattgt aagaacaatc aatgctgtta ttactgttcc 
     5641 caccatgatt gatgtggggt aaatattaag gagatggcct catgggaatt tgaccttgac 
     5701 tagaaataga gactgagagt gagcaaccag ctggaaggta ctatgccagt cctagcagaa 
     5761 aaatgtgtta ggggcctggc ccaaagcagt gttggttgct tacagtgttg attgattttg 
     5821 ttcttttttc ttaccacctc ttttctttcc ctctcatggt acctgctcat ggttatgaag 
     5881 ctttcaaagt aaagaacacg aaatacctcc caagtattac cagtgggtac caaaaaaatg 
     5941 tccccttgag tcttttcctt gtttttagat gttaattctc tcccttggca tccggttagc 
     6001 cccccagggg gggcagcatt gtggagaact tgatatttag ttactgatgc tcttccagga 
     6061 cacgaaaaga acccatcttt gaatatcaat gatttttttt ttttaagtac tgttccgggg 
     6121 agaaaaacag tctcaaaact tgaacttctt gggaatagaa gtgttgggct gagaagtaac 
     6181 attcccagga aatagtgaga agctcgccct gtgtttgaaa ccgtgttggt ctctgtgttc 
     6241 ctggaagaaa acagggaagc agcatctttt aaagcctgtt ctttaaggtg tctcgttaga 
     6301 gcccaaagtg gaatccggaa ggcagccaga gctgaggctg ccccaagact cagacttgct 
     6361 aagaattacg ccgccgactt caaacccaga gagcatcttt cttttaggcg aaaacgcata 
     6421 tatttatttt ttgtaagtta taccattctt tcacattaga taaactaagt tttgggggat 
     6481 ccttttgtaa tgacttacac tggaaatgcg aacatttgca gtaaaaaaat atatatatat 
     6541 ctatatattt tatttctttc taaa 
// 
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Mus musculus ATP-binding cassette, sub-family B (MDR/TAP), 
member 1A (Abcb1a), mRNA 
NCBI Reference Sequence: NM_011076.2 red highlight = human MDR1 primer 
ORIGIN       
        1 acagtggaac agcggtttcc aggagctgct ggtcccatct tccaaggctc tgctcaactc 
       61 agagccgctt cttccaaagt ctacatcttg gtggactttg cagaggaaac cgggaggtag 
      121 agacacgtga ggtcgtgatg gaacttgaag aggaccttaa gggaagagca gacaagaact 
      181 tctcaaagat gggcaaaaag agtaaaaagg agaagaaaga aaagaaacca gcagtcagtg 
      241 tgcttacaat gtttcgttat gcaggttggc tggacaggtt gtacatgctg gtgggaactc 
      301 tggctgctat tatccatgga gtggcgctcc cacttatgat gctgatcttt ggtgacatga 
      361 cagatagctt tgcaagtgta ggaaacgtct ctaaaaacag tactaatatg agtgaggccg 
      421 ataaaagagc catgtttgcc aaactggagg aagaaatgac cacgtacgcc tactattaca 
      481 ccgggattgg tgctggtgtg ctcatagttg cctacatcca ggtttcattt tggtgcctgg 
      541 cagctggaag acagatacac aagatcaggc agaagttttt tcatgctata atgaatcagg 
      601 agataggctg gtttgatgtg catgacgttg gggagctcaa cacccggctc acagatgatg 
      661 tttccaaaat taatgaagga attggtgaca aaatcggaat gttcttccag gcaatggcaa 
      721 cattttttgg tggttttata ataggattta cccgtggctg gaagctaacc cttgtgattt 
      781 tggccatcag ccctgttctt ggactgtcag ctggtatttg ggcaaagata ttgtcttcat 
      841 ttactgataa ggaactccat gcttatgcaa aagctggagc agttgctgaa gaagtcttag 
      901 cagccatcag aactgtgatt gcgtttggag gacaaaagaa ggaacttgaa aggtacaata 
      961 acaacttgga agaagctaaa aggctgggga taaagaaagc tatcacggcc aacatctcca 
     1021 tgggtgcagc ttttctcctt atctatgcat catatgctct ggcattctgg tatgggactt 
     1081 ccttggtcat ctccaaagaa tactctattg gacaagtgct cactgtcttc ttttccgtgt 
     1141 taattggagc attcagtgtt ggacaggcat ctccaaatat tgaagccttc gccaatgcac 
     1201 gaggagcagc ttatgaagtc ttcaaaataa ttgataataa gcccagtata gacagcttct 
     1261 caaagagtgg gcacaaacca gacaacatac aaggaaatct ggaatttaag aatattcact 
     1321 tcagttaccc atctcgaaaa gaagttcaga tcttgaaggg cctcaatctg aaggtgaaga 
     1381 gcggacagac ggtggccctg gttggcaaca gtggctgtgg aaaaagcaca actgtccagc 
     1441 tgatgcaaag gctctacgac cccctagatg gcatggtcag tatcgacgga caggacatca 
     1501 gaaccatcaa tgtgaggtat ctgagggaga tcattggtgt ggtgagtcag gaacctgtgc 
     1561 tgtttgccac cacgatcgcc gagaacattc gctatggccg agaagatgtc accatggatg 
     1621 agattgagaa agctgtcaag gaagccaatg cctatgactt catcatgaaa ctgccccacc 
     1681 aatttgacac cctggttggt gagagagggg cgcagctgag tgggggacag aaacagagaa 
     1741 tcgccattgc ccgggccctg gtccgcaatc ccaagatcct tttgttggac gaggccacct 
     1801 cagccctgga tacagaaagt gaagctgtgg ttcaggccgc actggataag gctagagaag 
     1861 gccggaccac cattgtgata gctcatcgct tgtctaccgt tcgtaatgct gacgtcattg 
     1921 ctggttttga tggtggtgtc attgtggagc aaggaaatca tgatgagctc atgagagaaa 
     1981 agggcattta cttcaaactt gtcatgacac agacagcagg aaatgaaatt gaattaggaa 
     2041 atgaagcttg taaatctaag gatgaaattg ataatttaga catgtcttca aaagattcag 
     2101 gatccagtct aataagaaga agatcaactc gcaaaagcat ctgtggacca catgaccaag 
     2161 acaggaagct tagtaccaaa gaggccctgg atgaagatgt acctccagct tccttttggc 
     2221 ggatcctgaa gttgaattca actgaatggc cttattttgt ggttggtata ttctgtgcca 
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     2281 taataaatgg aggcttacag ccagcattct ccgtaatatt ttcaaaagtt gtaggggttt 
     2341 ttacaaatgg tggcccccct gaaacccagc ggcagaacag caacttgttt tccttgttgt 
     2401 ttctgatcct tgggatcatt tctttcatta cattttttct tcagggcttc acatttggca 
     2461 aagctggaga gatcctcacc aagcgactcc gatacatggt tttcaaatcc atgctgagac 
     2521 aggatgtgag ctggtttgat gaccctaaaa acaccaccgg agcactgacc accaggctcg 
     2581 ccaacgatgc tgctcaagtg aaaggggcta cagggtctag gcttgctgtg attttccaga 
     2641 acatagcaaa tcttgggaca ggaatcatca tatccctaat ctatggctgg caactaacac 
     2701 ttttactctt agcaattgta cccatcattg cgatagcagg agtggttgaa atgaaaatgt 
     2761 tgtctggaca agcactgaaa gataagaagg aactagaagg ttctggaaag attgctacgg 
     2821 aagcaattga aaacttccgc actgttgtct ctttgactcg ggagcagaag tttgaaacca 
     2881 tgtatgccca gagcttgcag ataccataca gaaatgcgat gaagaaagca cacgtgtttg 
     2941 ggatcacgtt ctccttcacc caggccatga tgtatttttc ttatgctgct tgtttccggt 
     3001 tcggtgccta cttggtgaca caacaactca tgacttttga aaatgttctg ttagtattct 
     3061 cagctattgt ctttggtgcc atggcagtgg ggcaggtcag ttcattcgct cctgactatg 
     3121 cgaaagccac agtgtcagca tcccacatca tcaggatcat tgagaaaacc cccgagattg 
     3181 acagctacag cacgcaaggc ctaaagccga atatgttgga aggaaatgtg caatttagtg 
     3241 gagtcgtgtt caactatccc acccgaccca gcatcccagt gcttcagggg ctgagccttg 
     3301 aggtgaagaa gggccagacg ctggccctgg tgggcagcag tggctgcggg aagagcacag 
     3361 tggtccagct gctcgagcgc ttctacgacc ccatggctgg atcagtgttt ctagatggca 
     3421 aagaaataaa gcaactgaat gtccagtggc tccgagcaca gctgggcatt gtgtcccaag 
     3481 agcccattct ctttgactgc agcatcgcag agaacattgc ctacggagac aacagccggg 
     3541 tcgtgtctta tgaggagatt gtgagggcag ccaaggaggc caacatccac cagttcatcg 
     3601 actcgctacc tgataaatac aacaccagag taggagacaa aggcactcag ctgtcgggtg 
     3661 ggcagaagca gcgcatcgcc atcgcacgcg ccctcgtcag acagcctcac attttacttc 
     3721 tggacgaagc aacatcagct ctggatacag aaagtgaaaa ggttgtccag gaagcgctgg 
     3781 acaaagccag ggaaggccgc acctgcattg tgatcgctca ccgcctgtcc accatccaga 
     3841 acgcggactt gatcgtggtg attcagaacg gcaaggtcaa ggagcacggc acccaccagc 
     3901 agctgctggc gcagaagggc atctacttct caatggtcag tgtgcaggct ggagcaaagc 
     3961 gctcatgaac tgtgaccatg taagatgtta agtattttta ttgtttgtat tcatatatgg 
     4021 tgtttaatcc aagtcaaaag gaaaacactt actaaaatag ccagttatct attttctgcc 
     4081 acagtggaaa gcatttagtt tggtttagag tcttcagagg ctttgtaatt aaaaaaacaa 
     4141 aaatagatac agcatcaaat ggagattaat gctttaaaat gcactataaa atttataaaa 
     4201 gggttaaaag tgaatgtttg ataatatata cttttattta tactttctca tttgtaacta 
     4261 taactgattt ctgcttaaca aattatgtat gtatcaaaaa ttactgaaat gtttgtataa 
     4321 agtatatata gtgaaactga gcattcatat ttttgagtta ttttgctcaa aatgcatgcg 
     4381 aaattatata ttgtcccaac tggaatattg tacataattt tagcctttaa aaaacagtcc 
     4441 attactgggg ggagggggca tcactctatg ggcaaagtgt tactcagaca tgggcacctg 
     4501 agttcagatc cctaccacct aagtaagcag caaggtgtgg tgtttttgta atgccagtgc 
     4561 tagaggcaga aacagacaga tcctgcaggc tcagtggctg gccaaacagc ctagccaaca 
     4621 tagcgcgttc caggttcagt gagaaaactt gtctcaaaaa tcagagggaa aagcaaatga 
     4681 gggtgtcagc catgtgcact catgcaaatg ccatacatgc agaagtatgt gcacacacac 
     4741 gcacacatta accaacgact agcaaggaaa atgaaggtgg ataagagggg tgggactggg 
     4801 acaaaggagg gtacctggat gaatatgact gaaggacgtt atgtacacat atgaaaacgt 
     4861 cgtactgaaa ctcactacaa tgtatactta atatatgcta ataaaatatt tttaaaagaa 
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     4921 aaaaatatcc ataattgtaa ataagaggat cttataatta aaagacccta aggattc 
// 
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Mus musculus ATP-binding cassette, sub-family G (WHITE), member 
2 (Abcg2), mRNA 
NCBI Reference Sequence: NM_011920.3 
ORIGIN       
        1 atataaaaag atctctctgt ctggatttcc tcttttccaa tctccttgcc agataagagg 
       61 ggttaggttg tcttgagttg gaacccacat ttctttcttg attcaggata accagctaac 
      121 agatattcac tactgtcgtc ctgaaattaa ctgaggatat tcattaattt cctggaagct 
      181 agatttttga aaagtcttga ttttgcctgt ctcttgaggc aaaacttagc aactttgggg 
      241 attgataaat cttctgtctt cctggtcctc tccctgcttt ttctcaactc cactgcaagc 
      301 aagagtggac atactcttag ggtggctttt gtggcaggca tggatcctag ctgaactctt 
      361 tctccagtgt acaacattgc tgcatctcac tgaggcctga cagttctcct tttgacacct 
      421 cattacacat agcagagaaa ggcataaatc ctaaagatgt cttccagtaa tgaccacgtg 
      481 ttagtaccaa tgtcgcagag aaacaacaac ggccttccta ggatgaactc cagagccgtt 
      541 aggacgctcg cagaaggaga tgtgttgagt tttcatcaca tcacctatcg agtgaaagta 
      601 aagagtgggt ttctagtccg gaaaacagtt gagaaagaaa tactatcaga tatcaatggg 
      661 atcatgaaac ctggccttaa tgctattctg ggacccacag gcggaggcaa gtcttcgttg 
      721 ctagatgtct tagcagcaag gaaagatcca aagggattat ctggagatgt tttgataaat 
      781 ggagcacctc aacctgccca tttcaaatgc tgttcaggtt atgtggttca agatgacgtt 
      841 gtgatgggca ccctgacagt gagagaaaac ttacagttct cagcagctct tcgacttcca 
      901 acaactatga agaatcatga aaaaaatgaa cggattaaca caatcattaa agagttaggt 
      961 ctggaaaaag tagcagattc taaggtcgga actcagttta tccgtggcat ctctggagga 
     1021 gaaagaaaaa ggacaagcat agggatggag ctgatcactg acccttccat cctcttcctg 
     1081 gatgagccca cgactggttt ggactcaagc acagcgaatg ctgtcctttt gctcctgaaa 
     1141 aggatgtcta aacagggtcg aacaatcatc ttctccattc atcagcctcg gtattccatc 
     1201 tttaagttgt ttgacagcct caccttactg gcttccggga aactcgtgtt ccatgggcca 
     1261 gcacagaagg ccttggagta ctttgcatca gcaggttacc actgtgagcc ctacaacaac 
     1321 cctgcggatt ttttccttga tgtcatcaat ggagattctt ctgctgtgat gttaaataga 
     1381 gaggaacaag acaatgaagc aaacaagact gaagagcctt ccaagggaga gaagccagta 
     1441 atagaaaatt tatctgagtt ttatatcaac tctgccatct atggagaaac aaaagctgaa 
     1501 ttagatcaac ttccaggagc tcaggaaaag aaaggaacat cggccttcaa agagccagtc 
     1561 tatgttacct ctttctgtca ccagctccga tggattgcca ggcgctcatt taaaaacttg 
     1621 ctcgggaacc ctcaagcttc tgttgctcag ttaattgtta cagtcatact ggggcttatt 
     1681 attggtgcca tttactttga tctgaaatat gatgccgctg gaatgcaaaa tagagctgga 
     1741 gttttgtttt tcctgactac caaccagtgt ttttccagtg tgtcagctgt ggagctgttc 
     1801 gtagtggaga agaaactctt catacatgag tacatcagtg gatattacag agtgtcttct 
     1861 tacttctttg gaaaggtgat gtctgattta ctccccatga ggttcttgcc aagtgttata 
     1921 ttcacttgta tattatactt catgttagga ctgaagaaga cggtggatgc ttttttcatc 
     1981 atgatgttta cccttataat ggtggcttat acggccagtt ccatggcact ggccatagcc 
     2041 acaggccaaa gtgtggtgtc tgtagcaaca cttctcatga caatcgcttt tgtatttatg 
     2101 atgctctttt ctggcctctt ggtgaatctc agaaccattg ggccttggct gtcctggctt 
     2161 cagtacttta gcattcctcg atatggcttc acagctttgc agtataatga attcttggga 
     2221 caagagtttt gtccaggatt caatgtaacg gacaacagca cttgtgttaa cagctatgca 
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     2281 atatgtactg gtaacgagta cttgataaat cagggcatcg aactgtcacc ttggggactg 
     2341 tggaagaatc atgtggccct ggcttgtatg attattatct tcctcacaat tgcctacctg 
     2401 aaattgttgt ttcttaaaaa gtattcttaa tttccccttt aacggactat taattgtact 
     2461 ccaattaaat atgggcactt tgattaccat aaa 
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